<SEC-DOCUMENT>0001193125-23-149315.txt : 20230519
<SEC-HEADER>0001193125-23-149315.hdr.sgml : 20230519
<ACCEPTANCE-DATETIME>20230519160915
ACCESSION NUMBER:		0001193125-23-149315
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20230519
DATE AS OF CHANGE:		20230519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prelude Therapeutics Inc
		CENTRAL INDEX KEY:			0001678660
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				811384762
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-261019
		FILM NUMBER:		23940124

	BUSINESS ADDRESS:	
		STREET 1:		200 POWDER MILL ROAD
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803
		BUSINESS PHONE:		(302) 547-3768

	MAIL ADDRESS:	
		STREET 1:		200 POWDER MILL ROAD
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prelude Therapeutics Inc.
		DATE OF NAME CHANGE:	20160630
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d487902d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-261019 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><I>PROSPECTUS SUPPLEMENT </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><I>(To Prospectus Dated November&nbsp;24, 2021) </I></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g487902g01p31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><I>4,496,744 Shares of Common Stock </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase 12,895,256 Shares of Common Stock </I></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><I>We are offering 4,496,744 shares of our common stock and, in lieu of common stock to certain investors that so choose, <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 12,895,256 shares of common stock in this offering. </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><I>Our voting
common stock is quoted on the Nasdaq Global Select Market under the symbol &#147;PRLD.&#148; On May&nbsp;17, 2023, the last reported sale price of our common stock on the Nasdaq Global Select Market was $6.30&nbsp;per share. </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><I>The purchase price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant sold in this offering equals the price at which a share
of common stock is sold to the public in this offering, minus $0.0001, and the exercise price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant equals $0.0001 per share. This prospectus supplement also relates to the offering of the
shares of common stock issuable upon exercise of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><I>We have two
classes of common stock: the voting common stock and the <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock. For a description of the rights of the voting common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock,
please see &#147;Description of Capital Stock&#148; beginning on page 18 of the accompanying prospectus, as supplemented by the documents incorporated by reference herein and therein. Unless otherwise noted, all references in this prospectus
supplement to our &#147;common stock&#148; refer to our voting common stock. Our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock is not listed for trading on any securities exchange. There is no established public trading market for
the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, and we do not expect a market to develop. We do not intend to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on the Nasdaq Global Select Market or any other
national securities exchange or nationally recognized trading system.</I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><I>We are an &#147;emerging growth company&#148; and &#147;smaller
reporting company&#148; as defined under the U.S. federal securities laws and will be subject to reduced public company reporting requirements for this prospectus supplement and future filings. See &#147;Prospectus Summary&#151;Implications of Being
an Emerging Growth Company and a Smaller Reporting Company.&#148; </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Investing in our securities involves a high degree of risk.
See &#147;<A HREF="#supprom487902_4">Risk Factors</A>&#148; beginning on page&nbsp;S-8 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement. </I></B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Bodoni MT" ALIGN="center"><B><I>Per&nbsp;Share</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Bodoni MT" ALIGN="center"><B><I>of&nbsp;Common</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Stock </I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Bodoni MT" ALIGN="center"><B><I><FONT STYLE="white-space:nowrap">Per&nbsp;Pre-</FONT></I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Bodoni MT" ALIGN="center"><B><I>Funded</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Warrant</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Total </I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Public offering price</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>$</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>5.7500</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>$</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>5.7499</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>$</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>100,002,710</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Underwriting discounts and
commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>$</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>0.345</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>$</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>0.345</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>$</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>1,200,240</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Proceeds, before expenses, to
us<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>$</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>5.4050</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>$</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>5.4049</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>$</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>98,802,470</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><I>(1)</I></TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><I>See &#147;Underwriters&#148; for a description of the compensation payable to the underwriter.
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><I>(2)</I></TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><I>See below for details regarding the 2,317,787&nbsp;shares of common stock and 11,595,256&nbsp;pre-funded
warrants for which the underwriters will not receive any underwriting discounts or commissions. </I></P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><I>We have granted
the underwriter the right to purchase up to an additional 2,608,800 shares of our common stock from us at the public offering price, less the underwriting discounts and commissions, within 30 days from the date of this prospectus supplement. The
underwriter expects to deliver the shares of voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock and the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants against payment on or about May&nbsp;22, 2023. </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><I>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus supplement and the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="justify"><I>Investment entities affiliated with our 5% stockholders affiliated with our directors have expressed an interest in purchasing an aggregate
of 2,317,787&nbsp;shares of common stock and 11,595,256&nbsp;pre-funded warrants in this offering at the public offering price. The underwriter will not receive any underwriting discounts or commissions on securities purchased by such investment
entities. </I></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>Morgan Stanley </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>May 18,
2023 </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-12</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_9">DESCRIPTION OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-16</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_10">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR INVESTORS IN OUR COMMON
 STOCK AND <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-18</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_11">UNDERWRITERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_14">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom487902_15">INCORPORATION OF INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-36</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> </DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_4">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_5">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_6">INCORPORATION OF INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_8">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_10">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_11">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_12">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_13">DESCRIPTION OF SUBSCRIPTION RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_14">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_15">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_16">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus supplement and the accompanying prospectus are part of a registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> <FONT STYLE="white-space:nowrap">(Registration&nbsp;No.&nbsp;333-261019)</FONT> that we filed with the Securities and Exchange Commission, or the SEC, using a &#147;shelf&#148; registration process.
This document is in two parts. The first part is the prospectus supplement, including the documents incorporated by reference herein, which describes the specific terms of this offering and also adds to and updates the information contained in the
accompanying prospectus and the documents incorporated by reference therein. The second part, the accompanying prospectus, including the documents incorporated by reference therein, provides more general information, some of which may not apply to
this offering. Before you invest, you should carefully read this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein, as well as the additional information described in this prospectus
supplement under &#147;Where You Can Find More Information.&#148; This prospectus supplement may add to, update or change information contained in the accompanying prospectus. To the extent that any statement we make in this prospectus supplement is
inconsistent with statements made in the accompanying prospectus or any documents incorporated by reference therein, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying prospectus
and such documents incorporated by reference therein. However, if any statement in one of these documents is inconsistent with a statement in another document with a later date that is incorporated by reference herein, the statement in the document
having the later date modifies and supersedes the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither we nor the underwriter has authorized anyone
to provide you with any information or to make any representation, other than those contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, or in any free writing prospectus prepared by us or on our
behalf or to which we have referred you. Neither we nor the underwriter take any responsibility for, and we provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information
appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus is accurate only as of the date of those
respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are offering to sell, and seeking offers to buy, shares of our common stock and
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the offering of the securities in certain jurisdictions may be restricted by
law. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus supplement
outside the United States. This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any
jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless the context indicates
otherwise, as used in this prospectus supplement and the accompanying prospectus, the terms &#147;Company,&#148; &#147;Prelude,&#148; &#147;Registrant,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Prelude Therapeutics
Incorporated, a Delaware corporation. The mark &#147;Prelude Therapeutics,&#148; the Prelude logo and all product names are our common law trademarks. All other service marks, trademarks and trade names appearing in this prospectus supplement are
the property of their respective owners. Solely for convenience, the trademarks and tradenames referred to in this prospectus supplement appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor
to these trademarks and tradenames. This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein contain additional trade names, trademarks and service marks of other companies, which are
the property of their respective owners. We do not intend our use or display of other companies&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This summary highlights information contained in other parts of this prospectus supplement or incorporated by reference in
this prospectus supplement from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended
March&nbsp;31, 2023, and our other filings with the SEC listed below under the heading &#147;Incorporation of Information by Reference.&#148; This summary may not contain all the information that you should consider before investing in our
securities. You should read this entire prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein carefully, including &#147;Risk Factors&#148; and the financial data and related
notes and other information incorporated by reference herein and therein, before making an investment decision. See the section entitled &#147;Special Note Regarding Forward-Looking Statements.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a
clinical-stage fully integrated oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. By leveraging our core competencies in cancer biology and medicinal chemistry,
combined with our clinical development capabilities, we have built an efficient, fully-integrated drug discovery engine and the development expertise necessary to identify compelling biological targets and create new chemical entities, that we
rapidly advance into clinical trials. We believe our approach could result in better targeted cancer therapies. Our discovery excellence has been validated by our rapid progress in creating a wholly-owned, internally developed pipeline. Since our
inception in 2016, we have received clearance from the U.S. Food and Drug Administration for multiple investigational new drug applications, or INDs, and successfully advanced several programs into clinical trials. In addition, we have other unique
programs in various stages of preclinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By focusing on developing molecules using broad mechanisms that
have multiple links to oncogenic driver pathways in select patients, we have developed a diverse pipeline consisting of multiple distinct programs spanning methyltransferases, kinases, protein-protein interactions and targeted protein degraders. Our
pipeline is designed to serve patients with high unmet medical need, where there are limited or no treatment options. We believe we can best address these diseases by developing therapies that target primary and secondary resistance mechanisms. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our product candidate pipeline: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g487902g00q05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have several drug candidates in clinical development, and we believe we can generate <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical data in the next 12 to 24 months to guide our future regulatory pathways to approval. Our CDK9 and MCL1 inhibitors are selective and potent, with
potentially superior safety profiles. Our next generation CDK4/6 inhibitor is specifically designed to be a brain and tissue penetrant and our SMARCA2 molecule is a unique,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> protein degrader, targeting specific patient populations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our CDK9 candidate, PRT2527, is designed to be a potent and selective CDK9 inhibitor. In preclinical studies, PRT2527 was
shown to reduce MCL1 and MYC protein levels and was highly active in preclinical models at well-tolerated doses. Our preclinical studies suggest that PRT2527 demonstrates high kinase selectivity and potency, providing opportunity for a wider
therapeutic index compared to less selective CDK9 inhibitors, allowing for rapid development in combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Preclinical
data demonstrated that treatment with PRT2527 depleted oncogenic drivers with short half-lives, such as MYC and MCL1, and effectively induced apoptosis. PRT2527 treatment demonstrated robust efficacy in both hematological malignancies and solid
tumor models with MYC dysregulation. Dose dependent increases in exposure and target engagement were observed as evidenced by MYC and MCL1 depletion to levels associated with tumor regression in preclinical models. A Phase 1 trial is underway
evaluating escalating IV doses of PRT2527 as a monotherapy in patients with selected solid tumors. On April&nbsp;18, 2023 we presented the following findings at the 2023 American Association for Cancer Research annual meeting, or the 2023 AACR
Annual Meeting: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In adults with advanced solid tumors, PRT2527 was generally well-tolerated with manageable neutropenia and
absence of significant gastrointestinal events or hepatotoxicity. The short half-life of PRT2527 enables acute CDK9 inhibition over a defined period making it potentially suitable for weekly administration without inducing significant toxicity. The
observed dose-dependent downregulation of CDK9 transcriptional targets &#150; MYC and <FONT STYLE="white-space:nowrap">MCL-1</FONT> mRNA expression in PBMCs isolated from patients treated with PRT2527 &#150;was consistent with the degree of target
engagement required for preclinical efficacy. The 15 mg/m2 QW dose of PRT2527 was selected for further evaluation in dose-confirmation cohort. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The overall safety profile observed in this study supports further
development of PRT2527 in combination with other targeted therapies, including in hematologic malignancies. We expect to present a recommended phase two dose, or RP2D, in hematological malignancies in the second half of 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. The
potency and selectivity of PRT1419 is supported by preclinical data demonstrating nanomolar inhibition of MCL1 and no inhibition of related enzymes at 200 times higher concentration of our product candidate. The IV formulation of PRT1419 has
demonstrated a desirable pharmacokinetic, pharmacodynamic and safety profile with potential for differentiation from competitor compounds. We are enrolling patients in a Phase 1 solid tumor dose escalation and confirmation study, including a
significant number of patients at the recommended expansion dose of 80 mg/m2. On April&nbsp;18, 2023 we presented the following findings at 2023 AACR Annual Meeting: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PRT1419 demonstrated acceptable safety and tolerability profile in patients with advanced and metastatic solid
tumors, with the most common treatment-related adverse events of nausea, vomiting, and diarrhea. Neutropenia was deemed to be dose related. No cardiac toxicity was observed. Pharmacokinetics/pharmacodynamics and safety data in the 80 mg/m2 QW
PRT1419 dose cohort support further evaluation of this dose in future studies. Induction of <FONT STYLE="white-space:nowrap">activated-BAX</FONT> and cleaved <FONT STYLE="white-space:nowrap">caspase-3</FONT> was observed at 80mg/m2 and 120 mg/m2 QW
PRT1419, suggesting successful <FONT STYLE="white-space:nowrap">MCL-1</FONT> inhibition. No tumor reductions met response criteria. Further investigation of PRT1419 in patients with hematologic malignancy is ongoing. We intend to evaluate PRT1419 in
hematology malignancies in combinations, with the goal of establishing safety, clinical activity and a RP2D in hematology malignancies in the second half of 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The clinical pharmacodynamic profile of PRT1419 demonstrates the desired level of target engagement, as measured by caspase
activation in peripheral mononuclear cells and reduction of CD14+ monocytes to levels associated with tumor regressions in preclinical models of hematological cancers. Advancement in hematological cancers will include monotherapy expansions in
chronic lymphocytic leukemia and <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphoma based on a strong rationale for MCL1 inhibition and the need for novel treatments in second line. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In July 2022, we received IND clearance for PRT3645, a brain and tissue penetrant molecule that potently targets CDK4/6 with a
biased selectivity for CDK4. A Phase 1 clinical trial has been initiated for PRT3645 in biomarker enriched patients with select tumor types including sarcomas, mesothelioma, gliomas, head and neck cancers and
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, in addition to breast cancer with or without brain metastases. We expect to present initial clinical results from the Phase 1 clinical trial in the second half of 2023, and to
present a RP2D in solid tumors in the second half of 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2022, we received IND clearance for PRT3789, a
potent and selective SMARCA2 protein degrader. SMARCA2 degradation has the greatest potential in patients with SMARCA4 deficient cancers, including approximately <FONT STYLE="white-space:nowrap">5-10%</FONT> of
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers. A Phase 1 dose escalation study of PRT3789 is ongoing. We expect to present a clinical update on its Phase 1 dose escalation study in the second half of 2023. Prelude&#146;s
discovery team has also identified orally bioavailable and highly selective SMARCA2 degrader preclinical leads which were presented as a poster at the 2023 AACR Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2022, we announced that we will discontinue the internal development of our two clinical candidates that are
designed to be oral, potent and selective inhibitors of protein arginine methyltransferase 5, or PRMT5. Discontinuation of the PRMT5 programs will allow us to focus our efforts on our CDK9, MCL1, CDK4/6 and SMARCA2 programs. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-the-Market</FONT></FONT> Offering
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;15, 2023, we entered into an Open Market Sale
Agreement<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP>, or the Sale Agreement, with Jefferies LLC, as sales agent and/or principal, pursuant to which we may offer and sell, from time to time to or through Jefferies LLC, shares of common
stock having an aggregate offering price of up to $75.0&nbsp;million. To date, no shares of our common stock have been offered or sold pursuant to the Sale Agreement. We may terminate the Sale Agreement in accordance with its terms. Pursuant to the
terms of the underwriting agreement, we may not sell shares pursuant to the Sale Agreement until the earlier of (i)&nbsp;the exercise in full by the underwriter of its option to purchase additional shares of voting common stock or (ii) 30 days after
the date of the underwriting agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were formed under the laws of the State of Delaware in February 2016. Our principal executive offices are located at 200
Powder Mill Road, Wilmington, Delaware, 19803, and our telephone number is (302) <FONT STYLE="white-space:nowrap">467-1280.</FONT> Our website address is www.preludetx.com. The information contained on, or that can be accessed through, our website
is not part of, and is not incorporated by reference into, this prospectus supplement. Investors should not rely on any such information in deciding whether to purchase our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We qualify as an &#147;emerging growth company&#148; as defined in Rule 405 of the Securities Act of 1933, as amended, or the
Securities Act. An emerging growth company may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exception from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-
Oxley Act of 2002, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and
registration statements, including an exemption from complying with new pay versus performance disclosure requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes
on executive compensation or golden parachute arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, an emerging growth company can
take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. Any decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable. We have elected to use this
extended transition period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will cease to be an emerging growth company upon the earliest of (1)&nbsp;the end of the
fiscal year following the fifth anniversary of our initial public offering (i.e. December&nbsp;31, 2025); (2) the last day of the fiscal year during which our annual gross revenues are $1.235&nbsp;billion or more; (3)&nbsp;the date on which we have,
during the previous three-year period, issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; and (4)&nbsp;the end of any fiscal year in which the market value of our common stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the end of the second quarter of that fiscal year. We may choose to take advantage of some or all of these reduced reporting burdens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we are also a &#147;smaller reporting company,&#148; as defined in Rule 405 under the Securities Act. We may
continue to be a smaller reporting company in any given year if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million as of June&nbsp;30 in the most recently
completed fiscal year or (ii)&nbsp;our </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
annual revenue is less than $100&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is
less than $700&nbsp;million as of June&nbsp;30 in the most recently completed fiscal year. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure
requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,496,744 shares </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-funded</FONT> warrants offered by us </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are also offering, in lieu of common stock to certain investors, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to
purchase 12,895,256 shares of common stock. The purchase price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant equals the price per share at which the shares of common stock are being sold to the public in this offering, minus
$0.0001, and the exercise price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant equals $0.0001 per share. Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be exercisable at any time after the date of issuance.
See &#147;Description of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants.&#148; This prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of such
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have granted the underwriter an option for a period of 30 days to purchase up to 2,608,800 additional shares of our common stock.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">52,412,999 shares (or 55,021,799 shares if the underwriter exercises its option to purchase additional shares in full).
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-voting</FONT> common stock to be outstanding immediately after this
offering </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">12,850,259 shares </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We estimate that the net proceeds of this offering, after deducting underwriting discounts and commissions and estimated offering
expenses, will be approximately $98.5&nbsp;million (or approximately $112.6&nbsp;million if the underwriter exercises its option to purchase additional shares in full). We currently intend to use the net proceeds of this offering to advance our
current clinical pipeline, including PRT2527, PRT1419, PRT3645 and PRT3789; advance our research and discovery efforts including our efforts for a new SMARCA2 oral molecule; and support organizational growth and for working capital and other general
corporate purposes. See the section entitled &#147;Use of Proceeds.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Voting rights </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have two classes of common stock: the voting common stock <FONT STYLE="white-space:nowrap">and&nbsp;non-voting&nbsp;common</FONT>
stock. For a description of the rights of the voting common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, please see &#147;Description of Capital Stock&#148; beginning on page 18 of the accompanying prospectus, as
supplemented by the documents incorporated by reference herein and therein. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Indication of interest </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investment entities affiliated with our 5% stockholders affiliated with our directors have expressed an interest in purchasing an
aggregate of 2,317,787&nbsp;shares of common stock and 11,595,256 pre-funded warrants in this offering at the public offering price. The underwriter will not receive any underwriting discounts or commissions on securities purchased by such
investment entities. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You should read the section entitled &#147;Risk Factors&#148; in this prospectus supplement, the accompanying prospectus and the
documents incorporated by reference herein and therein for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;PRLD&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock is not listed for trading on any securities exchange.
There is no established public trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, and we do not expect a market to develop. We do not intend to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on
the Nasdaq Global Select Market or any other national securities exchange or nationally recognized trading system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
number of shares of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock to be outstanding after this offering is based on 47,916,255 shares of common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT>
common stock (of which 11,402,037 shares are <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock) outstanding as of March&nbsp;31, 2023 (including 131,468 unvested restricted shares outstanding as of March&nbsp;31, 2023) and excludes:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11,868,020 shares of common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31,
2023 under our 2016 Stock Incentive Plan, or the 2016 Plan, and our 2020 Equity Incentive Plan, or the 2020 Plan, with a weighted average exercise price of $10.82 per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">163,750 shares of common stock issuable upon vesting of restricted stock units outstanding as of
March&nbsp;31, 2023 under our 2016 Plan and our 2020 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">113,000 shares of common stock issuable upon the exercise of stock options granted after March&nbsp;31, 2023
under the 2020 Plan with an exercise price of $6.38; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,830,064 shares of common stock reserved for future issuance as of March&nbsp;31, 2023 under our stock-based
compensation plans, consisting of (i) 5,040,915 shares of common stock reserved for future issuance under the 2020 Plan, and (ii) 1,789,149 shares of common stock reserved for future issuance under our 2020 Employee Stock Purchase Plan, or 2020
ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as otherwise indicated, all information in this prospectus supplement assumes no exercise
of outstanding options and no vesting or settlement of restricted stock units described above, no exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered hereby, and no exercise of the underwriter&#146;s option to
purchase additional shares of common stock. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>An investment in shares of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants involves a high
degree of risk. Prior to making a decision about investing in shares of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, you should carefully consider the risk factors described below together with all of the risks,
uncertainties and assumptions discussed in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, as updated by our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for
the quarter ended March&nbsp;31, 2023, as well as any amendments thereto reflected in subsequent filings with the SEC, each of which are incorporated by reference in this prospectus supplement, and all of the other information in this prospectus
supplement, including our financial statements and related notes incorporated by reference herein. If any of the risks incorporated by reference or set forth below occurs, our business, operations and financial condition could suffer significantly.
As a result, you could lose some or all of your investment in our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. The risks and uncertainties we have described are not the only ones we face. Additional risks and
uncertainties not presently known to us or that we currently deem immaterial may also affect our business, operations and financial condition, or cause the value of our securities to decline. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase
shares of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants sold in this offering, you will experience immediate and substantial dilution. In addition, we may issue additional equity or convertible debt securities in
the future, which may result in additional dilution to you. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since the price per share of our common stock being
offered is higher than the net tangible book value per share of our common stock, you will suffer dilution with respect to the net tangible book value of the shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants you
purchase in this offering. Based on the public offering price of $5.7500&nbsp;per share and $5.7499 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant and our net tangible book value as of March&nbsp;31, 2023, if you purchase shares of
common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in this offering, you will suffer immediate dilution of $0.54 per share with respect to the net tangible book value of the common stock. For a more detailed discussion of
the foregoing, see the section entitled &#147;Dilution&#148; below. To the extent outstanding stock options or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercised, or restricted stock units vest and settle, there will be
further dilution to new investors. In addition, to the extent we need to raise additional capital in the future, under our Sale Agreement or otherwise, and we issue additional shares of common stock or securities convertible or exchangeable for our
common stock, our then existing stockholders may experience dilution and the new securities may have rights senior to those of our common stock offered in this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the
purposes described in the section entitled &#147;Use of Proceeds,&#148; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability
of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of
your investment. We expect to use the net proceeds from this offering to advance our current clinical pipeline, including PRT2527, PRT1419, PRT3645 and PRT3789; advance our research and discovery efforts including our efforts for a new SMARCA2 oral
molecule; and support organizational growth and for working capital and other general corporate purposes. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on
our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A sale of a substantial number of shares of our common stock may cause the price of our common stock
to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales of a substantial number of shares of our common stock in the public market could occur at any
time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. We had 47,916,255 shares of
common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock outstanding as of March&nbsp;31, 2023. We filed a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT>
<FONT STYLE="white-space:nowrap">(Registration&nbsp;No.&nbsp;333-261019)</FONT> that was declared effective by the SEC on November&nbsp;24, 2021, and which registers the offer and sale from time to time by the selling securityholders of up to
31,574,631 shares of our common stock. To the extent shares are sold into the market pursuant to this registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> under Rule&nbsp;144 of the Securities Act or otherwise, particularly in
substantial quantities, the market price of our common stock could decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot predict what effect, if any, sales
of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise
of outstanding options or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, or the perception that such sales may occur, could adversely affect the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may raise money through additional public or private offerings of our equity securities or equity-linked securities. For
example, in March 2023, we entered into the Sale Agreement pursuant to which we may offer and sell, from time to time to or through Jefferies LLC, shares of common stock having an aggregate offering price of up to $75.0&nbsp;million. Any sales of
our equity or equity-linked securities could have a material adverse effect on the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
connection with this offering, we and our directors, executive officers and certain of our affiliated stockholders have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements for a period of 90 days following this offering. The <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements are subject to various exceptions, and we and our directors and executive officers may be released from the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements prior to the expiration of
the <FONT STYLE="white-space:nowrap">lock-up</FONT> period at the sole discretion of Morgan Stanley&nbsp;&amp; Co. LLC. See the section entitled &#147;Underwriters.&#148; Upon expiration or earlier release of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, we and our directors and executive officers may sell shares into the market, which could adversely affect the market price of shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also expect that significant additional capital may be needed in the future to continue our planned operations. To raise
capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. These sales, or the perception in the market that the holders of a large
number of shares intend to sell shares, could reduce the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we have a
significant number of stock options outstanding, and may also choose to issue additional common stock, or securities convertible into or exchangeable for common stock, in the future in connection with a financing, an acquisition, a litigation
settlement, employee arrangements or otherwise. In the event that the outstanding options are exercised, or that we make additional issuances of common stock or other convertible or exchangeable securities, you could experience additional dilution.
Furthermore, we cannot assure you that we will be able to issue shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing
our securities in the future may have rights superior to investors purchasing shares in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The dual class structure of our common stock
may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The dual class structure of our common stock may limit your ability to influence corporate matters. Holders of our common stock
are entitled to one vote per share, while holders of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock are not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
entitled to any votes. Nonetheless, each share of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock may be converted at any time into one share of our common stock at the option
of its holder by providing written notice to us, subject to the limitations provided for in our restated certificate of incorporation to become effective upon the completion of this offering. Consequently, if holders of our <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock following this offering exercise their option to make this conversion, this will have the effect of increasing the relative voting power of those prior holders of our <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock, and correspondingly decreasing the voting power of the holders of our common stock, which may limit your ability to influence corporate matters. For example, immediately following this
offering, the common stock will have 100% of the voting power, but if the holders of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock were to convert all of their shares into common stock, the prior common stock would have 75.5% of
the voting power, and the former <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock would represent 24.5% of the voting power. Additionally, stockholders who hold, in the aggregate, more than 10% of our common stock and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock, but 10% or less of our common stock, and are not otherwise an insider of the company, may not be required to report changes in their ownership due to transactions in our <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock pursuant to Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and may not be subject to the <FONT STYLE="white-space:nowrap">short-swing</FONT>
profit provisions of Section&nbsp;16(b) of the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no public market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants being offered in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is no public trading market for the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on the Nasdaq
Global Select Market or any other national securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will not receive a significant amount or any additional funds upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant is exercisable for $0.0001 per share of common
stock underlying such warrant, which may be paid by way of a cashless exercise, in which the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant. Accordingly, we will not receive a significant amount or any additional funds upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will have no rights as stockholders until such holders exercise their <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants and acquire our shares of common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Until holders of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants exercise their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and acquire our shares of common stock, such holders will have no rights with respect to the shares of common
stock underlying such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. Upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the holders will be entitled to exercise the rights of a holder of common stock only
as to matters for which the record date occurs after the exercise date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant holders or beneficial holders of our common stock may not be
permitted to exercise <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants that they hold. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A holder of a <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant will not be entitled to exercise any portion of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant which, upon giving effect to such exercise, would cause the aggregate number of
shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% of the number of shares of our common stock that would be outstanding immediately after giving effect to the exercise. However, any holder may
increase or decrease such percentage to any other percentage not in excess of 19.99% upon at least 61 days&#146; prior notice from the holder to us. As a result, you may not be able to exercise your <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants for shares of our common stock at a time when it would be financially beneficial for you to do so. In such circumstance you could seek to sell your <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to realize value, but you may be
unable to do so in the absence of an established trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus supplement, the accompanying prospectus and documents incorporated herein by reference contain
&#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is
not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such statements include, but are not limited to, statements regarding expectations and intentions, costs and expenses, outcome
of contingencies, financial condition, results of operations, liquidity, objectives of management, debt financing, our future results of operations and financial position, business strategies, market size, potential growth opportunities, clinical
development activities, efficacy and safety profile of our product candidates, timing and results of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials, the receipt and timing of potential regulatory designations,
our ability to maintain and recognize the benefits of certain designations received by product candidates, the achievement of clinical and commercial milestones, the advancement of our technologies and our proprietary product candidates, the
successful achievement of the goals of our collaborations, the advancement of the product candidates that are the subjects of these collaborations, the approvals and commercialization of product candidates and other statements that are not
historical facts. You can find many of these statements by looking for words like &#147;believes,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;estimates,&#148; &#147;may,&#148; &#147;might,&#148; &#147;should,&#148; &#147;will,&#148;
&#147;could,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;project,&#148; &#147;seek&#148; or similar expressions in this prospectus supplement, in documents incorporated by reference into this prospectus supplement or any free writing
prospectus. We intend that such forward-looking statements be subject to the safe harbors created thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These
forward-looking statements are based on the current beliefs and expectations of our management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual
results may differ materially from current expectations and projections. Factors that might cause such a difference include those discussed in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2022, as updated by our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2023, as well as those discussed in this prospectus supplement, the accompanying prospectus, the
documents incorporated by reference into this prospectus supplement, the accompanying prospectus and any prospectus supplement or free writing prospectus. You are cautioned not to place undue reliance on these forward-looking statements, which speak
only as of the date of this prospectus supplement or, in the case of the accompanying prospectus or documents referred to or incorporated by reference, the date of those documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant
subject. These statements are based upon information available to us as of the date of this prospectus supplement, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and
our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon
these statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All subsequent written or oral forward-looking statements attributable to us or any person acting on
our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or
circumstances after the date of this prospectus supplement or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities law. If we do update one or more forward-looking statements, no inference
should be drawn that we will make additional updates with respect to those or other forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that the net proceeds of this offering, after deducting underwriting discounts and commissions and estimated
offering expenses, will be approximately $98.5&nbsp;million, or $112.6&nbsp;million if the underwriter&#146;s option to purchase additional shares is exercised in full. We will receive nominal proceeds, if any, from the exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently intend to use the net proceeds of this offering to
advance our current clinical pipeline, including PRT2527, PRT1419, PRT3645 and PRT3789; advance our research and discovery efforts including our efforts for a new SMARCA2 oral molecule; and support organizational growth and for working capital and
other general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2023, we had cash, cash equivalents and marketable securities of
$172.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following this offering, we expect our existing cash, cash equivalents and marketable securities
will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than
we currently expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The amounts and timing of our actual expenditures will depend on numerous factors, including the
progress of our clinical trials and other development efforts and other factors described under &#147;Risk Factors&#148; in this prospectus supplement and the documents incorporated by reference herein, as well as the amount of cash used in our
operations. As a result, our management will have broad discretion over the uses of the net proceeds, if any, we receive in connection with the securities offered pursuant to this prospectus supplement and investors will be relying on the judgment
of our management regarding the application of the proceeds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pending these uses, we intend to invest the net proceeds in
short-term or long-term, investment-grade, interest-bearing securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to
finance the operation and expansion of our business and do not anticipate paying any cash dividends on our common stock or <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock in the foreseeable future. Any future determination related to
our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and
subject to the restrictions contained in any future financing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you invest in our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in this offering, your
ownership interest will be immediately diluted to the extent of the difference between the public offering price per share of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant you will pay in this offering and the
adjusted net tangible book value per share of our common stock immediately after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our net tangible book
value as of March&nbsp;31, 2023 was approximately $174.7&nbsp;million, or $3.65 per share, based upon 47,916,255 shares of common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock outstanding as of March&nbsp;31, 2023. Net
tangible book value per share is determined by dividing our total tangible assets (which excludes deferred offering costs) less total liabilities by the number of shares of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT>
common stock outstanding as of March&nbsp;31, 2023. Dilution with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible
book value per share of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After giving effect to the issuance and sale of shares of our common stock and
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants at the public offering price of $5.7500 per share of common stock and $5.7499 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant (which equals the public offering price per
share of the common stock less the $0.0001 per share exercise price of each such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant) and after deducting underwriting discounts and commissions and estimated offering expenses and excluding
proceeds, if any, from the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued pursuant to this offering or any resulting accounting associated with the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, our
as adjusted net tangible book value as of March&nbsp;31, 2023 would have been approximately $273.2&nbsp;million, or $5.21 per share. This represents an immediate increase in net tangible book value of $1.56 per share to existing stockholders and
immediate dilution of $0.54 per share to investors purchasing our common stock, <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in this offering at the public offering
price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table illustrates this dilution on a per share basis (assuming no exercise of the pre-funded
warrants issued in this offering): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.7500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of March&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to investors purchasing our common
stock, <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to investors purchasing our common stock,
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants exercise the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants offered hereby, the as adjusted net tangible book value per share of our common stock after giving effect to this offering would be $4.18 per share, and the dilution in net tangible book value
per share to investors purchasing common stock in this offering would be $1.57 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriter exercises
its option to purchase 2,608,800 additional shares in full, the as adjusted net tangible book value per share of our common stock after giving effect to this offering would be $5.22 per share, and the dilution in net tangible book value per share to
investors purchasing common stock in this offering would be $0.53 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing table and calculations are
based on 47,916,255 shares of common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock (of which 11,402,037 shares are <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock) outstanding as of March&nbsp;31, 2023
(including 131,468 unvested restricted shares outstanding as of March&nbsp;31, 2023) and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11,868,020 shares of common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31,
2023 under the 2016 Plan and the 2020 Plan, with a weighted average exercise price of $10.82 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">163,750 shares of common stock issuable upon vesting of restricted stock units outstanding as of
March&nbsp;31, 2023 under our 2016 Plan and our 2020 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">113,000 shares of common stock issuable upon the exercise of stock options granted after March&nbsp;31, 2023
under the 2020 Plan with an exercise price of $6.38; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,830,064 shares of common stock reserved for future issuance as of March&nbsp;31, 2023 under our <FONT
STYLE="white-space:nowrap">stock-based</FONT> compensation plans, consisting of (i) 5,040,915 shares of common stock reserved for future issuance under the 2020 Plan, and (ii) 1,789,149 shares of common stock reserved for future issuance under the
2020 ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent that outstanding options or pre-funded warrants have been or may be exercised,
or restricted stock units have vested or may vest, or other shares are issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to issue additional common stock, or securities
convertible into or exchangeable for common stock, in the future. The issuance of these securities could result in further dilution for investors purchasing our common stock in this offering </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_9"></A>DESCRIPTION
<FONT STYLE="white-space:nowrap">OF&nbsp;PRE-FUNDED&nbsp;WARRANTS</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a brief summary of certain
terms and conditions of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered by this prospectus supplement. The following description is subject in all respects to the provisions contained in the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be issued as individual warrant agreements to the
investors. The form of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be filed as an exhibit to our Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> that we expect to file with the SEC in connection with this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Term </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants do not expire. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercisability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercisable at any time after their original issuance. The <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and by payment in full of the exercise price in immediately available
funds for the number of shares of common stock purchased upon such exercise. As an alternative to payment in immediately available funds, the holder may elect to exercise the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant through a
cashless exercise, in which the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. No fractional shares of
common stock will be issued in connection with the exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise Limitations
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, we may not effect the exercise of any <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant, and a holder will not be entitled to exercise any portion of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, which, upon giving effect to such exercise, would cause the aggregate
number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% of the number of shares of our common stock that would be outstanding immediately after giving effect to the exercise. However, any
holder may increase or decrease such percentage to any other percentage not in excess of 19.99% upon at least 61 days&#146; prior notice from the holder to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise Price </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
exercise price per whole share of our common stock purchasable upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is $0.0001 per share of common stock. The exercise price of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and the number of shares of our common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is subject to appropriate adjustment in the event of
certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transferability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject
to applicable laws, the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may be assigned by the holder without our consent. The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be held in definitive form by the warrant
agent. The ownership of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and any transfers of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be registered in a warrant register maintained by the warrant agent. We
will initially act as warrant agent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not plan on applying to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on The Nasdaq Global Select
Market, any other national securities exchange or any other nationally recognized trading system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fundamental Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of a fundamental transaction, as described in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and
generally including but not limited to any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our
properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of the voting power of our capital stock, or any person or group becoming the beneficial owner of 50% of the voting power of our capital
stock, upon consummation of such a fundamental transaction, the holders of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be entitled to receive upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants
the kind and amount of securities, cash or other property that the holders would have received had they exercised the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants immediately prior to such fundamental transaction without regard to any
limitations on exercise contained in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Rights as a Stockholder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except by virtue of such holder&#146;s ownership of shares of our common stock, the holder of a
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrant. In the event of certain distributions, including cash dividends, if any, to all holders of our common stock for no consideration, the holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant shall be entitled to participate in
such distributions to the same extent as if a holder of shares of our common stock, in which case such distribution shall be held in abeyance for the benefit of such holder until the earlier of such time as the ownership limitations would not be
exceeded or the warrant is exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_10"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR INVESTORS
IN OUR COMMON STOCK AND <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following summary describes
the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants acquired in this offering. This discussion does not address all
aspects of U.S. federal income taxes, does not discuss the potential application of the alternative minimum tax or Medicare Contribution tax and does not deal with state or local taxes, U.S. federal gift and estate tax laws, except to the limited
extent provided below, or any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences that may be relevant to investors in light of their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Special rules different from those described below may apply to certain investors that are subject to special treatment under
the Internal Revenue Code of 1986, as amended, or the Code, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies, banks and other financial institutions;</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations (including private foundations) and <FONT
STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign governments and international organizations;</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers and traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and certain former citizens or long-term residents of the United
States;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) that own, or are deemed to own,
more than 5% of our common stock (directly, indirectly or by attribution) or more than 5% of our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons required for U.S. federal income tax purposes to conform the timing of income accruals to their
financial statements under Section&nbsp;451(b) of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our common stock as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion
transaction,&#148; &#147;synthetic security&#148; or integrated investment or other risk reduction strategy;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Holders (as defined below) whose functional currency for U.S. tax purposes is not the U.S.
dollar;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who do not hold our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as
&#147;capital assets&#148; within the meaning of Section&nbsp;1221 of the Code (generally, for investment purposes); and</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships and other pass-through entities, and investors in such pass-through entities (regardless of their
places of organization or formation). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such investors are urged to consult their own tax advisors to
determine the U.S. federal, state, local and other tax consequences that may be relevant to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, the
discussion below is based upon the provisions of the Code, and Treasury regulations, rulings and judicial decisions thereunder as of the date hereof, and such authorities may be repealed, revoked or modified, possibly retroactively, and are subject
to differing interpretations which could result in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the Internal Revenue Service, or the IRS, with respect to the statements made and the
conclusions reached in the following summary, and there can be no assurance that the IRS will agree with such statements and conclusions or will not take a contrary position regarding the tax consequences described herein, or that any such contrary
position would not be sustained by a court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this discussion, a &#147;U.S. Holder&#148; means a
beneficial owner of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, other than a partnership or other pass-through entity, that is, for U.S. federal income tax purposes, (a)&nbsp;an individual citizen or resident of
the United States, (b)&nbsp;a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes), created or organized in or under the laws of the United States, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
any state thereof or the District of Columbia, (c)&nbsp;an estate the income of which is subject to U.S. federal income taxation regardless of its source, or (d)&nbsp;a trust if it (1)&nbsp;is
subject to the primary supervision of a court within the United States and one or more U.S. persons (within the meaning of Section&nbsp;7701(a)(30) of the Code) have the authority to control all substantial decisions of the trust or (2)&nbsp;has a
valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. A <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is, for U.S. federal income tax purposes, a beneficial owner of common stock or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants that is not a U.S. Holder or a partnership or other pass-through entity for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you are an individual <FONT STYLE="white-space:nowrap">non-U.S.</FONT> citizen, you may, in some cases, be deemed to be a
resident alien (as opposed to a nonresident alien) by virtue of being present in the United States for at least 31 days in the calendar year and for an aggregate of at least 183 days during a three-year period ending in the current calendar year.
Generally, for this purpose, all the days present in the current year, <FONT STYLE="white-space:nowrap">one-third</FONT> of the days present in the immediately preceding year, and <FONT STYLE="white-space:nowrap">one-sixth</FONT> of the days present
in the second preceding year, are counted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Resident aliens are generally subject to U.S. federal income tax as if they
were U.S. citizens. Individuals who are uncertain of their status as resident or nonresident aliens for U.S. federal income tax purposes are urged to consult their own tax advisors regarding the U.S. federal income tax consequences of the ownership
or disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">PERSONS CONSIDERING THE PURCHASE OF OUR COMMON STOCK OR <FONT
STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS PURSUANT TO THIS OFFERING SHOULD CONSULT THEIR OWN TAX ADVISORS CONCERNING THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK AND <FONT
STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS IN LIGHT OF THEIR PARTICULAR SITUATIONS AS WELL AS ANY CONSEQUENCES ARISING UNDER THE LAWS OF ANY OTHER TAXING JURISDICTION, INCLUDING ANY STATE, LOCAL OR
<FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES OR ANY U.S. FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX CONSEQUENCES, AND THE POSSIBLE APPLICATION OF TAX TREATIES. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Characterization of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants for Tax Purposes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although the characterization of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for U.S. federal income tax
purposes is not entirely clear, because the exercise price of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is a nominal amount, we expect to treat the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as our common stock
for U.S. federal income tax purposes and a holder of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants should generally be taxed in the same manner as a holder of common stock as described below. Accordingly, for U.S. federal income tax
purposes, no gain or loss should be recognized upon the exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, and upon exercise, the holding period of the share of common stock received should include the holding period of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant. Similarly, the tax basis of a share of common stock received upon exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should include the tax basis of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant increased by the exercise price of $0.0001 per share. The balance of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax purposes,
and the discussion below, to the extent it pertains to our common stock, is generally intended to also pertain to the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our position with respect to the characterization of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is not
binding on the IRS and the IRS may treat the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as warrants to acquire our common stock and, if so, the amount and character of your gain with respect to an investment in our <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants could change. You should consult your tax advisor regarding the characterization of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for U.S. federal income tax purposes, and the
consequences to you of an investment in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants based on your own particular facts and circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Consequences to U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Distributions on Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As stated under &#147;Dividend Policy,&#148; we do not expect to make distributions on our common stock in the foreseeable
future. In the event that we do make distributions of cash or other property, distributions paid on common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be treated as a dividend to the extent paid out of our current or
accumulated earnings and profits, and will be includible in your income as ordinary income when received. However, with respect to dividends received by individuals, such dividends are generally taxed at the lower applicable long-term capital gains
rates, provided certain holding period requirements are satisfied. Distributions in excess of our current and accumulated earnings and profits will be treated as a return of capital to the extent of a U.S. Holder&#146;s tax basis in the common stock
(or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant) and thereafter as capital gain from the sale or exchange of such common stock (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant). The tax treatment of such gain is further
described in &#147;&#151;Sale or Other Disposition of Common Stock or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants&#148; below. Dividends received by a corporation may be eligible for a dividends received deduction, subject to
applicable limitations. Any such distributions will also be subject to the discussions below under the section titled &#147;&#151;Information Reporting and Backup Withholding.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should consult its tax advisor regarding the tax
treatment of any distribution with respect to such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant that is held in abeyance in connection with any applicable limitation on the holder&#146;s beneficial ownership of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Disposition of Common Stock or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For U.S. federal income tax purposes, gain or loss realized on the sale or other disposition of common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants will be capital gain or loss, and will be long-term capital gain or loss if you have held the common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for more than one year.
The amount of the gain or loss will equal the difference between your tax basis in the common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants disposed of and the amount realized on the disposition. Long-term capital gains
recognized by <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders will be subject to reduced tax rates. The deductibility of capital losses is subject to limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Certain Adjustments to the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The exercise terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may be adjusted under certain
circumstances. Under Section&nbsp;305 of the Code, an adjustment to the number of shares of common stock that will be issued on the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, or an adjustment to the exercise price
of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, may be treated as a constructive distribution to a U.S. Holder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants if, and to the extent that, such adjustment has the
effect of increasing such U.S. Holder&#146;s proportionate interest in our &#147;earnings and profits&#148; or assets, depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or
other property to our shareholders). Adjustments to the exercise price of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or number of shares of common stock that will be issued on the exercise of a
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant that are made pursuant to a bona fide reasonable adjustment formula that has the effect of preventing dilution of the interest of the U.S. Holder of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants generally should not be considered to result in a constructive distribution. Such constructive distribution would be treated as a dividend, return of capital or capital gain as described
under the heading &#147;U.S. Holder&#151;Distributions on Common Stock&#148; above. Any such constructive distribution would be taxable whether or not there is an actual distribution of cash or other property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Information reporting requirements generally will apply to payments of dividends on our common stock, constructive dividends on
our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, and gross proceeds on the sale or other disposition of our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, unless the U.S. Holder is an exempt recipient
(such as a corporation). Backup withholding (currently at a 24% rate) will apply to those payments if the U.S. Holder fails to provide its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
correct taxpayer identification number, or certification of exempt status, or if the U.S. Holder is notified by the IRS that it has failed to report in full payments of interest and dividend
income. Any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against a U.S. Holder&#146;s U.S. federal income tax liability provided the required information is furnished timely to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a beneficial owner of our common
stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants that, for U.S. federal income tax purposes, is neither a U.S. Holder (as defined above) nor a partnership or other pass-through entity. If you are not a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, this section does not apply to you. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Distributions on Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As stated under &#147;Dividend Policy,&#148; we do not expect to make any distributions on our common stock in the foreseeable
future. If we do make distributions on our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, however, such distributions made to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will constitute dividends for U.S.
tax purposes to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Distributions in excess of our current and accumulated earnings and profits will constitute a return of
capital that is applied against and reduces, but not below zero, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in our common stock (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants). Any remaining
excess will be treated as gain realized as described below under the section titled &#147;&#151;Sale or Other Disposition of Common Stock and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any distribution on our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants that is treated as a
dividend paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is not effectively connected with the holder&#146;s conduct of a trade or business in the United&nbsp;States will generally be subject to withholding tax at a 30% rate
or such lower rate as may be specified by an applicable income tax treaty between the United States and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s country of residence. To obtain a reduced rate of withholding under a treaty,
a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be required to provide the applicable withholding agent with a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other appropriate form, certifying the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s entitlement to benefits under that treaty. Such form must be
provided prior to the payment of dividends and must be updated periodically. If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds stock through a financial institution or other agent acting on the holder&#146;s behalf, the holder will
be required to provide appropriate documentation to such agent. The holder&#146;s agent may then be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. If you are eligible for a
reduced rate of U.S. withholding tax under an income tax treaty, you should consult with your own tax advisor to determine if you are able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund
with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We generally are not required to withhold tax on dividends paid to a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are effectively connected with the holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a
permanent establishment that the holder maintains in the United&nbsp;States) if a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> stating that the dividends are so connected, is furnished to us (or, if shares of our common
stock are held through a financial institution or other agent, to the applicable withholding agent). In general, such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates
applicable to U.S. persons, unless a specific treaty exemption applies. A corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder receiving effectively connected dividends may also be subject to an additional &#147;branch profits
tax,&#148; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s effectively connected
earnings and profits, subject to certain adjustments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See also the section below titled &#147;&#151;Foreign
Accounts&#148; for additional withholding rules that may apply to dividends paid to certain foreign financial institutions or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Disposition of Common Stock and
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussion below under the sections
titled &#147;&#151;Information Reporting and Backup Withholding&#148; and &#147;&#151;Foreign Accounts,&#148; a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income or withholding tax with
respect to gain realized on a sale or other disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants unless (a)&nbsp;the gain is effectively connected with a trade or business of the holder in the United States
(and, if required by an applicable income tax treaty, is attributable to a permanent establishment that the holder maintains in the United States), (b) the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual and
is present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions are met, or (c)&nbsp;we are or have been a &#147;United States real property holding corporation&#148; within the meaning of
Code Section&nbsp;897(c)(2) at any time within the shorter of the five-year period preceding such disposition or the holder&#146;s holding period in the common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you are a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in (a)&nbsp;above, you will be required to pay
tax on the net gain derived from the sale at the regular graduated U.S. federal income tax rates applicable to U.S. persons, unless a specific treaty exemption applies. Corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders described in
(a)&nbsp;above may also be subject to the additional branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. If you are an individual <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
described in (b)&nbsp;above, you will be required to pay a flat 30% tax on the gain derived from the sale, which gain may be offset by certain U.S. source capital losses (even though you are not considered a resident of the United States), provided
you have timely filed U.S. federal income tax returns with respect to such losses. With respect to (c)&nbsp;above, in general, we would be a U.S. real property holding corporation if interests in U.S. real estate comprised (by fair market value) at
least half of our worldwide real property interests plus our other assets used or held for use in a trade or business. We believe that we are not, and do not anticipate becoming, a U.S. real property holding corporation. However, there can be no
assurance that we will not become a U.S. real property holding corporation in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Certain Adjustments to the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The exercise terms of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may be adjusted under certain circumstances. Under Section&nbsp;305 of the Code, an adjustment to the number of shares of common stock that will be issued on the exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, or an adjustment to the exercise price of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, may be treated as a constructive distribution to a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants if, and to the extent that, such adjustment has the effect of increasing such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder&#146;s proportionate interest in our &#147;earnings and profits&#148; or assets, depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or other property to our
shareholders). Adjustments to the exercise price of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or number of shares of common stock that will be issued on the exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant
that are made pursuant to a bona fide reasonable adjustment formula that has the effect of preventing dilution of the interest of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants generally should not be considered to result in a constructive distribution. Such constructive distribution would be treated as a dividend, return of capital or capital gain as described under the heading &#147;Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders&#151;Distributions on Common Stock&#148; above. Any such constructive distribution would be taxable whether or not there is an actual distribution of cash or other property. Any distribution treated
as a dividend would generally be subject to 30% U.S. withholding tax, as described in &#147;&#151;Distributions on Common Stock&#148; above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Federal Estate Tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The estates of nonresident alien individuals generally are subject to U.S. federal estate tax on property with a U.S. situs.
Because we are a U.S. corporation, our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be U.S. situs property and, therefore, will be included in the taxable estate of a nonresident alien decedent, unless an
applicable estate tax treaty between the United States and the decedent&#146;s country of residence provides otherwise. The terms &#147;resident&#148; and &#147;nonresident&#148; are defined differently for U.S. federal estate tax purposes than for
U.S. federal income tax purposes. Investors are urged to consult their own tax advisors regarding the U.S. federal estate tax consequences of the ownership or disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, we or certain financial middlemen must report information to the IRS with respect to any dividends we pay on our
common stock or any constructive dividends deemed paid on the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants including the amount of any such dividends, the name and address of the recipient, and the amount, if any, of tax withheld. A
similar report is sent to the holder to whom any such dividends are paid. Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities in the recipient&#146;s country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dividends paid by us (or our paying agents) to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may also be subject
to U.S. backup withholding. U.S. backup withholding generally will not apply to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder who provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as applicable, or otherwise establishes an exemption, provided that the applicable withholding agent does not have actual knowledge or reason to know the holder is a
U.S. person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under current U.S. federal income tax law, U.S. information reporting and backup withholding requirements
generally will apply to the proceeds of a disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants effected by or through a U.S. office of any broker, U.S. or <FONT STYLE="white-space:nowrap">non-U.S.,</FONT>
unless the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as applicable, or otherwise meets documentary evidence requirements for establishing <FONT STYLE="white-space:nowrap">non-U.S.</FONT> person status or
otherwise establishes an exemption. Generally, U.S. information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder where the transaction is
effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker. Information reporting and backup withholding requirements may, however, apply to a
payment of disposition proceeds if the broker has actual knowledge, or reason to know, that the holder is, in fact, a U.S. person. For information reporting purposes, certain brokers with substantial U.S. ownership or operations will generally be
treated in a manner similar to U.S. brokers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Backup withholding is not an additional tax. If backup withholding is
applied to you, you should consult with your own tax advisor to determine whether you have overpaid your U.S. federal income tax, and whether you are able to obtain a tax refund or credit of the overpaid amount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Accounts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition to, and separately from the withholding rules described above, U.S. federal withholding taxes may apply under the Foreign Account Tax Compliance Act, or FATCA, on certain types of payments, including dividends to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends paid in respect of our common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, constructive distributions deemed paid with respect to the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and the gross proceeds of the disposition on our common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants paid to a &#147;foreign financial institution&#148; or a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (1)&nbsp;the
foreign financial institution agrees to undertake certain diligence and reporting obligations, (2)&nbsp;the <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States
owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity
otherwise qualifies for an exemption from these rules. The 30% federal withholding tax described in this paragraph cannot be reduced under an income tax treaty with the United States. If the payee is a foreign financial institution and is subject to
the diligence and reporting requirements in (1)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United States
persons&#148; or &#147;United States-owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT>
foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Treasury Secretary has issued proposed regulations providing that the
withholding provisions under FATCA do not apply with respect to payment of gross proceeds from a sale or other disposition of our notes or common stock, which may be relied upon by taxpayers until final regulations are issued. Prospective investors
should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND
DISPOSING OF OUR COMMON STOCK AND <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> OR U.S. FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS SUCH AS ESTATE AND GIFT TAX. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_11"></A>UNDERWRITERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus supplement, the
underwriters named below, for whom Morgan Stanley&nbsp;&amp; Co. LLC is acting as representative, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares of common stock and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number&nbsp;of<BR>Shares of<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number of<BR><FONT STYLE="white-space:nowrap">Pre-Funded</FONT><BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,496,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,895,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,496,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,895,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters and the representative are collectively referred to as the
&#147;underwriters&#148; and the &#147;representative,&#148; respectively. The underwriters are offering the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants subject to their acceptance of the shares from us and
subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the shares of voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants offered by this prospectus supplement are subject to certain conditions precedent. The underwriters are obligated to take and pay for all of the shares of common stock and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants offered by this prospectus supplement if any such shares and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are taken. However, the underwriters are not required to take or pay for
the shares of common stock, including the number of shares underlying the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants covered by the underwriters&#146; option to purchase additional shares described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters initially propose to offer part of the shares of common stock and
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants directly to the public at the offering price listed on the cover page of this prospectus supplement and part to certain dealers at a price that represents a concession not in excess of
$0.207 per share of common stock or per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant under the public offering price. After the initial offering of the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants, the offering price and other selling terms may from time to time be varied by the representative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have
granted to the underwriters an option, exercisable for 30 days from the date of this prospectus supplement, to purchase up to 2,608,800 additional shares of voting common stock at the public offering price listed on the cover page of this prospectus
supplement, less underwriting discounts and commissions. The number of shares subject to the underwriters&#146; option equals 15% of the total number of shares of common stock plus the number of shares underlying the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional shares of common stock
as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants listed next to the names of all underwriters in the
preceding table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent shares of common stock offered hereby are purchased by existing stockholders that hold
shares of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, such shares may initially be issued in the form of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock that will be convertible into an equivalent number of
shares of our voting common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the per share and
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the
underwriters&#146; option to purchase up to an additional 2,608,800 shares of voting common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share of<BR>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR><FONT STYLE="white-space:nowrap">Pre-Funded</FONT><BR>Warrant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.7500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.7499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,002,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,003,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions to be paid by us<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,200,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,100,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.4050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.4049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,802,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">112,903,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The underwriters will not receive any underwriting discounts or commissions on 2,317,787 shares of common
stock and 11,595,256 pre-funded warrants that investment entities affiliated with our 5% stockholders affiliated with our directors have expressed an interest in purchasing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are approximately
$272,000. We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority of up to $30,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our common stock is listed on The Nasdaq Global Select Market under the trading symbol &#147;PRLD&#148;. The <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock is not listed on any national securities exchange. We do not intend to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on The Nasdaq Global Select Market, any other
nationally recognized securities exchange or any other nationally recognized trading system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and all directors and
officers and certain stockholders have agreed that, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC, on behalf of the underwriters, we and they will not, and will not publicly disclose an intention to, during the period ending
90 days after the date of this prospectus supplement, or the restricted period: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock or any securities
convertible into or exercisable or exchangeable for shares of common stock or <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">file any registration statement with the SEC relating to the offering of any shares of common stock or any
securities convertible into or exercisable or exchangeable for common stock or <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the common stock or <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">whether any such transaction described above is to be settled by delivery of common stock, <FONT STYLE="white-space:nowrap">non-voting</FONT>
common stock or such other securities, in cash or otherwise. In addition, we and each such person agrees that, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC on behalf of the underwriters, we or such other person will not,
during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">References to common stock in the following description refer to both voting and non-voting common stock. The restrictions
described in the immediately preceding paragraph do not apply to our directors, officers and securityholders with respect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions relating to shares of common stock or other securities acquired in the offering or in open market
transactions after the completion of the offering, provided that no filing under Section&nbsp;16(a) of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the Exchange Act shall be required or shall be voluntarily made during the restricted period in connection with subsequent sales of common stock or other securities acquired in the offering or
such open market transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers or dispositions of shares of common stock or any security convertible into or exercisable or
exchangeable for common stock (i)&nbsp;as a bona fide gift or charitable contribution, (ii)&nbsp;by will or intestacy or to any member of the holder&#146;s immediate family or to a trust for the direct or indirect benefit of the holder and/or any
member of the holder&#146;s immediate family, (iii)&nbsp;to any corporation, partnership, limited liability company or other business entity, all of the beneficial ownership interests of which, in each such case, are held by the holder or any member
of the holder&#146;s immediate family, (iv)&nbsp;if the holder is an entity, to limited partners, members, shareholders or holders of similar equity interests in the holder, or (v)&nbsp;if the holder is an entity, to another corporation,
partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act) of the holder, or to any investment fund or other entity controlled or managed by the holder or
affiliated with the holder; provided that, in the case of any transfer or distribution pursuant to this clause, (A)&nbsp;each transferee, donee or distributee shall sign and deliver a substantially similar
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement and (B)&nbsp;no filing under Section&nbsp;16(a) of the Exchange Act reporting a reduction in beneficial ownership of shares of common stock or any securities convertible into or exercisable
or exchangeable for common stock shall be required or shall be voluntarily made during the restricted period (other than, in the case of a transfer or other disposition pursuant to clause (i)&nbsp;above, a Form 4 or clause (ii)&nbsp;above, a Form 5
in each case required to be filed under the Exchange Act if the holder is subject to Section&nbsp;16 reporting with respect to Prelude under the Exchange Act; any such filing will indicate by footnote disclosure or otherwise the nature of the
transfer or disposition); and provided further that any such transfer pursuant to this clause shall not involve a transfer or distribution for value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of shares of common stock or any security convertible into or exercisable or exchangeable for shares
of common stock by operation of law pursuant to a qualified domestic order or other court order or in connection with a divorce settlement; provided that (i)&nbsp;any filing under Section&nbsp;16(a) of the Exchange Act made during the restricted
period shall clearly indicate in the footnotes thereto that (A)&nbsp;the filing relates to the circumstances described in this clause and (B)&nbsp;no securities were sold by the holder, and (ii)&nbsp;the holder does not otherwise voluntarily effect
any other public filing or report regarding such transfers during the restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)&nbsp;the exercise of options or other similar awards or the vesting or settlement of awards granted
pursuant to our equity incentive plans as described in this prospectus supplement and outstanding on the date of the underwriting agreement (including the delivery and receipt of shares of common stock, other awards or any securities convertible
into or exercisable or exchangeable for shares of common stock in connection with such exercise, vesting or settlement), or (ii)&nbsp;the transfer or disposition of shares of common stock or any securities convertible into shares of common stock by
the holder to the company (or the purchase and cancellation of the same by the company) upon a vesting or settlement event of our securities or upon the exercise of options to purchase our securities on a &#147;cashless&#148; or &#147;net
exercise&#148; basis solely to the extent permitted by the instruments representing such options pursuant to our equity incentive plans as described in this prospectus supplement and solely to cover withholding tax obligations in connection with
such transaction and any transfer to the company for the payment of taxes as a result of such transaction, provided that (A)&nbsp;the shares of common stock received upon the exercise or settlement of the option are subject to the same restrictions,
(B)&nbsp;no public disclosure or filing under Section&nbsp;16(a) of the Exchange Act shall be voluntarily made during the restricted period and (C)&nbsp;to the extent a filing under Section&nbsp;16(a) of the Exchange Act is required during the
restricted period as a result of transfers in this clause, it shall clearly indicate that the filing relates to the circumstances described in this clause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers to the company pursuant to the repurchase of shares of common stock in connection with the
termination of the holder&#146;s employment with the company or other service relationship with the company pursuant to contractual agreements with the company as in effect as of the date of this prospectus supplement, provided that no public
disclosure or filing under Section&nbsp;16(a) of the Exchange Act shall be required or shall be voluntarily made during the restricted period; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions in connection with the conversion of <FONT STYLE="white-space:nowrap">non-voting</FONT> common
stock to voting common stock, provided that any such shares of voting common stock received upon such conversion or reclassification remain subject to the same restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilitating the establishment of a trading plan on behalf of a stockholder, officer or director pursuant to
Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of common stock, provided that (i)&nbsp;such plan does not provide for the transfer of common stock during the restricted period and (ii)&nbsp;to
the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the holder or the company regarding the establishment of such plan, such announcement or filing shall include a
statement to the effect that no transfer of common stock may be made under such plan during the restricted period; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers pursuant to a bona fide third-party tender offer for all outstanding shares of common stock or
securities convertible into or exercisable or exchangeable for shares of common stock, merger, amalgamation, consolidation or other similar transaction approved by our board of directors and made to all holders of our securities involving a
&#147;change of control&#148; (as defined in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement) of the company (including, without limitation, the entering into any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar
agreement pursuant to which the holder may agree to transfer, sell, tender or otherwise dispose of shares of common stock or other such securities in connection with such transaction, or vote any shares of common stock or other such securities in
favor of any such transaction); provided that in the event that such tender offer, merger, amalgamation, consolidation or other such transaction is not completed, such securities held by the holder shall remain subject to the same restrictions.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The restrictions on transfers or other dispositions by us described above do not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the securities to be sold in this offering, including the issuance by us of shares of common stock upon the
exercise of the prefunded warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance by us of shares of common stock or securities convertible into or exercisable for shares of
common stock upon the exercise of an option or warrant or the conversion of a security outstanding on the date of this prospectus supplement and described herein; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance by us of shares of common stock or <FONT STYLE="white-space:nowrap">non-voting</FONT> common
stock upon the exchange of any security exchangeable therefor or the conversion of any security convertible therefor pursuant to a contractual arrangement or other right described herein, provided that each recipient of such issuance executes and
delivers a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance by us of shares of voting common stock in connection with a conversion of non-voting common stock
to voting common stock, provided that any such shares of voting common stock received upon such conversion or reclassification shall be subject to the lock-up agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilitating the establishment of a trading plan on behalf of one of our shareholders, officers or directors
pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of common stock, provided that such plan does not provide for the transfer of common stock during the restricted period and, to the
extent a public announcement or filing under the Exchange Act is required of or voluntarily made by us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common stock may
be made under such plan during the restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the grant of any options to purchase shares of common stock or other awards granted under a stock incentive
plan or stock purchase plan described in this prospectus supplement, and the issuance by us of shares of common stock upon the exercise thereof, provided that each recipient of such grant executes and delivers a
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our filing of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor
form relating to the shares of common stock granted pursuant to or reserved for issuance under a stock incentive plan or stock purchase plan described in this prospectus supplement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares of common stock or other securities issued in connection with a transaction with an unaffiliated third
party that includes a debt financing or a bona fide commercial relationship (including joint ventures, marketing or distribution arrangements, collaboration agreements, or intellectual property license agreements) or any acquisition of assets or
acquisition of not less than a majority or controlling portion of the equity of another entity, provided that (1)&nbsp;the aggregate number of shares issued does not exceed 5% of the total number of outstanding shares of our common stock immediately
following the closing of this offering (giving effect to the shares of common stock issuable upon exercise of the pre-funded warrants) and (2)&nbsp;the recipient of any such securities during the restricted period enters into a <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares of common stock in connection with sales under the Sale Agreement, provided no sales shall be made
under the Sale Agreement until the earlier of (i)&nbsp;the exercise in full by the underwriters of their option to purchase additional shares of voting common stock or (ii) 30 days after the date of the underwriting agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Morgan Stanley&nbsp;&amp; Co. LLC, in its sole discretion, may release the common stock and other securities subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to
facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to
purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number of shares available for purchase by the underwriters under the option. The underwriters can close out a
covered short sale by exercising the option or purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared
to the price available under the option. The underwriters may also sell shares in excess of the option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short
position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an
additional means of facilitating this offering, the underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common
stock above independent market levels or prevent or retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A prospectus supplement in electronic format may be made available on websites maintained by one or more
underwriters, or selling group members, if any, participating in this offering. The representative may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions
will be allocated by the representative to underwriters that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which
may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective
affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. For example, one of the
underwriters also served as an underwriter in our initial public offering in September 2020 and in our follow-on offering in January 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may
make or hold a broad array of investments and actively trade debt and equity securities (or related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long and short positions in such
securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or express independent research
views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investment entities affiliated with our 5% stockholders affiliated with our directors have expressed an interest in purchasing
an aggregate of 2,317,787 shares of common stock and 11,595,256 pre-funded warrants in this offering at the public offering price. The underwriter will not receive any underwriting discounts or commissions on securities purchased by such investment
entities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to
Prospective Investors in Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of common stock
<FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrant</FONT> shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of shares of common stock
<FONT STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrant</FONT> shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or
damages if this prospectus supplement or the accompanying prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed
by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or
consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the
government of <FONT STYLE="white-space:nowrap">a&nbsp;non-Canadian&nbsp;jurisdiction,</FONT> section 3A.4) of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts
<FONT STYLE="white-space:nowrap">(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in
connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to each Member State of the European Economic Area (each, a Relevant State), no securities have been offered or
will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Relevant State or, where appropriate,
approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that securities may be offered to the public in that Relevant State at any time under the
following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
Prospectus Regulation), subject to obtaining the prior consent of the underwriter for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>provided</I>&nbsp;that no such offer of securities shall require us or the underwriter to publish a prospectus pursuant to Article 3 of the
Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this provision, the expression an &#147;offer to the
public&#148; in relation to any securities in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to
purchase or subscribe for any securities, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129, as amended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice
to Prospective Investors in the United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No securities have been offered or will be offered pursuant to the
offering to the public in the United&nbsp;Kingdom prior to the publication of a prospectus in relation to the securities which has been approved by the Financial Conduct Authority, except that the securities may be offered to the public in the
United Kingdom at any time under the following exemptions under the UK Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
UK Prospectus Regulation), subject to obtaining the prior consent of the underwriter for any such offer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Section&nbsp;86 of the Financial Services and Markets Act 2000 (the
FSMA), </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>provided</I>&nbsp;that no such offer of the securities shall require us or the underwriter to publish a
prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the securities
in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities and the
expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the UK Prospectus Regulation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the FSMA) in
connection with the issue or sale of any securities may only be communicated or caused to be communicated in circumstances in which Section&nbsp;21(1) of the FSMA does not apply to the Company. Each purchaser of securities must comply with all
applicable provisions of the FSMA and the Financial Services Act 2012 with respect to anything done by it in relation to any securities in, from or otherwise involving the United Kingdom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus supplement is only being distributed to, and is only directed at, persons in the United&nbsp;Kingdom that are
qualified investors as defined in the UK Prospectus Regulation that are also (i)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the Order) or
(ii)&nbsp;high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of the Order or (iii)&nbsp;persons to whom an invitation or inducement to engage in investment activity (within
the meaning of section 21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (each such person being referred to as a &#147;relevant person&#148;). This prospectus
supplement and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a relevant
person should not act or rely on this prospectus supplement or any of its contents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any person in the United Kingdom that
is not a relevant person should not act or rely on the information included in this prospectus supplement or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this prospectus supplement relates
to may be made or taken exclusively by relevant persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of common stock <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrant</FONT> shares have not been
offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the SFO) of
Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong
(the CO) or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the securities has been or may be issued or has been or may be in the possession of any person for the
purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with
respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of common stock <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrant</FONT> shares have not been and
will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares of common stock <FONT STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrant</FONT> shares nor any interest
therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under
the laws of Japan), or to others <FONT STYLE="white-space:nowrap">for&nbsp;re-offering&nbsp;or</FONT> resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration
requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For Qualified Institutional Investors, or QII </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the
FIEL) in relation to the shares of common stock constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph 1, Article <FONT STYLE="white-space:nowrap">23-13</FONT> of
the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock. The shares of common stock may only be transferred to QIIs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For <FONT STYLE="white-space:nowrap">Non-QII</FONT> Investors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the
FIEL) in relation to the shares of common stock constitutes either a &#147;small number private placement&#148; or a &#147;small number private secondary distribution&#148; (each as is described in Paragraph 4,
<FONT STYLE="white-space:nowrap">Article&nbsp;23-13</FONT> of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article&nbsp;4 of the FIEL, has not been made in relation to the shares of common stock.
The shares of common stock may only be transferred en bloc without subdivision to a single investor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore Securities and Futures Act
Production Classification </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Solely for the purposes of its obligations pursuant to sections 309B(1)(a) and
309B(1)(c) of the Securities and Futures Act (Chapter 289 of Singapore) (the SFA), we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A of the SFA) that the shares of common stock
<FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrants</FONT> are &#147;prescribed capital markets products&#148; (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as
defined in MAS Notice <FONT STYLE="white-space:nowrap">SFA&nbsp;04-N12:&nbsp;Notice</FONT> on the Sale of Investment Products and MAS <FONT STYLE="white-space:nowrap">Notice&nbsp;FAA-N16:&nbsp;Notice</FONT> on Recommendations on Investment
Products).<B><I> </I></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of common stock <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrant</FONT> shares may not be publicly
offered in Switzerland and will not be listed on the SIX Swiss Exchange (SIX) or on any other stock exchange or regulated trading facility </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
in Switzerland. This prospectus supplement does not constitute a prospectus within the meaning of, and has been prepared without regard to, the disclosure standards for issuance prospectuses
under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in
Switzerland. Neither this prospectus supplement nor any other offering or marketing material relating to the shares of common stock and&nbsp;pre-funded&nbsp;warrant shares or the offering may be publicly distributed or otherwise made publicly
available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither this prospectus supplement nor any other offering or marketing material relating to the
offering, the Company, the shares of common stock or <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrant</FONT> shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus
supplement will not be filed with, and the offer of shares of common stock <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrant</FONT> shares will not be supervised by, the Swiss Financial Market Supervisory Authority, and the offer of
these securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (CISA). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend
to acquirers of shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the Dubai International Financial Centre </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus supplement relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services
Authority, or DFSA. This prospectus supplement is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for
reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this prospectus supplement. The
securities to which this prospectus supplement relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not
understand the contents of this prospectus supplement, you should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to
its use in the DIFC, this prospectus supplement is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient and may not be reproduced or used
for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to
Prospective Investors in Australia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus supplement and the accompanying prospectus: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not constitute a disclosure document under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the
Corporations Act); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission (ASIC), as a
disclosure document for the purposes of the Corporations Act, and does not purport to include the information required of a disclosure document under Chapter 6D.2 of the Corporations Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or
more of the categories of investors, or Exempt Investors, available under section 708 of the Corporations Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of common stock <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrant</FONT> shares may not be directly
or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the shares of common stock <FONT STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrant</FONT> shares may be issued, and no draft or
definitive offering memorandum, advertisement or other offering material relating to any securities may be distributed in Australia, except where disclosure to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the
securities, you represent and warrant to us that you are an Exempt Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As any offer of shares of common stock <FONT
STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrant</FONT> shares under this prospectus supplement will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia
within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the shares you undertake to us that you will not,
for a period of 12 months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those securities to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the
Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Israel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the State of Israel this prospectus supplement shall not be regarded as an offer to the public to purchase common shares <FONT
STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrant</FONT> shares under the Israeli Securities Law, 5728-1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain
provisions of Section&nbsp;15 of the Israeli Securities Law, 5728-1968, including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed Investors; or
(ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728-1968, subject to certain conditions, or the &#147;Qualified Investors.&#148; The Qualified
Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. We have not and will not take any action that would require it to publish a
prospectus in accordance with and subject to the Israeli Securities Law, 5728- 1968. We have not and will not distribute this prospectus supplement or make, distribute or direct an offer to subscribe for our common shares <FONT
STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrant</FONT> shares to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the
Israeli Securities Law, 5728-1968. In particular, we may request, as a condition to be offered common shares <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrant</FONT> shares, that Qualified Investors will each represent, warrant and
certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728-1968; (ii) which of the categories listed in the First
Addendum to the Israeli Securities Law, 5728-1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728-1968 and the regulations promulgated thereunder in
connection with the offer to be issued common shares <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrant</FONT> shares; (iv)&nbsp;that the common shares <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrant</FONT> shares
that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728-1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale within the State of Israel, other
than in accordance with the provisions of the Israeli Securities Law, 5728-1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of
their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The validity of the common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered hereby and certain
legal matters in connection with this offering will be passed upon by Fenwick&nbsp;&amp; West LLP, San Francisco, California. Cooley LLP, New York, New York is acting as counsel for the underwriter in connection with this offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our financial statements included in
our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, as set forth in their report, which is incorporated by reference in this prospectus supplement and elsewhere in the registration
statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> <FONT
STYLE="white-space:nowrap">(Registration&nbsp;No.&nbsp;333-261019)&nbsp;under</FONT> the Securities Act with respect to the shares of common stock offered hereby. This prospectus supplement, which constitutes a part of the registration statement,
does not contain all of the information set forth in the registration statement or the exhibits filed therewith. For further information about us and the shares of common stock offered hereby, reference is made to the accompanying prospectus and
registration statement of which it is a part and the exhibits filed therewith. Statements contained in this prospectus supplement regarding the contents of any contract or any other document that is filed as an exhibit to the accompanying prospectus
and the registration statement of which it is a part are not necessarily complete, and in each instance we refer you to the copy of such contract or other document filed as an exhibit to the registration statement or the exhibits to the reports or
other documents incorporated by reference in this prospectus supplement for a copy of such contract or other document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
are subject to the informational requirements of the Exchange Act and are required to file annual, quarterly and other reports, proxy statements and other information with the SEC. The SEC maintains an Internet site (http://www.sec.gov) that
contains reports, proxy and information statements, and various other information about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Information about us is also
available at our website at www.preludetx.com. However, the information on our website is not a part of this prospectus supplement and is not incorporated by reference into this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom487902_15"></A>INCORPORATION OF INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The SEC allows us to &#147;incorporate by reference&#148; information that we file with the SEC, which means that we can
disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus supplement and the accompanying prospectus, and information we file later with the SEC
will automatically update and supersede this information. A Current Report (or portion thereof) furnished, but not filed, on Form <FONT STYLE="white-space:nowrap">8-K</FONT> shall not be incorporated by reference into this prospectus supplement and
the accompanying prospectus. We incorporate by reference the documents listed below and any future filings we make with the SEC under Section&nbsp;13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of any offering of shares of
common stock made by this prospectus supplement and accompanying prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001678660/000095017023007989/prld-20221231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2022, filed with the SEC on March&nbsp;15, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001678660/000095017023018478/prld-20230331.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the fiscal quarter ended March&nbsp;31, 2023, filed with the SEC on May&nbsp;8, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Preliminary Proxy Statement on Schedule 14A, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000095017023013260/preliminary_2023_proxy.htm">April&nbsp;18,
 2023</A> and our Definitive Proxy Statement on Schedule 14A, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000095017023015497/def_proxy_2023.htm">April&nbsp;28, 2023</A> (but, in each case, only with respect to
information required by Part III of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, which information shall update and supersede information included in Part&nbsp;III of our Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000095017023001023/prld-20230119.htm">January&nbsp;23,
 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001678660/000119312523071400/d405925d8k.htm">March&nbsp;
15, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000095017023007983/prld-20230315.htm">March&nbsp;
15, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000119312523146980/d488347d8k.htm">May&nbsp;17, 2023</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000119312520246935/d899345d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on September&nbsp;16, 2020 under Section&nbsp;12(b) of the Exchange Act, as the description therein has been updated and superseded by the description of our capital stock contained
in <A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000095017023007989/prld-ex4_4.htm">Exhibit 4.4</A> of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2022, as filed with
the SEC on March&nbsp;15, 2023, including any amendment or report filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will furnish without charge to you, on written or oral request, a copy of any or all of such documents that has been
incorporated herein by reference in this prospectus supplement (other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus supplement incorporates). Written or oral
requests for copies should be directed to Prelude Therapeutics Incorporated, Attn: Chief Legal Officer, 200 Powder Mill Road Wilmington, Delaware 19803, and our telephone number is (302) <FONT STYLE="white-space:nowrap">467-1280.</FONT> See the
section of this prospectus supplement entitled &#147;Where You Can Find More Information&#148; for information concerning how to read and obtain copies of materials that we file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any statement contained in this prospectus supplement, or in a document all or a portion of which is incorporated by
reference, shall be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such
statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$400,000,000 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g487902g42h54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Prelude Therapeutics Incorporated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock, Preferred Stock, </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities, Warrants, Subscription Rights and Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>31,574,631 shares of Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Offered by the Selling Stockholders </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">From time to
time, we may offer up to $400,000,000 aggregate dollar amount of shares of our common stock or preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase our common
stock, preferred stock or debt securities and/or units consisting of some or all of these securities, in any combination, together or separately, in one or more offerings, in amounts, at prices and on the terms that we will determine at the time of
the offering and which will be set forth in a prospectus supplement and any related free writing prospectus. This prospectus describes the general manner in which those securities may be offered using this prospectus. We will specify in an
accompanying prospectus supplement and any related free writing prospectus the terms of securities offered and the offering thereof and may also add, update or change information contained in this prospectus. The total amount of these securities
will have an initial aggregate offering price of up to $400,000,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">In addition, this prospectus relates to the offer and sale from time
to time of up to 31,574,631 shares of common stock under this prospectus by the selling stockholders identified in the &#147;Selling Stockholders&#148; section of this prospectus or their permitted transferees, pledgees, donees or other successors
in interest. The selling stockholders or their permitted transferees, pledgees, donees or other successors in interest may sell the shares of common stock in a number of different ways and at varying prices. We provide more information about how the
selling stockholders may sell the shares of common stock in the section of this prospectus titled &#147;Selling Stockholders Plan of Distribution.&#148; We will not receive any of the proceeds from the sale of our common stock by the selling
stockholders. We have paid or will pay the fees and expenses incident to the registration of the shares of common stock for sale by the selling stockholders. The selling stockholders will bear all discounts, concessions, commissions and stock
transfer taxes, if any, attributable to its sales of shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">You should read this prospectus, the information incorporated, or deemed to be
incorporated, by reference in this prospectus, and any applicable prospectus supplement and related free writing prospectus carefully before you invest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#147;PRLD.&#148; On November&nbsp;11, 2021, the last reported
sales price for our common stock was $16.76 per share. None of the other securities we may offer are currently traded on any securities exchange. The applicable prospectus supplement and any related free writing prospectus will contain information,
where applicable, as to any other listing on The Nasdaq Global Select Market or any securities market or exchange of the securities covered by the prospectus supplement and any related free writing prospectus. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>An investment in our securities involves a high degree of risk. You should carefully consider the information under the heading &#147;<A HREF="#tx487902_3">Risk
 Factors</A>&#148; beginning on page 6 of this prospectus before investing in our securities. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Common stock, preferred stock, debt
securities, warrants, subscription rights and/or units may be sold by us, or the selling stockholders to or through underwriters or dealers, directly to purchasers or through agents designated from time to time. For additional information on the
methods of sale, you should refer to the section entitled &#147;Plan of Distribution&#148; in this prospectus. If any underwriters, dealers or agents are involved in the sale of any securities with respect to which this prospectus is being
delivered, the names of such underwriters or agents and any applicable fees, discounts or commissions, details regarding over-allotment options, if any, and the net proceeds to us will be set forth in a prospectus supplement. The price to the public
of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is November 24, 2021 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_4">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_5">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_6">INCORPORATION OF INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_8">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_10">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_11">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_12">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_13">DESCRIPTION OF SUBSCRIPTION RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_14">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_15">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx487902_16">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a
&#147;shelf&#148; registration process. Under this shelf registration process, from time to time, we may sell any combination of the securities described in this prospectus in one or more offerings, up to a total dollar amount of $400,000,000, and
the selling stockholders may sell up to 31,574,631 shares of our common stock from time to time in one or more offerings as described in this prospectus. We have provided to you in this prospectus a general description of the securities we may
offer. Each time we, or the selling stockholders, sell securities under this shelf registration process, we, or the selling stockholders, will provide a prospectus supplement that will contain specific information about the terms of the offering.
We, or the selling stockholders, may also add, update or change in the prospectus supplement any of the information contained in this prospectus. To the extent there is a conflict between the information contained in this prospectus and the
prospectus supplement, you should rely on the information in the prospectus supplement; <I>provided</I> that, if any statement in one of these documents is inconsistent with a statement in another document having a later date&nbsp;-&nbsp;for
example, a document incorporated by reference in this prospectus or any prospectus supplement&nbsp;-&nbsp;the statement in the document having the later date modifies or supersedes the earlier statement. You should read both this prospectus and any
prospectus supplement together with additional information described under the heading &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we, nor any agent, the selling stockholders, underwriter or dealer have authorized anyone to give you any information or to make any
representation other than the information and representations contained in or incorporated by reference into this prospectus or any applicable prospectus supplement. We and any agent, the selling stockholders, underwriter or dealer take no
responsibility for, and can provide no assurance as to the reliability of, any other information others may give you. You may not imply from the delivery of this prospectus and any applicable prospectus supplement, nor from a sale made under this
prospectus and any applicable prospectus supplement, that our affairs are unchanged since the date of this prospectus and any applicable prospectus supplement or that the information contained in any document incorporated by reference is accurate as
of any date other than the date of the document incorporated by reference, regardless of the time of delivery of this prospectus and any applicable prospectus supplement or any sale of a security. This prospectus and any applicable prospectus
supplement may only be used where it is legal to sell the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>THIS PROSPECTUS MAY NOT BE USED TO OFFER AND SELL SECURITIES
UNLESS IT IS ACCOMPANIED BY AN ADDITIONAL PROSPECTUS OR A PROSPECTUS SUPPLEMENT. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus, unless the context otherwise
requires, the terms &#147;Prelude,&#148; &#147;Prelude Therapeutics,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Prelude Therapeutics Incorporated, a Delaware corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained in other parts of this prospectus or incorporated by reference in this prospectus from our<A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000156459021013330/prld-10k_20201231.htm">
<U>Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December 31, 2020</U></A><U></U>, our <U><A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000156459021056509/prld-10q_20210930.htm">Quarterly
 Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended September</A></U><A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000156459021056509/prld-10q_20210930.htm" ><U></U>
<U>&nbsp;30, 2021</U></A><U></U> and our other filings with the SEC listed below under the heading &#147;Incorporation of Information by Reference.&#148; This summary may not contain all the information that you should consider before investing in
securities. You should read the entire prospectus and the information incorporated by reference in this prospectus carefully, including &#147;Risk Factors&#148; and the financial data and related notes and other information incorporated by
reference, before making an investment decision. See &#147;Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key
driver mechanisms in cancers with high unmet need. By leveraging our core competencies in cancer biology and medicinal chemistry, combined with our target class- and technology platform-agnostic approach, we have built an efficient, fully-integrated
drug discovery engine to identify compelling biological targets and create new chemical entities, or NCEs, that we rapidly advance into clinical development. We believe our approach could result in better targeted cancer therapies. Our discovery
excellence has been validated by our rapid progress in creating a wholly-owned, internally developed pipeline. Since our inception in 2016, we have received clearance from the U.S. Food and Drug Administration, or the FDA, for four investigational
new drug applications, or INDs, and successfully advanced these programs into clinical development. In addition, we have three unique programs in various stages of preclinical development that we plan to advance into clinical development beginning
in 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By focusing on developing agents using broad mechanisms that have multiple links to oncogenic driver pathways in select
patients, we have developed a diverse pipeline consisting of six distinct programs spanning methyltransferases, kinases, protein-protein interactions and targeted protein degraders. Our pipeline is geared towards serving patients with high unmet
medical need where there are limited or no treatment options. We are exploring therapies in both solid tumors and hematological malignancies such as adenoid cystic carcinoma, or ACC, homologous recombination deficient positive, or HRD+, cancers,
myelofibrosis, or MF, and glioblastoma multiforme, or GBM, amongst others. We believe we can best address these diseases by developing therapies that target primary and secondary resistance mechanisms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidates are designed to be oral, potent and selective inhibitors of protein arginine methyltransferase 5, or PRMT5. The
potency and selectivity of our product candidates is supported by preclinical data demonstrating nanomolar inhibition of PRMT5 and no inhibition of related enzymes at 1,000 times higher concentration of our product candidates. Updated data from the
dose escalation phase of the ongoing Phase 1 trial of PRT543 was presented at the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AACR-NCI-EORTC</FONT></FONT> Virtual International Conference on Molecular Targets and Cancer
Therapeutics held October&nbsp;7, 2021 through October&nbsp;10, 2021. As of an August&nbsp;6, 2021 data cutoff date, the dose escalation portion of the ongoing Phase 1 trial of PRT543 enrolled a total of 49 patients across 18 unselected advanced
solid tumors and lymphoma. Patients enrolled received an average of three prior lines of therapy. PRT543 demonstrated target engagement and inhibition of PRMT5 functional activity as evidenced by a 69% reduction in serum symmetric dimethylarginine,
or sDMA, at a dose of 45 mg/5x per week. In addition, PRT543 demonstrated signs of preliminary clinical activity, including a durable complete response, or CR, maintained for over 18 months in a patient with HRD+ ovarian cancer who remains on
treatment and prolonged stable disease, or SD, persisting for over six months in five patients, including four patients with ACC and one patient with uveal melanoma. A complete response is defined as the disappearance of all target lesions. PRT543
was generally well tolerated: the most common grade 3 or higher treatment-related adverse events, or AE, </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
occurring in at least 5% of patients were thrombocytopenia (27%) and anemia (12%), both of which were reversible upon treatment interruption. Patients were largely able to remain on therapy with
few <FONT STYLE="white-space:nowrap">AE-related</FONT> dose interruptions (27%), reductions (22%), or discontinuations (4%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient
enrollment is continuing in specific biomarker-selected solid tumor and hematologic malignancy expansion cohorts. We anticipate presenting data from the expansion cohorts of the trial at medical meetings throughout 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also advancing PRT811, a second PRMT5 inhibitor that we have optimized for high brain exposure, in a Phase 1 clinical trial in solid
tumors, including GBM. Updated data from the dose escalation phase of the ongoing Phase 1 trial of PRT811 was presented at the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">AACR-NCI-EORTC</FONT></FONT> Virtual International
Conference on Molecular Targets and Cancer Therapeutics held October&nbsp;7, 2021 through October&nbsp;10, 2021. As of an August&nbsp;13, 2021 data cutoff date, the dose escalation portion of the ongoing Phase 1 trial of PRT811 enrolled a total of
45 patients, including 27 patients across 16 unselected advanced solid tumors and 18 patients with high-grade gliomas, including 17 patients with glioblastoma multiforme, or GBM. PRT811 demonstrated dose dependent inhibition of PRMT5 activity as
evidenced by an 83% reduction in serum sDMA at a dose of 600 mg daily (QD). In addition, PRT811 demonstrated signs of preliminary clinical activity, including an IDH1 mutated GBM patient who experienced a partial response, or PR, that evolved into a
durable CR for more than 13 months and remains on treatment. In addition, a patient with splicing-mutant, or SF3B1, uveal melanoma demonstrated SD for more than six months with a 25% tumor regression and remains on treatment. At a post data-cutoff
on September&nbsp;20, 2021, one additional patient (800 mg QD) with SF3B1 uveal melanoma had an unconfirmed PR and 47% decrease in target lesion, and a patient with triple negative breast cancer (800 mg QD) demonstrated a 27% decrease in target
lesions. Both patients continue treatment. PRT811 was generally well-tolerated; the most common grade 3 or higher treatment-related AE was thrombocytopenia (7%), which was reversible upon treatment interruption. Patients were largely able to remain
on therapy with few <FONT STYLE="white-space:nowrap">AE-related</FONT> dose interruptions (13%), reductions (4%), or discontinuations (3%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The study remains ongoing, and the Company expects to commence enrollment in the expansion portion of the trial in the fourth quarter of 2021.
Data from the expansion cohorts are expected to be presented at medical meetings throughout 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PRT1419, our third clinical candidate,
is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. The potency and selectivity of PRT1419 is supported by preclinical data demonstrating nanomolar inhibition of MCL1 and no inhibition of related enzymes at 200
times higher concentration of our product candidate. We have begun enrolling patients with hematologic malignancies, including patients with myelodysplastic syndrome, or MDS, acute myeloid leukemia, or AML,
<FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphoma, or NHL, and multiple myeloma, or MM, into the dose escalation portion of a Phase 1 open-label, multicenter clinical trial for the oral formulation of PRT1419. We expect to add dose
expansion and combination cohorts to the Phase 1 clinical trial in the second half of 2021. Additionally, in March 2021, the FDA cleared our IND for an intravenous, or IV, formulation of PRT1419. The Phase 1 trial of the IV formulation of PRT1419,
which leverages the optimized physicochemical properties of PRT1419, is now underway in patients with solid tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently received
clearance for an IND application for our fourth clinical candidate, PRT2527. We remain on track to initiate a clinical trial for PRT2527 by year end. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Securities We May Offer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With this
prospectus, we may offer common stock, preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase our common stock, preferred stock or debt securities, and/or units
consisting of some or all of these securities in any combination. The </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate offering price of securities that we offer with this prospectus will not exceed $400,000,000. Each time we offer securities with this prospectus, we will provide offerees with a
prospectus supplement that will contain the specific terms of the securities being offered. The following is a summary of the securities we may offer with this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Common Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer shares of our
common stock, par value $0.0001 per share. We have two classes of common stock: the voting common stock and the <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock. For a description of the rights of the voting common stock and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock, please see &#147;Description of Capital Stock&#148; beginning on page 18 of this prospectus. Unless otherwise noted, all references in this prospectus to our &#147;common stock&#148; refer
to our voting common stock. The <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock is not listed for trading on any securities exchange. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer shares of
our preferred stock, par value $0.0001 per share, in one or more series. Our board of directors or a committee designated by the board will determine the dividend, voting, conversion and other rights of the series of shares of preferred stock being
offered. Each series of preferred stock will be more fully described in the particular prospectus supplement that will accompany this prospectus, including redemption provisions, rights in the event of our liquidation, dissolution or the winding up,
voting rights and rights to convert into common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Debt Securities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer general obligations, which may be secured or unsecured, senior or subordinated and convertible into shares of our common stock or
preferred stock. In this prospectus, we refer to the senior debt securities and the subordinated debt securities together as the &#147;debt securities.&#148; Our board of directors will determine the terms of each series of debt securities being
offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under an indenture between us and a trustee. In this document, we have summarized general
features of the debt securities from the indenture. We encourage you to read the indenture, which is an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer warrants for the
purchase of debt securities, shares of preferred stock or shares of common stock. We may issue warrants independently or together with other securities. Our board of directors will determine the terms of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Subscription Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer
subscription rights for the purchase of common stock, preferred stock or debt securities. We may issue subscription rights independently or together with other securities. Our board of directors will determine the terms of the subscription rights.
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Units </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer units consisting of some or all of the securities described above, in any combination, including common stock, preferred stock,
warrants and/or debt securities. The terms of these units will be set forth in a prospectus supplement. The description of the terms of these units in the related prospectus supplement will not be complete. You should refer to the applicable form of
unit and unit agreement for complete information with respect to these units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were formed under the laws of the State of Delaware in February 2016. Our principal executive offices are located at 200 Powder Mill Road,
Wilmington, Delaware, 19803, and our telephone number is (302) <FONT STYLE="white-space:nowrap">467-1280.</FONT> Our website address is www.preludetx.com. The information contained on, or that can be accessed through, our website is not part of, and
is not incorporated by reference into, this prospectus. Investors should not rely on any such information in deciding whether to purchase our securities. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of securities will
contain a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading &#147;Risk Factors&#148; in
the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks,
uncertainties and assumptions discussed under Part II, Item 1A, &#147;Risk Factors,&#148; in our <U><A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000156459021056509/prld-10q_20210930.htm">Quarterly Report
 on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September</A></U><A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000156459021056509/prld-10q_20210930.htm" ><U></U><U>&nbsp;
30, 2021</U></A><U></U>, which is incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. The risks and uncertainties we have described are not the only
ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_4"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and documents incorporated herein by reference contain &#147;forward-looking statements&#148; within the meaning of the
Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results
could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such statements include, but are not limited to, statements regarding expectations and intentions, costs and expenses, outcome of
contingencies, financial condition, results of operations, liquidity, objectives of management, debt financing, our future results of operations and financial position, the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic,
business strategies, market size, potential growth opportunities, clinical development activities, efficacy and safety profile of our product candidates, timing and results of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and
clinical trials, the receipt and timing of potential regulatory designations, our ability to maintain and recognize the benefits of certain designations received by product candidates, the achievement of clinical and commercial milestones, the
advancement of our technologies and our proprietary product candidates, the successful achievement of the goals of our collaborations, the advancement of the product candidates that are the subjects of these collaborations, the approvals and
commercialization of product candidates and other statements that are not historical facts. You can find many of these statements by looking for words like &#147;believes,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;estimates,&#148;
&#147;may,&#148; &#147;might,&#148; &#147;should,&#148; &#147;will,&#148; &#147;could,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;project,&#148; &#147;seek&#148; or similar expressions in this prospectus, in documents incorporated by
reference into this prospectus or any free writing prospectus. We intend that such forward-looking statements be subject to the safe harbors created thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on the current beliefs and expectations of our management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results may differ materially from current expectations and projections. Factors that might cause such a difference include those
discussed in Part II, Item 1A, &#147;Risk Factors,&#148; in <U><A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000156459021056509/prld-10q_20210930.htm">Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September</A></U><A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000156459021056509/prld-10q_20210930.htm" ><U></U><U>&nbsp;30,
2021</U></A><U></U>, as well as those discussed in this prospectus, the documents incorporated by reference into this prospectus and any free writing prospectus. You are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this prospectus or, in the case of documents referred to or incorporated by reference, the date of those documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in
their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this
prospectus or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities law. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional
updates with respect to those or other forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_5"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with respect
to the securities offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, the exhibits filed therewith or the documents incorporated by
reference therein. For further information about us and the securities offered hereby, reference is made to the registration statement, the exhibits filed therewith and the documents incorporated by reference therein. Statements contained in this
prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and in each instance, we refer you to the copy of such contract or other document filed
as an exhibit to the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the informational requirements of the Securities Exchange Act of 1934, as
amended, or the Exchange Act and are required to file annual, quarterly and other reports, proxy statements and other information with the SEC. The SEC maintains an Internet site (http://www.sec.gov) that contains reports, proxy and information
statements, and various other information about us. You may also inspect the documents described herein at our principal executive offices, 200 Powder Mill Road, Wilmington, Delaware, 19803, during normal business hours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about us is also available at our website at http://www.preludetx.com. However, the information on our website is not a part of
this prospectus and is not incorporated by reference into this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_6"></A>INCORPORATION OF INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information that we file with the SEC, which means that we can disclose important
information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information we file later with the SEC will automatically update and supersede this information. A
Current Report (or portion thereof) furnished, but not filed, on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> shall not be incorporated by reference into this prospectus. We incorporate by reference the documents listed below and any future
filings we make with the SEC under Section&nbsp;13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of any offering of securities made by this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000156459021013330/prld-10k_20201231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2020, filed with the SEC on March 16, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000156459021026308/prld-10q_20210331.htm">March&nbsp;31,
 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000156459021043718/prld-10q_20210630.htm">June&nbsp;
30, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000156459021056509/prld-10q_20210930.htm">September&nbsp;30, 2021</A>, filed with the SEC on May&nbsp;11, 2021, August&nbsp;12, 2021 and
November&nbsp;12, 2021, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000119312521020863/d116309d8k.htm">January&nbsp;28,
 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000119312521073187/d152125d8k.htm">March&nbsp;8, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000119312521196185/d182680d8k.htm">June&nbsp;
22, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000119312521218690/d172272d8k.htm">July&nbsp;
19, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000119312521275680/d198573d8k.htm">September&nbsp;
17, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1678660/000156459021056478/prld-8k_20211105.htm">November&nbsp;12, 2021</A> (solely with respect to Item 5.02); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000119312521140361/d167512ddef14a.htm">Schedule
 14A</A>, filed with the SEC on April&nbsp;30, 2021 (but only with respect to information required by Part III of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020, which information
updated and superseded information included in Part III of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000119312520246935/d899345d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT> </A>filed with the SEC on September&nbsp;16, 2020 under Section&nbsp;12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000095017023007989/prld-ex4_4.htm">Exhibit&nbsp;4.4</A>&nbsp;to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">filings we make with the SEC pursuant to the Exchange Act after the date of the initial registration statement,
of which this prospectus is a part, and prior to the effectiveness of the registration statement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish
without charge to you, on written or oral request, a copy of any or all of such documents that has been incorporated herein by reference (other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the
documents that this prospectus incorporates). Written or oral requests for copies should be directed to Prelude Therapeutics Incorporated, 200 Powder Mill Road, Wilmington, Delaware, 19803, and our telephone number is (302) <FONT
STYLE="white-space:nowrap">467-1280.</FONT> See the section of this prospectus entitled &#147;Where You Can Find More Information&#148; for information concerning how to obtain copies of materials that we file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in this prospectus, or in a document, all or a portion of which is incorporated by reference, shall be modified or
superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or
superseded shall not, except as so modified or superseded, constitute a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds to us from the sale of our securities under this prospectus. Unless otherwise
provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of securities under this prospectus for general corporate purposes, which may include funding research, clinical and process development and
manufacturing of our product candidates, increasing our working capital, reducing indebtedness as applicable, acquisitions or investments in businesses, products or technologies that are complementary to our own and capital expenditures. We will set
forth in the applicable prospectus supplement our intended use for the net proceeds received from the sale of any securities. We will not receive any of the proceeds from the sale of common stocks being offered by any of the selling stockholders.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_8"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the <FONT STYLE="white-space:nowrap">Post-IPO</FONT> Registration Rights Agreement, or
<FONT STYLE="white-space:nowrap">Post-IPO</FONT> RRA, between us and each of Baker Brothers and its affiliates, or Baker Bros., OrbiMed and its affiliates, or OrbiMed, and Kris Vaddi and his affiliated entities, the RRA Investors are entitled to
rights, or the <FONT STYLE="white-space:nowrap">RRA-Investors&#146;</FONT> rights, with respect to the registration of their shares under the Securities Act that supersede such rights as described above held by the RRA Investors under the amended
and restated investors rights agreement by and among us and certain of our shareholders, or the investors rights agreement. These registration rights include the right to demand that we file with the SEC a Form
<FONT STYLE="white-space:nowrap">S-3</FONT> registration statement (except if we are not then eligible to register for resale the registrable securities on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> in which case, such registration shall be
on another appropriate form in accordance with the Securities Act) covering the registration of their registrable securities for resale, subject to certain conditions. In accordance with this obligation, this prospectus also relates to the possible
resale by Baker Bros or OrbiMed, who we refer to in this prospectus as the &#147;selling stockholders,&#148; of up to 31,574,631 shares of our common stock held by such holders. Kris Vaddi and his affiliated entities have waved the <FONT
STYLE="white-space:nowrap">RRA-Investors&#146;</FONT> rights in connection with the filing of this prospectus with respect to the shares held by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the number of shares of common stock beneficially owned by the selling stockholders, the number of shares of
common stock that may be offered under this prospectus and the number of shares of common stock beneficially owned by the selling stockholders assuming all of the shares covered hereby are sold. Percentage ownership of our common stock is based on
47,215,352 shares of our common stock outstanding on November&nbsp;2, 2021 (of which 11,402,037 shares are <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock). We have determined beneficial ownership in accordance with the rules of the
SEC, and thus it represents sole or shared voting or investment power with respect to our securities, and the information is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our
knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable. We have deemed all shares of common stock
subject to options or other convertible securities held by that person or entity that are currently exercisable or that will become exercisable within 60 days of November&nbsp;2, 2021 to be outstanding and to be beneficially owned by the person or
entity holding the option for the purpose of computing the percentage ownership of that person or entity but have not treated them as outstanding for the purpose of computing the percentage ownership of any other person or entity. The number of
shares of common stock in the column &#147;Shares of common stock being offered by the selling stockholders&#148; represents all of the common stock shares that the selling stockholders may offer hereunder. The selling stockholders may sell some,
all or none of the common stock shares that may be offered hereunder. We do not know when the common stock shares will be sold by the selling stockholders, and the selling stockholders may offer the common stock shares from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no conversion rights, while holders of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock
have the right to convert each share of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock into one share of common stock at such holder&#146;s election, provided that as a result of such conversion, such holder, together with its
affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 9.99% of our common stock immediately prior to and following such conversion, unless otherwise as expressly provided for in our restated
certificate of incorporation. However, this ownership limitation may be increased (not to exceed 19.99%) or decreased to any other percentage designated by such holder of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock upon 61
days&#146; notice to us. The information under the heading &#147;13(d) beneficial ownership&#148; in the table below presents the beneficial ownership of the selling stockholders reflecting the 9.99% limitation. Solely for purposes of the table
below, the information under the headings &#147;Beneficial ownership before the offering&#148; and &#147;Beneficial ownership after the offering&#148; disregards the 9.99% limitation. Unless otherwise indicated, the address of each beneficial owner
listed in the table below is c/o Prelude Therapeutics Incorporated, 200 Powder Mill Road, Wilmington, Delaware 19803. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information set
forth below is based upon information obtained from the selling stockholders and upon information known to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Julian Baker, a member of our board of directors, is affiliated with Baker Bros., and David
Bonita, M.D., a member of our board of directors, is affiliated with OrbiMed. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial<BR>ownership<BR>after<BR>the<BR>offering(2)(3)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>13(d) beneficial<BR>ownership(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial ownership<BR>before the<BR>offering(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>shares<BR>being<BR>offered by<BR>the selling<BR>stockholders</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Selling Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Bros. Advisors LP and Affiliates(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,716,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,854,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,854,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Entities(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,716,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,719,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,719,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the 9.99% limitation on beneficial ownership described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Solely for purposes of this table, disregards the 9.99% limitation on beneficial ownership described above.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes that all shares being registered in this prospectus are resold to third parties and that the selling
stockholders sell all shares of common stock registered under this prospectus held by them or that they may acquire upon conversion of other classes of our common stock held by them. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information contained on a Schedule 13D/A filed January&nbsp;29, 2021. Represents (i) 14,267 shares of
voting common stock subject to options that are exercisable within 60 days of November&nbsp;2, 2021 and 5,188 shares of voting common stock from exercise of options, (ii) 870,873 shares of our voting common stock and 509,480 shares of our <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock held by 667, L.P. (&#147;667&#148;) and (iii) 9,247,763 shares of our voting common stock and 5,212,371 shares of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by
Baker Brothers Life Sciences, L.P. (&#147;Life Sciences&#148;, and together with 667the &#147;Baker Funds&#148;). Baker Bros. Advisors LP, or the Adviser, serves as the investment adviser to the Baker Funds and has complete and unlimited discretion
and authority with respect to their investments and voting power over the securities held by the Baker Funds. Baker Bros. Advisors (GP) LLC, or the Adviser GP, is the sole general partner of the Adviser. Julian C. Baker and Felix J. Baker are the
managing members of the Adviser GP. The shares of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock are only convertible to voting common stock to the extent that after giving effect to such conversion the holders thereof, together
with their affiliates and any members of a Section&nbsp;13(d) group with such holders, would beneficially own, for purposes of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Securities Exchange Act of 1934, as amended, no more than
9.99% of the outstanding shares of common stock (the &#147;Beneficial Ownership Limitation&#148;). By written notice to the Company, the Baker Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that
Baker Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Company. Julian C. Baker is also a member of our board of directors. Julian C. Baker, Felix J.
Baker, the Adviser GP and the Adviser disclaim beneficial ownership of these securities held directly by the Baker Funds, except to the extent of their pecuniary interest therein. The address for the Adviser, the Adviser GP, Felix J. Baker and
Julian C. Baker is c/o Baker Bros. Advisors LP, 860 Washington Street, 3rd Floor, New York, NY 10014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based solely on information contained on a Schedule 13D/A filed January&nbsp;14, 2021. Represents (i) 526,300
shares of voting common stock purchased by OrbiMed Partners Master Fund Limited, or OPM, (ii) 9,250,191 shares of voting common stock purchased by OrbiMed Private Investments VI, LP, or OPI VI, (iii) 263,200 shares of voting common stock purchased
by The Biotech Growth Trust PLC, or BIOG, and together with OPM and OPI VI, the OrbiMed Entities, (iv) 5,596,886 shares of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock purchased by OPI VI and (v) 83,300 shares of <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock purchased by BIOG. OrbiMed Capital GP VI LLC, or OrbiMed GP VI, is the general partner of OPI VI and OrbiMed Advisors LLC, or OrbiMed Advisors, a registered investment adviser under the
Investment Advisors Act of 1940, as amended, is the managing member of OrbiMed GP VI. By virtue of such relationships, OrbiMed GP VI and OrbiMed </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Advisors may be deemed to have voting and investment power over the securities held by OPI VI and as a result may be deemed to have beneficial ownership over such securities. David Bonita, a
member of OrbiMed Advisors, is a member of our board of directors. Each of OrbiMed GP VII, OrbiMed Advisors, and David Bonita disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein
if any. OrbiMed Capital LLC, or OrbiMed Capital, is the portfolio manager to BIOG and the investment advisor to OPM. By virtue of such relationships, OrbiMed Capital may be deemed to have voting and investment power over the securities held by BIOG
and OPM, and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise voting and investment power through a management
committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild. The address of the OrbiMed Entities is 601 Lexington Avenue, 54th Floor, New York, NY 10022. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities covered by this prospectus to one or more underwriters for public offering and sale by them, and may also sell the
securities to investors directly or through agents. We will name any underwriter or agent involved in the offer and sale of securities in the applicable prospectus supplement. We have reserved the right to sell or exchange securities directly to
investors on our own behalf in jurisdictions where we are authorized to do so. We may distribute the securities from time to time in one or more transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may directly solicit offers to purchase the securities being offered by this prospectus. We may also designate agents to solicit offers to
purchase the securities from time to time. We will name in a prospectus supplement any agent involved in the offer or sale of our securities. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best efforts basis, and
a dealer will purchase securities as a principal for resale at varying prices to be determined by the dealer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we utilize an
underwriter in the sale of the securities being offered by this prospectus, we will execute an underwriting agreement with the underwriter at the time of sale and we will provide the name of any underwriter in the prospectus supplement that the
underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we, or the purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of
underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the
purchasers for whom they may act as agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide in the applicable prospectus supplement any compensation we pay to
underwriters, dealers, or agents in connection with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters to participating dealers. Underwriters, dealers and agents participating in the distribution of
the securities may be deemed to be underwriters within the meaning of the Securities Act of 1933, as amended, or the Securities Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may
be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, and to reimburse them for certain expenses.
We may grant underwriters who participate in the distribution of our securities under this prospectus an option to purchase additional securities to cover any over-allotments in connection with the distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities we offer under this prospectus may or may not be listed through The Nasdaq Global Select Market or any other securities
exchange. To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include short sales of the securities,
which involves the sale by persons participating in the offering of more securities than we sold to them. In these circumstances, these persons would cover such short positions by making purchases in the open market or by exercising their option to
purchase additional securities. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers
participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level
above that which might otherwise prevail in the open market. These transactions may be discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may engage in at the market offerings into an existing trading market in accordance with
Rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus
supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including short sale transactions. If so, the third party may use securities
pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and they may use securities received from us in settlement of those derivatives to close out any related open borrowings of
stock. The third party in these sale transactions will be an underwriter and will be identified in the applicable prospectus supplement. In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in
turn may sell the securities short using this prospectus. The financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will file a prospectus supplement to describe the terms of any offering of our securities covered by this prospectus. The prospectus
supplement will disclose: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of any underwriters, including any managing underwriters, as well as any dealers or agents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities from us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the net proceeds to us from the sale of the securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delayed delivery arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment or other options under which underwriters, if any, may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any underwriting discounts, commissions or other items constituting underwriters&#146; compensation, and any
commissions paid to agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in a subscription rights offering, whether we have engaged dealer-managers to facilitate the offering or
subscription, including their name or names and compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other facts material to the transaction. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will bear all or substantially all of the costs, expenses and fees in connection with the registration of our securities under this
prospectus. The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> of the Exchange Act, trades in the secondary market generally are required to settle
in two business days, unless the parties to any such trade expressly agree otherwise or the securities are sold by us to an underwriter in a firm commitment underwritten offering. The applicable prospectus supplement may provide that the original
issue date for your securities may be more than two scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the second business day before the original issue
date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than two scheduled business days after the trade date for your securities, to make alternative settlement
arrangements to prevent a failed settlement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Stockholders Plan of Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time, offer and sell up to 31,574,631 shares in the aggregate of our common stock, which we refer to
as the Selling Stockholders Shares. The selling stockholders may, from time to time, sell, transfer or otherwise dispose of any or all of the Selling Stockholders Shares on any stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exchange, market or trading facility on which our common stock is traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at
prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. To the extent any of the selling stockholders gift, pledge, grant a security interest in, distribute or otherwise transfer
their Selling Stockholder Shares, such donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> may offer and sell the shares from time to time under this
prospectus, provided that this prospectus has been amended under applicable provision of the Securities Act to include the names of such donees, pledgees, transferees or other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> as selling stockholders under this prospectus and such other information as may be necessary or required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. They may
use any one or more of the following methods when disposing of the Selling Stockholder Shares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which a broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which a broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;at the market&#148; or through market makers or into an existing market for the shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales entered into after the effective date of the registration statement of which this prospectus is a
part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise, after the effective date of the registration statement of which this prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the distribution of the shares by any selling stockholders to its partners, members or shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through broker-dealers that agree with the selling stockholders to sell a specified number of such shares at a
stipulated price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through one or more underwritten offerings on a firm commitment or best efforts basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of the Selling Stockholder Shares, the selling stockholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the shares in the course of hedging the positions they assume. The selling stockholders may also sell the Selling Stockholder Shares short and deliver these
shares to close out their short positions, or loan or pledge the Selling Stockholder Shares to broker dealers that in turn may sell these shares. The selling stockholders may also enter into options or other transactions with broker-dealers or other
financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of the Selling Stockholder Shares, which, subject to the amendment or supplement of this
prospectus or the registration statement of which this prospectus forms a part to reflect such transaction and any other information necessary or required, such broker-dealer or other financial institution may resell pursuant to this registration
statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling stockholders from the sale of the Selling Stockholder Shares will be the purchase price
less discounts or commissions, if any. Each of the selling stockholders reserves the right to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of its Selling Stockholder Shares to be made directly or through agents. We will
not receive any of the proceeds from the sale of the Selling Stockholder Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a
portion of the Selling Stockholder Shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and any broker-dealers that act in connection with the sale of the Selling Stockholder Shares may be deemed to be
&#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act in connection with such sales, and any commissions received by such broker-dealers and any profit on the resale of the securities sold by them while acting as
principals may be deemed to be underwriting discounts or commissions under the Securities Act. In the event that any selling stockholder is deemed to be an &#147;underwriter&#148; within the meaning of Section&nbsp;2(11) of the Securities Act, the
selling stockholder will be subject to the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the Selling Stockholder Shares
against certain liabilities, including liabilities arising under the Securities Act. To the extent required, the Selling Stockholder Shares to be sold, the names of the selling stockholders, the offering price, the names of any agents, dealers or
underwriters, any commissions or discounts with respect to a particular offering, the method of distribution, and any other terms and conditions of the offering of such shares will be set forth in an accompanying prospectus supplement or, if
appropriate, an amendment to the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To comply with the securities laws of some
states, if applicable, the Selling Stockholder Shares may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the Selling Stockholder Shares may not be sold unless they have been
registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of the Selling Stockholder Shares in the market and to the activities of the selling stockholders and their affiliates. These rules may limit the timing of purchases
and sales of the Selling Stockholder Shares by such selling stockholders. Regulation M may also restrict the ability of any person engaged in the distribution of the Selling Stockholder Shares to engage in market-making activities with respect to
the shares. All of the foregoing may affect the marketability of the Selling Stockholder Shares and the ability of any person or entity to engage in market-making activities with respect to the Selling Stockholder Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the <FONT STYLE="white-space:nowrap">Post-IPO</FONT> RRA, we have agreed to bear all expenses in connection with the registration
of the Selling Stockholder Shares. The selling stockholders have agreed to bear all underwriting discounts, selling commissions, and share transfer taxes applicable to the sale of the Selling Stockholder Shares, and fees and disbursements of counsel
for the selling stockholders, other than the fees and disbursements of one counsel for the selling stockholders, which we have agreed to pay in an amount not to exceed $50,000. We have also agreed to indemnify the selling stockholders against
certain liabilities, including liabilities for violations of the Securities Act, Exchange Act and state securities laws and liabilities relating to this prospectus and the registration statement of which it forms a part, including amendments and
supplements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that any selling stockholder will sell any or all of the Selling Stockholder Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_10"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following description summarizes the most important terms of our capital stock, our restated certificate of incorporation and our
restated bylaws. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description, you should refer to our restated certificate of incorporation and restated bylaws, which are included as
exhibits to the registration statement of which this prospectus forms a part, and to the applicable provisions of Delaware law. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 487,149,741 shares of common stock, $0.0001 par value per share, 12,850,259 shares of <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock, $0.0001 par value per share, and 10,000,000 shares of undesignated preferred stock, $0.0001 par value per share. Our board of directors is authorized, without stockholder approval, to issue
additional shares of our capital stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock and <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no conversion rights, while holders of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock
have the right to convert each share of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock into one share of common stock at such holder&#146;s election, provided that as a result of such conversion, such holder, together with its
affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 9.99% of our common stock immediately prior to and following such conversion, unless otherwise as expressly provided for in our restated
certificate of incorporation. However, this ownership limitation may be increased (not to exceed 19.99%) or decreased to any other percentage designated by such holder of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock upon
61&nbsp;days&#146; notice to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock and our <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that
our board of directors may determine. See the section entitled &#147;Dividend Policy.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise expressly provided in our restated certificate of incorporation or as required by applicable law, on any matter that is
submitted to a vote by our stockholders, holders of our common stock are entitled to one vote per share of common stock, and holders of our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock are not entitled to any votes per share of <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock, including for the election of directors. We have not provided for cumulative voting for the election of directors in our restated certificate of incorporation, which means that holders of a
majority of the shares of our common stock are able to elect all of our directors. Our restated certificate of incorporation established a classified board of directors, to be divided into three classes with staggered three-year terms. Only one
class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Preemptive or Similar Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither our common stock nor our <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock is entitled to preemptive rights, and neither
is subject to conversion, redemption or sinking fund provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right to Receive Liquidation Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the assets legally available for distribution to our
stockholders would be distributable ratably among the holders of our common stock and our <FONT STYLE="white-space:nowrap">non-voting</FONT> common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of
liquidation preferences, if any, on any outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had no shares of preferred stock outstanding as of September&nbsp;30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to
establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without
further vote or action by our stockholders. Our board of directors is also able to increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further
vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance
of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and might
adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30,
2021, we had outstanding options to purchase an aggregate 8,091,689 shares of our common stock, with a weighted average exercise price of $15.30. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2021, the holders of 34,244,941 shares of our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock are entitled to rights with respect to the registration of these shares (or, in the case of the <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock, the shares of common stock into which such shares are convertible) under the Securities Act as described below. We refer to these shares collectively as registrable securities. These rights
are provided under the terms of the IRA between us and the holders of these shares, which was entered into in connection with our redeemable convertible preferred stock financings prior to our IPO and under the terms of the <FONT
STYLE="white-space:nowrap">Post-IPO</FONT> RRA between us and the RRA Investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning on March&nbsp;23, 2021, if the holders of not less than 50% of the then-outstanding registrable securities may request the
registration under the Securities Act of any registrable securities, if the anticipated aggregate offering price, net of selling expenses, would exceed $10.0&nbsp;million, we are obligated to provide notice of such request to all holders of
registration rights and, as soon as practicable and in any event within 60 days, file a Form <FONT STYLE="white-space:nowrap">S-1</FONT> registration statement under the Securities Act covering all registrable securities that the initiating holders
requested to be registered and any additional registrable securities requested to be included in such registration by any other holders. We are only required to file two registration statements that are declared effective upon exercise of these
demand registration rights. We may postpone taking action with respect to such filing not more than once during any <FONT STYLE="white-space:nowrap">12-month</FONT> period for a period of not more than 90 days, if after receiving a request for
registration, we furnish to the holders requesting such registration a certificate signed by our Chief Executive Officer stating that, in the good faith judgment of our board of directors, it would be materially detrimental to us and our
stockholders; provided that we may not register any securities for our own account or that of any other stockholder during such <FONT STYLE="white-space:nowrap">90-day</FONT> period other than under certain circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of at least 25% of the then-outstanding registrable securities can request that we register all or part of their shares on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and if the aggregate price to the public of the shares offered, net of selling expenses, is at least
$5.0&nbsp;million. The stockholders may only require us to effect two registration statements on Form <FONT STYLE="white-space:nowrap">S-3</FONT> in a <FONT STYLE="white-space:nowrap">12-month</FONT> period. We may postpone taking action with
respect to such filing not more than once during any <FONT STYLE="white-space:nowrap">12-month</FONT> period for a period of not more than 90 days, if after receiving a request for registration, we furnish to the holders requesting such registration
a certificate signed by our Chief Executive Officer stating that, in the good faith judgment of our board of directors, it would be materially detrimental to us and our stockholders; provided that we may not register any securities for our own
account or that of any other stockholder during such <FONT STYLE="white-space:nowrap">90-day</FONT> period other than under certain circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
we register any of our securities for public sale in cash, holders of then-outstanding registrable securities or their permitted transferees will have the right to include their registrable securities in the registration statement. However, this
right does not apply to a registration relating to any of our employee benefit plans, a corporate reorganization or transaction under Rule 145 of the Securities Act, a registration that requires information that is not substantially the same as the
information required to be included in a registration statement covering the sale of the registrable securities, or a registration in which the only common stock being registered is common stock issuable upon conversion of debt securities that are
also being registered or issuable upon the exercise of warrants. In an underwritten offering, if the total number of securities requested by stockholders to be included in the offering exceeds the number of securities to be sold (other than by us)
that the underwriters determine in their reasonable discretion is compatible with the success of the offering, then we will be required to include only that number of securities that the underwriters and us, in our sole discretion, determine will
not jeopardize the success of the offering. If the underwriters determine that less than all the registrable securities requested to be registered can be included in the offering, the number of registrable shares to be registered will be allocated
(i)&nbsp;first, among holders of our preferred stock, in proportion to the amount of common stock issued or issuable upon conversion of the preferred stock owned by each such holder to be included in such offering, and (ii)&nbsp;second, among all
other holders of our registrable securities, in proportion to the amount of other registrable securities owned by each such holder. However, (i)&nbsp;the number of shares issued or issuable upon conversion of the preferred stock, to be registered by
the holders of our preferred stock, cannot be reduced unless all other securities (other than as offered by us) are first excluded entirely, and (ii)&nbsp;the number of shares to be registered by holders of all other registrable securities cannot be
reduced unless all other securities (other than as offered by us and the shares of common stock issued or issuable on conversion of our preferred stock) are first entirely excluded. The number of registrable securities included in the offering may
not be reduced below 25% of the total number of securities included in such offering, except for in connection with an initial public offering, in which case the underwriters may exclude these holders entirely. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally will pay all expenses, other than underwriting discounts and selling commissions incurred in connection with each of the
registrations described above, including the reasonable fees and disbursements, not to exceed $15,000, of one counsel for the selling holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration rights described above will expire, with respect to any particular holder of these rights, on the earliest to occur of
(a)&nbsp;at such time that all of the holder&#146;s registrable securities can be sold without limitation in any three-month period without registration in compliance with Rule 144 or a similar exemption under the Securities Act and (b)&nbsp;at such
time that our common stock is trading on a national securities exchange and all of the holder&#146;s registrable securities can be sold during a three-month period without registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the <FONT STYLE="white-space:nowrap">Post-IPO</FONT> RRA between us and each of Baker Brothers and its affiliates, OrbiMed and its
affiliates and Kris Vaddi and his affiliated entities, the RRA Investors are entitled to rights with respect to the registration of their shares under the Securities Act that supersede such rights as described above held by the RRA Investors under
the IRA. These registration rights include the right to demand that we file with the SEC a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement (except if we are not then eligible to register for resale the registrable securities
on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> in which case, such registration shall be on another appropriate form in accordance with the Securities Act) covering the registration of their registrable securities for resale, subject to
certain conditions, as well as rights to be permitted an aggregate of five underwritten public offerings between the RRA Investors during the term of the <FONT STYLE="white-space:nowrap">Post-IPO</FONT> RRA, subject to a limitation of an aggregate
of two underwritten public offerings per calendar year, to effect the sale of their common stock for sale. The RRA Investors also have piggy-back rights to participate in registrations demanded by any of the other RRA Investors. The <FONT
STYLE="white-space:nowrap">Post-IPO</FONT> RRA requires us to pay expenses relating to such registrations and indemnify these holders against certain liabilities. Our registration obligations under this registration rights agreement would continue
in effect until the earliest of (i)&nbsp;December 20, 2030, (ii)&nbsp;when the applicable registrable securities have been resold by the holders pursuant to an effective registration statement, (iii)&nbsp;when the applicable registrable securities
have been resold pursuant to Rule 144 or (iv)&nbsp;when the applicable registrable securities may be resold pursuant to Rule 144 without limitations as to volume or manner of sale. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions
of Delaware General Corporation Law, or DGCL, our restated certificate of incorporation and our restated bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions,
which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of
increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their
terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
subject to the provisions of Section&nbsp;203 of the DGCL regulating corporate takeovers. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested
stockholder&#148; for a period of three years following the date on which the person became an interested stockholder unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the date of the transaction, the board of directors of the corporation approved either the business
combination or the transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (i)&nbsp;shares owned by persons who are directors and also officers and
(ii)&nbsp;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or subsequent to the date of the transaction, the business combination is approved by the board of directors
of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of
transactions together resulting in a financial benefit to the interested stockholder. An interested stockholder is a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation&#146;s
outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section&nbsp;203 may also discourage
attempts that might result in a premium over the market price for the shares of common stock held by stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Takeover Effects of Certain
Provisions of Our Restated Certificate of Incorporation and Restated Bylaw </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation and our
restated bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Board of Directors Vacancies</I>. Our restated certificate of incorporation and restated bylaws authorizes
only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire
board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more
difficult to change the composition of our board of directors but promotes continuity of management. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Classified Board</I>. Our restated certificate of incorporation and restated bylaws provide that our board of
directors is classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for
stockholders to replace a majority of the directors on a classified board of directors. See the section entitled &#147;Management&#151;Board Composition.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stockholder Action; Special Meetings of Stockholders</I>. Our restated certificate of incorporation provide
that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our restated
bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our restated bylaws provide that special meetings of our stockholders may be called only by a majority of our board of
directors, the chairman of our board of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a
proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Advance Notice Requirements for Stockholder Proposals and Director Nominations</I>. Our restated bylaws
provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also specify
certain requirements regarding the form and content of a stockholder&#146;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our
annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of
directors or otherwise attempting to obtain control of our company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Cumulative Voting</I>. The DGCL provides that stockholders are not entitled to the right to cumulate votes
in the election of directors unless a corporation&#146;s certificate of incorporation provides otherwise. Our restated certificate of incorporation and restated bylaws do not provide for cumulative voting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Directors Removed Only for Cause</I>. Our restated certificate of incorporation provides that stockholders may
remove directors only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding common stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Amendment of Charter Provisions</I>. Any amendment of the above provisions in our restated certificate of
incorporation would require approval by holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Issuance of Undesignated Preferred Stock</I>. Our board of directors has the authority, without further action
by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of
preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by merger, tender offer, proxy contest or other means. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Choice of Forum</I>. Our restated certificate of incorporation provides that, to the fullest extent permitted
by law, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising
pursuant to the DGCL, our restated certificate of incorporation or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. The enforceability of similar choice of forum provisions in other
companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our restated bylaws also provide that the federal
district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the Federal Forum Provision. While
there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court which recently found that such provisions are facially valid under Delaware law or determine that the Federal Forum Provision should be
enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state
court. Neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act. Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all
claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations
thereunder also must be brought in federal court. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder. Any person or entity purchasing or otherwise acquiring
or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit a stockholder&#146;s ability to bring a claim in a
judicial forum of their choosing for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock is Computershare Trust Company, N.A. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Nasdaq Global Select Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;PRLD.&#148; The
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock is not listed for trading on any securities exchange and we do not plan to list the <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock on any securities exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_11"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt
securities offered by this prospectus and any accompanying prospectus supplement under an indenture to be entered into between us and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will include those
stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as in effect on the date of the indenture. We have filed a copy of the form of indenture as an exhibit to the registration statement in
which this prospectus is included. The indenture will be subject to and governed by the terms of the Trust Indenture Act of 1939. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may
offer under this prospectus up to an aggregate principal amount of $400,000,000 in debt securities, or if debt securities are issued at a discount, or in a foreign currency, foreign currency units or composite currency, the principal amount as may
be sold for an aggregate public offering price of up to $400,000,000. Unless otherwise specified in the applicable prospectus supplement, the debt securities will represent our direct, unsecured obligations and will rank equally with all of our
other unsecured indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities in one or more series with the same or various maturities, at par, at a
premium, or at a discount. We will describe the particular terms of each series of debt securities in a prospectus supplement relating to that series, which we will file with the SEC. The prospectus supplement relating to the particular series of
debt securities being offered will specify the particular amounts, prices and terms of those debt securities. These terms may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount, and, if a series, the total amount authorized and the total amount outstanding;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issue price or prices, expressed as a percentage of the aggregate principal amount of the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which principal is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates (which may be fixed or variable) or, if applicable, the method used to determine such
rate or rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates from which interest, if any, will be payable and any regular record date for the interest
payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal and, if applicable, premium and interest, is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions upon which we may, or the holders may require us to, redeem or repurchase the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which such debt securities may be issuable, if other than denominations of $1,000 or any
integral multiple of that number; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities are to be issuable in the form of certificated securities (as described below) or
global securities (as described below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount that will be payable upon declaration of acceleration of the maturity date if
other than the principal amount of the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal and, if applicable,
premium and interest, will be made; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal and, if applicable, premium or interest, on the debt securities are to be made in one or
more currencies or currency units other than the currency of denomination, the manner in which the exchange rate with respect to such payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if amounts of principal and, if applicable, premium and interest may be determined by reference to an index based
on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index, then the manner in which such amounts will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions, if any, relating to any collateral provided for such debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to or change in the covenants and/or the acceleration provisions described in this prospectus or in
the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any events of default, if not otherwise described below under &#147;Events of Default&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, for conversion into or exchange for shares of our common stock or preferred
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which the debt securities shall be subordinated in right of payment to our
other indebtedness. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue discount debt securities that provide for an amount less than the stated principal
amount to be due and payable upon acceleration of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities in bearer form, with or without coupons. If we issue discount debt securities or
debt securities in bearer form, we will describe material U.S. federal income tax considerations and other material special considerations which apply to these debt securities in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If we do, we
will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign currency or currencies or foreign currency unit or units in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities offered under this prospectus and any prospectus supplement will be subordinated in right of payment to certain of our
outstanding senior indebtedness. In addition, we will seek the consent of the holders of any such senior indebtedness prior to issuing any debt securities under this prospectus to the extent required by the agreements evidencing such senior
indebtedness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registrar and Paying Agent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities may be presented for registration of transfer or for exchange at the corporate trust office of the security registrar or at
any other office or agency that we maintain for those purposes. In addition, the debt securities may be presented for payment of principal, interest and any premium at the office of the paying agent or at any office or agency that we maintain for
those purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities may be convertible into or exchangeable for shares of our common stock. The terms and conditions of conversion or exchange will
be stated in the applicable prospectus supplement. The terms will include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion or exchange price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion or exchange period; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions regarding the convertibility or exchangeability of the debt securities, including who may convert or
exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">events requiring adjustment to the conversion or exchange price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions affecting conversion or exchange in the event of our redemption of the debt securities; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any anti-dilution provisions, if applicable. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registered Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we
decide to issue debt securities in the form of one or more global securities, then we will register the global securities in the name of the depositary for the global securities or the nominee of the depositary, and the global securities will be
delivered by the trustee to the depositary for credit to the accounts of the holders of beneficial interests in the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
prospectus supplement will describe the specific terms of the depositary arrangement for debt securities of a series that are issued in global form. None of us, the trustee, any payment agent or the security registrar will have any responsibility or
liability for any aspect of the records relating to or payments made on account of beneficial ownership interests in a global debt security or for maintaining, supervising or reviewing any records relating to these beneficial ownership interests.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not have any covenants or other provisions providing for a put or increased interest or otherwise that would afford holders
of our debt securities additional protection in the event of a recapitalization transaction, a change of control or a highly leveraged transaction. If we offer any covenants or provisions of this type with respect to any debt securities covered by
this prospectus, we will describe them in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in this prospectus or the applicable prospectus supplement, our debt securities will not have the benefit of any
covenants that limit or restrict our business or operations, the pledging of our assets or the incurrence by us of indebtedness. We will describe in the applicable prospectus supplement any material covenants in respect of a series of debt
securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger, Consolidation or Sale of Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The form of indenture provides that we will not consolidate with or merge into any other person or convey, transfer, sell or lease our
properties and assets substantially as an entirety to any person, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are the surviving person of such merger or consolidation, or if we are not the surviving person, the person
formed by the consolidation or into or with which we are merged or the person to which our properties and assets are conveyed, transferred, sold or leased, is a corporation organized and existing under the laws of the U.S., any state or the District
of Columbia or a corporation or comparable legal entity organized under the laws of a foreign jurisdiction and has expressly assumed all of our obligations, including the payment of the principal of and, premium, if any, and interest on the debt
securities and the performance of the other covenants under the indenture; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately before and immediately after giving effect to the transaction on a pro forma basis, no event of
default, and no event which, after notice or lapse of time or both, would become an event of default, has occurred and is continuing under the indenture. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the applicable prospectus supplement, the following events will be events of default under the indenture with
respect to debt securities of any series: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to pay any principal or premium, if any, when it becomes due; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to pay any interest within 30 days after it becomes due; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to observe or perform any other covenant in the debt securities or the indenture for 90 days after
written notice specifying the failure from the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of that series; and certain events involving bankruptcy, insolvency or reorganization of us
or any of our significant subsidiaries. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee may withhold notice to the holders of the debt securities of any
series of any default, except in payment of principal of or premium, if any, or interest on the debt securities of a series, if the trustee considers it to be in the best interest of the holders of the debt securities of that series to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default (other than an event of default resulting from certain events of bankruptcy, insolvency or reorganization) occurs, and
is continuing, then the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of any series may accelerate the maturity of the debt securities. If this happens, the entire principal amount, plus
the premium, if any, of all the outstanding debt securities of the affected series plus accrued interest to the date of acceleration will be immediately due and payable. At any time after the acceleration, but before a judgment or decree based on
such acceleration is obtained by the trustee, the holders of a majority in aggregate principal amount of outstanding debt securities of such series may rescind and annul such acceleration if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all events of default (other than nonpayment of accelerated principal, premium or interest) have been cured or
waived; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all lawful interest on overdue interest and overdue principal has been paid; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rescission would not conflict with any judgment or decree. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the acceleration occurs at any time when we have outstanding indebtedness that is senior to the debt securities, the payment
of the principal amount of outstanding debt securities may be subordinated in right of payment to the prior payment of any amounts due under the senior indebtedness, in which case the holders of debt securities will be entitled to payment under the
terms prescribed in the instruments evidencing the senior indebtedness and the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default resulting from certain
events of bankruptcy, insolvency or reorganization occurs, the principal, premium and interest amount with respect to all of the debt securities of any series will be due and payable immediately without any declaration or other act on the part of
the trustee or the holders of the debt securities of that series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt
securities of a series will have the right to waive any existing default or compliance with any provision of the indenture or the debt securities of that series and to direct the time, method and place of conducting any proceeding for any remedy
available to the trustee, subject to certain limitations specified in the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No holder of any debt security of a series will have
any right to institute any proceeding with respect to the indenture or for any remedy under the indenture, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder gives to the trustee written notice of a continuing event of default; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the affected
series make a written request and offer reasonable indemnity to the trustee to institute a proceeding as trustee; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee fails to institute a proceeding within 60 days after such request; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of a majority in aggregate principal amount of the outstanding debt securities of the affected series
do not give the trustee a direction inconsistent with such request during such <FONT STYLE="white-space:nowrap">60-day</FONT> period. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not, however, apply to a suit instituted for payment on debt securities of any series on or after the due dates expressed
in the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will periodically deliver certificates to the trustee regarding our compliance with our obligations under the
indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we and the trustee may, without the consent of holders of the debt securities of one or more series, amend the indenture or
the debt securities of one or more series, or supplement the indenture, for certain specified purposes, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide that the surviving entity following a change of control permitted under the indenture will assume all
of our obligations under the indenture and debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for certificated debt securities in addition to uncertificated debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC under the Trust Indenture Act of 1939; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series
as permitted by the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency, or make any other change that does not materially and adversely
affect the rights of any holder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to appoint a successor trustee under the indenture with respect to one or more series. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we and the trustee may, with the consent of holders of at least a majority in principal amount of an outstanding series of
debt securities, amend or supplement the indenture or the debt securities series, or waive compliance in a particular instance by us with any provision of the indenture or the debt securities. We may not, however, without the consent of each holder
affected by such action, modify or supplement the indenture or the debt securities or waive compliance with any provision of the indenture or the debt securities in order to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities whose holders must consent to an amendment, supplement, or waiver to the
indenture or such debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or change the time for payment of interest or reduce the amount of or postpone the date for
payment of sinking fund or analogous obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or change the stated maturity of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any debt security payable in money other than that stated in the debt security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the amount or time of any payment required or reduce the premium payable upon any redemption, or change
the time before which no such redemption may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a default in the payment of the principal of, premium, if any, or interest on the debt securities or a
redemption payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a redemption payment with respect to any debt securities or change any provision with respect to redemption
of debt securities; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take any other action otherwise prohibited by the indenture to be taken without the consent of each holder
affected by the action. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture permits us, at any time, to elect to discharge our obligations with respect to one or more series of debt securities by following
certain procedures described in the indenture. These procedures will allow us either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to defease and be discharged from any and all of our obligations with respect to any debt securities except for
the following obligations (which discharge is referred to as &#147;legal defeasance&#148;): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to register the transfer or exchange of such debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to replace temporary or mutilated, destroyed, lost or stolen debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to compensate and indemnify the trustee; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to maintain an office or agency in respect of the debt securities and to hold monies for payment in trust; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to be released from our obligations with respect to the debt securities under certain covenants contained in
the indenture, as well as any additional covenants which may be contained in the applicable supplemental indenture (which release is referred to as &#147;covenant defeasance&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise either defeasance option, we must irrevocably deposit with the trustee or other qualifying trustee, in trust for that
purpose: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">money; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Government Obligations (as described below) or Foreign Government Obligations (as described below) that
through the scheduled payment of principal and interest in accordance with their terms will provide money; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of money and/or U.S. Government Obligations and/or Foreign Government Obligations sufficient in the
written opinion of a nationally-recognized firm of independent accountants to provide money; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">that, in each case specified above,
provides a sufficient amount to pay the principal of, premium, if any, and interest, if any, on the debt securities of the series, on the scheduled due dates or on a selected date of redemption in accordance with the terms of the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, defeasance may be effected only if, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of either legal or covenant defeasance, we deliver to the trustee an opinion of counsel, as specified
in the indenture, stating that as a result of the defeasance neither the trust nor the trustee will be required to register as an investment company under the Investment Company Act of 1940; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of legal defeasance, we deliver to the trustee an opinion of counsel stating that we have received
from, or there has been published by, the Internal Revenue Service a ruling to the effect that, or there has been a change in any applicable federal income tax law with the effect that (and the opinion shall confirm that), the holders of outstanding
debt securities will not recognize income, gain or loss for U.S. federal income tax purposes solely as a result of such legal defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner, including as a result of
prepayment, and at the same times as would have been the case if legal defeasance had not occurred; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of covenant defeasance, we deliver to the trustee an opinion of counsel to the effect that the
holders of the outstanding debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of covenant defeasance and will be subject to U.S. federal income tax
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
on the same amounts, in the same manner and at the same times as would have been the case if covenant defeasance had not occurred; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain other conditions described in the indenture are satisfied. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with our remaining obligations under the indenture and applicable supplemental indenture after a covenant defeasance of
the indenture and applicable supplemental indenture, and the debt securities are declared due and payable because of the occurrence of any undefeased event of default, the amount of money and/or U.S. Government Obligations and/or Foreign Government
Obligations on deposit with the trustee could be insufficient to pay amounts due under the debt securities of the affected series at the time of acceleration. We will, however, remain liable in respect of these payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;U.S. Government Obligations&#148; as used in the above discussion means securities that are direct obligations of or <FONT
STYLE="white-space:nowrap">non-callable</FONT> obligations guaranteed by the United States of America for the payment of which obligation or guarantee the full faith and credit of the United States of America is pledged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Foreign Government Obligations&#148; as used in the above discussion means, with respect to debt securities of any series that
are denominated in a currency other than U.S. dollars, (1)&nbsp;direct obligations of the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is pledged or (2)&nbsp;obligations
of a person controlled or supervised by or acting as an agent or instrumentality of such government the timely payment of which is unconditionally guaranteed as a full faith and credit obligation by that government, which in either case under
clauses (1)&nbsp;or (2), are not callable or redeemable at the option of the issuer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regarding the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will identify the trustee with respect to any series of debt securities in the prospectus supplement relating to the applicable debt
securities. You should note that if the trustee becomes a creditor of ours, the indenture and the Trust Indenture Act of 1939 limit the rights of the trustee to obtain payment of claims in certain cases, or to realize on certain property received in
respect of any such claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted to continue to engage in, other transactions with us and our affiliates. If, however, the trustee acquires any &#147;conflicting
interest&#148; within the meaning of the Trust Indenture Act of 1939, it must eliminate such conflict or resign. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a
majority in principal amount of the then outstanding debt securities of any series may direct the time, method and place of conducting any proceeding for exercising any remedy available to the trustee. If an event of default occurs and is
continuing, the trustee, in the exercise of its rights and powers, must use the degree of care and skill of a prudent person in the conduct of his or her own affairs. Subject to that provision, the trustee will be under no obligation to exercise any
of its rights or powers under the indenture at the request of any of the holders of the debt securities, unless they have offered to the trustee reasonable indemnity or security. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Individual Liability of Incorporators, Stockholders, Officers or Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that no incorporator and no past, present or future stockholder, officer or director of our company or any successor
corporation in those capacities will have any individual liability for any of our obligations, covenants or agreements under the debt securities or such indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures and the
debt securities will be governed by, and construed in accordance with, the laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_12"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the
purchase of our debt securities, preferred stock, common stock, or any combination thereof. Warrants may be issued independently or together with our debt securities, preferred stock or common stock and may be attached to or separate from any
offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent. The warrant agent will act solely as our agent in connection with the
warrants. The warrant agent will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. This summary of certain provisions of the warrants is not complete. For the terms of a particular
series of warrants, you should refer to the prospectus supplement for that series of warrants and the warrant agreement for that particular series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Debt Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement
relating to a particular issue of warrants to purchase debt securities will describe the terms of the debt warrants, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the debt warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price for the debt warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of the debt warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the debt securities, including any conversion rights, purchasable upon exercise of
the debt warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date from and after which the debt warrants and any debt securities issued with them will be
separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise
price for the warrants, which may be payable in cash, securities or other property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the debt warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of the debt warrants that may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt warrants represented by the debt warrant certificates or debt securities that may be issued upon
exercise of the debt warrants will be issued in registered or bearer form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currency units in which the offering price, if any, and the exercise price are payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, a discussion of material U.S. federal income tax considerations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the antidilution provisions of the debt warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the redemption or call provisions, if any, applicable to the debt warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions with respect to the holder&#146;s right to require us to repurchase the debt warrants upon a
change in control or similar event; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the debt warrants, including procedures and limitations relating to the exchange,
exercise, and settlement of the debt warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt warrant certificates will be exchangeable for new debt warrant
certificates of different denominations. Debt warrants may be exercised at the corporate trust office of the warrant agent or any other office indicated in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the prospectus supplement. Prior to the exercise of their debt warrants, holders of debt warrants will not have any of the rights of holders of the debt securities purchasable upon exercise and
will not be entitled to payment of principal or any premium, if any, or interest on the debt securities purchasable upon exercise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Warrants
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to a particular series of warrants to purchase our common stock or preferred stock will describe
the terms of the warrants, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price for the warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the common stock or preferred stock that may be purchased upon exercise of the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date from and after which the warrants and any securities issued with the warrants will be
separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock or preferred stock that may be purchased upon exercise of a warrant and the
exercise price for the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants shall commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currency units in which the offering price, if any, and the exercise price are payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, a discussion of material U.S. federal income tax considerations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the antidilution provisions of the warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the redemption or call provisions, if any, applicable to the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions with respect to a holder&#146;s right to require us to repurchase the warrants upon a change in
control or similar event; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including procedures and limitations relating to the exchange, exercise and
settlement of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of equity warrants will not be entitled: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to vote, consent, or receive dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or
any other matter; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercise any rights as stockholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_13"></A>DESCRIPTION OF SUBSCRIPTION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue subscription rights to purchase our common stock, preferred stock or debt securities. These subscription rights may be offered
independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the subscription rights in such offering. In connection with any offering of subscription rights, we may enter into a
standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to any subscription rights we offer, if any, will, to the extent applicable, include specific terms
relating to the offering, including some or all of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price, if any, for the subscription rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price payable for our common stock, preferred stock or debt securities upon the exercise of the
subscription rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subscription rights to be issued to each stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and terms of our common stock, preferred stock or debt securities which may be purchased per each
subscription right; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which the subscription rights are transferable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the subscription rights, including the terms, procedures and limitations relating to the
exchange and exercise of the subscription rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the subscription rights shall commence, and the date on which the
subscription rights shall expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which the subscription rights may include an over-subscription privilege with respect to
unsubscribed securities or an over-allotment privilege to the extent the securities are fully subscribed; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the material terms of any standby underwriting or purchase arrangement which may be entered into
by us in connection with the offering of subscription rights. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description in the applicable prospectus supplement
of any subscription rights we offer will not necessarily be complete and will be qualified in its entirety by reference to the applicable subscription rights certificate, which will be filed with the SEC if we offer subscription rights. We urge you
to read the applicable subscription rights certificate and any applicable prospectus supplement in their entirety. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_14"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units consisting of some or all of the securities described above, in any combination, including common stock, preferred stock,
warrants and/or debt securities. The terms of these units will be set forth in a prospectus supplement. The description of the terms of these units in the applicable prospectus supplement will not be complete. You should refer to the applicable form
of unit and unit agreement for complete information with respect to these units. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_15"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fenwick&nbsp;&amp; West LLP, San Francisco, California, will issue an opinion about certain legal matters with respect to the securities. Any
underwriters, selling stockholders or agents will be advised about legal matters relating to any offering by their own counsel. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx487902_16">
</A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our financial statements included
in our <U><A HREF="http://www.sec.gov/Archives/edgar/data/1678660/000156459021013330/prld-10k_20201231.htm">Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December 31, 2020</A></U>, as set forth in their
report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as
experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g487902g01p31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>4,496,744 Shares of Common Stock </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase 12,895,256 Shares of Common Stock </I></P>
<P STYLE="margin-top:130pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>PROSPECTUS SUPPLEMENT </I></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:165pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><I>Morgan Stanley </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>May 18, 2023 </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g487902g00q05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g487902g00q05.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2=,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )S"^$ ,CA"24T$!       #QP!6@ #&R5'' (   +LL@ X0DE-!"4
M   !#4XA'A[GX?\ M4]1"'C;U@.$))300Z      #O    $     $
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M,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M   $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='
M9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M   0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&
M1O=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U
M)L=                $)L9"!5;G1&(U)L=                %)S;'15;G
M1&(U!X;$!D'?$         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&
M]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M 08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&
MQO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 *
M#OB  !  ( H.^(  $  CA"24T$)@      #@             _@   .$))30
M0-       $    >#A"24T$&0      !    !XX0DE- _,       D
M    $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0
M!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M   0 U     0 M    !@       3A"24T#^       <   ______________
M_______________P/H     /____________________________\#Z
M#_____________________________ ^@     ______________________
M_______P/H   X0DE-! @      !     !   "0    D      .$))300>
M     $     #A"24T$&@     #-0    8              @D   0;
M    $                          0             $&P   @D
M               0                         0     0       &YU;&
MP    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   @D     4F
M=H=&QO;F<   0;    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&
MEC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M    9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&
M5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'
M-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,96
M9T;&]N9P          0G1O;6QO;F<   ()     %)G:'1L;VYG   $&P
M-U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M   0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V
M]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M  #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96
MYU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&
MQO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S97
M1L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M    (_\        #A"24T$$0       0$ .$))3004       $    !#A"24
MT$#      =$     $   "@    3P   >   )0@   <]  8  '_V/_B#%A)0T
M-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #
M$  &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !     -
M,M2% @(
M          $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&
M)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H   )
M  %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<
M/4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D
M,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7
M)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M       !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C
M$Y-C8M,BXQ
M                !865H@        \U$  0    $6S%A96B
M          6%E:(        &^B   X]0   Y!865H@        8ID  +>%
M 8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R
M]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                           &
M1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('
M-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="
M!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M!D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@24
M5#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&
MET:6]N(&EN($E%0S8Q.38V+3(N,0
M  =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(
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M^$?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B
M2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI
M$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FF
MB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ
M16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:W/JI<\/M["59)(^P((8[:%IXT11,Q>*V3$+X2-V9M;@ %V5]*QEDY:2O*"
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M=RRCPW (!\,]*W*KQ:TTI2E*4I2E*5BT&^TF'?O6CW^"6GW_ ,]ZNN/MB?\
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M/:X..MUE6DD<#KPD[,GA4T@ "*Q)D*9-I4/BZSMMLEQ94@^R .,6-F$)./\
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M[1=W:JO*'CEMQ@L\1O%8S)(L$T%BL4:B(HV)X5[3(V<:>:S+@MG!"U*V@:#
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M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5B$-71:P**.7"N"+=O$
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MOCJFL[E8H9C"VB=YXXL89V:WY?.!C4F1-'-CW=5!U=TG!Q(2(6= PU(%+>
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M$HW_ +-BD,;E!038!4E+TF<L$LH\R6+0HQ<WE"DP>,1W/+DMA&5CBM@]ER[
MVC36TJJ)W49+<MI($2#,+F1E29(K;,NDEDRKDZB7Q(&E#A74G0#T&K#$ON-.
M2#*^7#.1>U.@&BE[:]=RF$3F9S9GF%?26$10(\ETHV.::X0YTU$21-C:,,I]
M9DT'RN"S&,F6@]T,?QQOB_:DQ.1^-QMQ>YX@O:!%<06\!$BQS2R""*U1C,"Z
M%N:UMJ9HKB&52P82'#(\UMRL"197*,[#!(4%F<C3MC;7C#*1UVZ&H9-]G]/I
ME$Y7"U=E:G?%70:8H%MJA(I:/SAY+97QAPT.[UB7CT<;)A(SJ(:0(([$8QP4
M1\4/9L(C&!\/8)!T) XVCRAMXIHIUM+N.,/!R[1YN; (8>*F_%T))>_/>LJ]
MF:5U!9FFE:5BYC%?96*E=:%L-EPN&U-"(V3 V2//?"CH-*@ ;U?P/9^SJ/R:
M-$+R#5LD9-M[0K<3T_( YA28PQC".16P]S>B>NUK,W*2325!YPF.*+.'X=,:
M=;&G-VQUH>3N(A/Y103QR*(KF(GA\MD$C=.5.TW#;6RYMR,@DQ26Y9,*Y:-D
M&4,9#]CM&0C+*WKHDR005 EDDTKZ"' (V&03OD5=N5'!G9O(/:)B7BIG! 0=
MPW(I!7;QD[9G1[$QHK8.HB@ @TC\=:*R/RLM.;2;*2RB6'E&(<<A$8Y&H[@H
M4-&*^$\>M>'6JPR0W$C@ ,%8-&66_M[Q9%,DI$6E(.7RXHDU.[2R22'0J=GM
MGE?4&4#(.^0<<MXR#A<MG63NV-@ !OFQ[#[.Z1$L=EX0EUIYP$G< E.N16O)
MI&W^$"B=YEHG4FJG>SAXX4.>)93Z-%=6+*"DT6#3,O%)I(A:LD!.L\U'<[?R
MCC5;<7 O.9!/#<M=0RKVF7D7]Y=BU9W8?[-,EWW\EM$\,;B)U&*X]IEF9=&&
M5ET,.X-44<8<  ]]>7@8ZJS#.:]0HD&5CD4C$>763<K@8\%#+.$<<L$EU18U
MLQ462QS_ '>*:N:%\\,<OW5L<K6R[[7KY>:02S32@$"2620 [D!W+ $C8D X
M-;$&E54_<J!^88K(:JJ5*4KQ/E_;O=FQHF>;,TULC;LM$3[6&U=J0F8C&FI-
MDEFK"11[8DF'%6C<H-CC@>_20=(*)X.F;A9LMC:V:2F>%[7K[.+R'\H[Z"VO
M+:TB>WN;2TFA8W=LA:-[:(J2K2!E)'@P!'B*QF\MXRR,Y#*[@C0Y&=;>(4@_
M ?1UJQ?9&G91_#=-?H3VO]5:G_-[Y4_@4/SVT^MIVZV]N?A1Q^M:?9&O91_#
M=-?H3VO]5:?S>^5/X%#\]M/K:&_M1_2';_<?]WTC\]/LC7LH_ANFOT)[7^JM
M/YO?*G\"A^>VGUM.WVWWP],[(Q_4,T^R->RC[_ZMTU[O[R>UOJM^O6WNT_F]
M\J?P*'Y[:?6T[?:@9+G'XC[_ *,T^R-.RC^&Z:_0GM?ZJT_F]\J?P*'Y[:?6
MT-_:@X+GXCX_/IQ3[(U[*/X;IK]">U_JK3^;WRI_ H?GMI];0W]L.LA^(_[O
M7T=:?9&O91_#=-?H3VO^/[5J?S>^5/X%#\]M/K:=NMCTD/Q'_=]%/LC3LH_7
M[-TU]VWW$]K^YZ_^2M/YO/*G\"A^>VGUOIIVZV]N?B/Z-CMMG.U6'']D3=E9
M:4*D_9KFGD>0%!A93V%MJ>%Y2F0<.,L/%^B_AVM9)3#*V?@^#>]_!M?K;I5G
M\WWE1R@O8H=7,+8[9:]-(&<\W'4';K7.W6VKV9]C[1_/^+5^^R-.RC^&Z:_0
MGM?ZJU7_ #>^5/X%#\]M/K:EVZVZ:S\1_HI]D:]E'\-TU^A/:_U6I_-[Y4_@
M4/SVT^MKG;[8_=GXC_N_ZV\XKEA^R,NRC44P3]G"9X>,SQP\-32NUL4\/"OT
M\)3*\5Z8X8]>N65^ZUNMZ?S>^5/X##\]M/K:=OMA]V>F?8/^[X>->S6OM@PG
M:\)C&R-<2</,X+,P[,_%Y. >HD!)D2^3LHW=-'2&66&5O_&262R\%9LX35;.
M$TG"*J>'Q]Q;SVD\MM<Q/#/"[1RQ2 JZ.IP00?S@C9@002"#6I65U#*0RL 0
M1T(/^O?'0UF-4U*E*4I2E*5@[C[I0G]X\A_P]&/U^>KQ]K/U^SQ^&WV.7Q\_
MHJ)]F/Q6_6E9Q5%2I2E*4I2E*4I2E*4I2E*4K!Y7]L.L_P!^1+_%W.ZT0_8[
MK\G7_%6U0;V4?XY_9O6<5GJ=*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E:6<V-/\ $3=\)BL-Y72V-07%C(E)7JR8N=JH
M:=G\4EX-!))S(]:S-,X#+LBS!F110)>0+.FMVSYOB2:*8YM;X^UP6\XO8S2S
M<*BEGU1B&ZA%J;RWEBD)*QW,)1T*L4)34 V5;2<:@:)TA<*LK!3G4AUZ&!7&
M2IR#MD9ZC<9'2M-B'9[=F<]US'.+K;<#T/(<]W1WD0B<%<H[)<CIEN0K&7;>
M)S0C,W9]Y-BA0E&9.B\CGFM)I@Z:N!I<5CDHZS=O/8'E!Y3"X?B;6@:,6,O#
M]#<+_P#1T-DD@YT*PB,0JBRQ%92Y8J5:-R%4*M/9[7 C#[\Q7R)<R&3 *G))
M.=)! &,YU;DDGOP[AQV8#?4VSM1A]U1^:(RB:0;<>YMB2'D^+V!MTV4U$:!&
M(:0G4_-R,N59QB**L@[!$>K@.#-63F^&>&#LHN[<QEXUY3FZM;IK22$Q03VE
MG;Q\,:"T1+M62806Z1HAEE[Q+#4Q8;;* .\BU*L-8.I@[L9 S$ITU,2=ESZ/
M.=]ZF?9_%S@;MO9L\G,LG<?2E',K3L:UK( 4?W0-CHW<T9!DT7< G$9$"RS=
MX<FD9>X(-XC-XRX6721M@Q_VXCGDEGCM>*<>L[6WAA@DY/![R6XCDDLFD:SE
M="+B"5W0JD,BDM-!(!OWNZ0")/#;N[,S#5,@4@28#C;#*,[L,###S>_F1>/X
MCAMQ7@DNO!]VPARRE&QW[_9NT]C;R 2Z4S':*HM!ODVFTY.'O 7D@N+A& L>
M MDQR&1\(C9$;A9-VY6S\0?C/%)X>T64X,5NJVMK;V,D,4-J')S!"D>1&\K,
MS2=[5(Y&KHHG&((@VEUW;OLSAF+'P8D]0-@-L =*W,!G0DG#"Y'&C(J0QXXP
M:E IT&0:%@Q@8]1Q<,B(LHP6<,2#!VAG@NU>-%UF[A'/%1)3/#*V5_&DC>)W
MCE1XY(V*/'(I1T=3AE=& 964[%2 0=B*N!! ((((R"#D$><$;$5=:A7:4I2E
M*4I2E*4I4/0=HX?Z A[!HG=9V]T]'VC5&V6&%U7#F%-$44[9J98)XWS4SQQM
MEGECACUZY98XVO>VVZ(7B-PQ.RWLI)] G8DX'^0JN/>),#K&N!_PC:O*8-HW
MFYK;7NIM=1(CM=#7@#4W'_&:,&TPQF<W:;%9ZCGP*?"8LLEO34)(7'(_-AFN
MGCF-Q_8H.!-W2S9,)&S<2SD0C#ZI[_@ES/>7$R6ANI+R_,#- T,#6QO+>2!Y
MAV&[5I)(&N%$KVSSD ZWCF*.<8BN%5$4R!%CCU ,"P;EN&"Y=3@,$[NL+OMD
M;5FY?3/-DBE+RSB;[P=R)P*W*@)69;/'0T>^>B^/VM%],N48=&IPZB<:<O\
M?0V6O7K82Y5;K.'A8')"I/7+QJS<4QWO U6->18JH:Q)#6KS, _$+GMRM-)
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M9]L0"&1K;W'^2;%+A]5;(C6);("7E=RB3+23&/7D4F,14:106F.T043>HR%
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MO;B. I_Z%$4TLKWJ8TRW5[#%JE2-Y%5'#LI-5<VZ5H!(9%61D#$1KJR3<ZE
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MO%LFE9R0?+7NL\>+6S<N5;W464SSOUJ3.[X+NSE55%U,6THHPJ#).%4;*HV
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MA C)I?74^R<K>>PT(V ]\J2MAC=%I:/Y)N+74NH\;63MXS9:"%A="=Y8X^S
MEH85G<'M5M@:'GMU )V+<S(\%.=JY-0,>D G6=F8J#ZV_B%;W^GPU9O2+D_\
M#^A?X2&POZ*U2Y?#/PN^_LZW_P":4S+[2/Y1OJJ>D7)_X']"_P (_87]%:G+
MX9^%WW]G6_\ S2F9?:1_*M]53TBY/_ _H7^$AL+^BM3E\-_"[[^SK?\ YG3,
MOM(_3ZXWU7T4](N3_P #^A?X1^POZ*U.7PS\+OO[.M_^:4S+OW(_1ZXWZ?6M
MOTT](N3_ ,#^A?X2&POZ*U.7PS\+OO[.M_\ FE,R^TC^4;ZJGI%R?^!_0O\
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M!@?>!/@:^MN5N@LC60_V3(?8!C"VTYQV+>51;V-5!SJ;N]=I#$IAY[\@S/\
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MNXEN=*.%M3:B2!1!B&7!,FJ7M(#%HXU2%VC/!:@!>\"8V+(Q0$C,FO#$G<#
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M %IG%]I/I0^:N9L;,9J%W0/;L?$K.+.2:R>&3(.Q2\1@EC=*ZELU<_VGA?\
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M3U.3ED)_.&_\CN/,/V2=C[V.>O>SS@[/8^Q&P>;\L9@%Q2E<NPQ\N$Z['OO
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M/"8]?0,_H/CX@>CKO3]O"[5?XY,^_)K6GU(I_(KR6]QX/E;GZ^N=LN>O-;S
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MA(#,MS,LP:*V>W-NLJ3,H)#!KNV4!%?4TRA23JQ!;J)PNG5EPI12N&8.'*D
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M_O7C[_-M&_O?KWT_E_Y*>Z;?,>(?PM<[!=8^Q[[C.N/_ #8]<G._CUZ 5O\
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M+P0,XYB$@9QD'7C!P<_JJ\_8\O:W_%B&?>]G7CY^E'^?K4/Y?^2GNFWS&_\
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M@UM$V=2DZG,C$GV3&+DDGP^Q[8\#N-ZQ)3@IIASG)7I$SM(H?F[J3^G<J?;
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MVL41%PJHD"JJ"ZMQ:W!&^7>2$:.9*9)$RW+=-39&W0MK)<MW<DL3G0Q=1Y@
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M<O')($C"M*\6L1O(1W6=1(5+A0[J%$C/I&)\M=?,W+8(!))P#U \<>(&<#?
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M6:\0DL;A+-E203LG=$<CE(Y&&=:1R.-,<CJJ.2NECJ7,1-$7Y8D4ODC3G?(
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MH =A!AB^V1L(=(32C?+=8A39,?D;!';3*S\%?7;0N_8&=NDMO$E13Y*,Q&$
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MVTPR&1-1ZAF7.  <'P(9U8#H65BI8'&,8K8VO-JVE*4I2OY.7:1=W:'<[O\
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M [6::C*:(<$Y (1@KK8SZ"RV3S0'&V.R)G(HE&7T>.-]2C@A5!DA''1R58;
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M2WXIG>H_RT\E_=BW^)<?4[UWLER,>LML,8U#Z<9\^WP^%4_:1.U4^)IL2_\
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MFA(^6&J'FG-ZX>F\ZXHN-- A4>@>KI"Q?K1YCKC9XAFOL,_L(==$3D0],"R
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M)--W>RQ)MLS+:G':,ZM@XF!\=N+XR&NUM:3$M-6H539K#8#J9MAPO-S*)P3
MS%8LJW%Q<+A<;FYP)8\*N/)N^XAZG&R[)%:0VO$);J=[CB'%&E':84@+]F:
M1,6Q% LD(74TC][387F6Y2/F"0.S,\:H L<> %R=V!SDY+')(&D C/M57Q=;
MJ4I2E*4I42Z]8JE-%0<8ADG@N1U+&6*.:M\L4L%7<.9-T\E<L,5,[)XYJ8WS
MOCAGE;&U[XXY7Z6OMNF"\1N7.2%O9F(\2!.Q/7Q./&JD&84 \8E SZ4 W_SK
MRK8]FAN>T'@T%(;(@. K74(<Q."68N9/CE"'.P^,>R]<[P*"\_1]MF5<2O=L
MNC<O%+N_-ZZ41 Y8]197Q@PE]9+Y4V3W%Q<):W >ZNN?<%A$3.MOQ2VN>'HX
MYI"B&QBEA=5RIFD^Z7#KBCLI%1$9U(CB$: $X0M$5E8=W?5(01G<*N=BS Y'
ML?@EOO<Q>92>>X:&47.G'Y@;"%I?,YC&$;-8QP_%C!;XR:U,-S33*&>/$S<E
MG3>)K>9FTF"*-V!YUYUP2SVW'K"R2&*#M^(XA$TXAAAE),W%W9Q&EVPRD?$(
M JF8:VCD!:,!";7MGD)9M&2VH LS 8$0 R5'4QMG;8$>RW%8I'>%6]G&Y)P+
M("(,Q19L=;2$!NQ:2SB[^*HK\B.3&U)+!M7MKPI!H7O*(++(EK?9N.1N(HL
M9A3!XQF@IF($.+WXYP]+6"13.Y9KJ.2QY< 64^I_#;6*XNO7F*&*>*6ZML),
M6D08:!BSB'9I2S+E5VC(?+94"21BB;#(92JODK@'[KI4[<:^%NU]-;4B\TFD
ML!2-E'089CZ1!YGDR+^;AVHHO <=>N8[?2P\X=@04R)?E0C4QN:\=Q4:@Y+[
M';"6)*/6V#BO&[.^MIHK>&2$RR,QB>$,A<WDTYN1)VUDBN)(W59&2S,G>DB[
M2T)P;(;9XV#.P;3C!#'('+"Z"- +(".Z"^-E8KJZ:XSCC#NW;&[)_&HJ&7BS
MM-;D(_D&^#3.=QE]L,7,=QZMF$$UE*B<@UDYA)F+900!(M7@B,*>;F'!H+DZ
M6+12-V>*PXQZ=OQ:PL["%YG$P(X:L=@A@D6V>&RO(;BYA6.YYR2B>6*Z=9UL
MVDG "RRX$R4/!+)*=/=(,I,AU#6&>-E1LJ5(*J4[NL!2=AG!F\/P)V"T<HG<
MR$)9GP#+5&6O,G4O)R//712)<H)!M^:>B9 3J77 :/##6NR]HH(81:#1P>WN
MY?PVXP?#_P#;;GSFX];D&/3,T<C7(N,0I%VF.3AB6<(E5KJX>1DG7F,TL\C$
M*LVMIL@7BV(.<@$8*]XG2W-,A(PJ@ @XP% &2H&DU9XIV?VS[GM9>GCO4[Z)
M1 E#?9,$LSDK/8<@WT9&;?;DML;(#EX.,'9["D+N<1K$B$?.I.T>,FI9$M,B
MK07'AN-DWE!:Z+KLZW:RS+/V8LD*=@65K/3:6[I*S=G18)<2*L1#%&2%&:1J
MBMM)E-10A=(;#/ZYI#Y=E(QJ)*G!)\<L<#-@8]G=O0-'HD!C6QX1%<1NFHC&
MI.Y$'YK98_M=EH_<VM)W+W+C".-'Y#TY+3."(%)8Z>MI<N "ORETFYP.$:O=
M!\I.'--=2R6D\PDOI98$>. +%9F_LKJ"$ 2$1\A()]$**T(=U3)C9RL.R3!8
MPLBKIC 8AF),G*D1GW4:M1=<L2&QD[$"LDV?PJWQ-3&NWD&C7'+3(2#G(5(
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M1+B:K-!U, S%ZZ(!]=SP.QBEOH()IKF>UN.(P\A;BUBN8TM$=H).RRQH;U)
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M A=UM,F '/W4*?23Q:[-NR?M!L;+E*F?@R:<V=B96N;!)(S>NZ&$]K:X9)X
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M%^MNNB&TNKE)Y+>WFFCM8^;</'&SK!'DCF2E00B9!&IL#:H,Z(5#,JESA02
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M .&RA(."V00CE'N%KQ)U[MQY' 6UMARC9.U(T90!%VUQ[8)%=@[9:IOHJ-
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MDY35<()F74N"(U'LD&I59LY(&PP,^?9C:6Q^T2AF@.()R(;MV3LZ1\KX3/\
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M1!M.6U8R<UILFF?6\I;NA(U!)ZHO?8CH68X)( Z_ /.WL^>S4V?R$B^O]I[
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M=.D#>M&F: D^HI@4DHXH39M'J'(TX/)<0(W"N"JDGE3=\);%M$N.&\EW!SJ
M,@=59+DC4FZ1LJNRGI,P#$2S;6RS#O-]D+*,9W.,%@5Z'KC:MC)YR!Y0QWM
M-3D7>V-V[' 3"7<:T&F@-8F]M:ID46C\LA(MM,U7FL);I62<?MXZK<'2D@ED
MYGXJ0C)* &!"(H=-HH6!M/,^"+AW"I."7B+:6-LT,/$\W]TMI=QRR0W#&'%S
M#>QW]E<B-8XH('C9)'<,T$R,1)/F2\V,F21M31>MIK0@,@R"K1F-T+;E@1@$
M]X'<?J!K\PKUJP$$0S$ZN#E<$\5E!D!'D,$<\KXX*YLH\BYQ3RRM:^6..>25
ML<LK6O>UKWO:W6M$JAKJ1<D!KAUSX@&0C._COXU!3A%/F0']%>;4,YI<46&I
MQ)2>:*%:QE.\8CKJ:336+N+:>C[;8;/9$#.;":R=T2/2P)$Y%'W3,-,/(FT]
M-"IZ[>,U!2\/3D)-L+=?1S<%XJ;IU@OS<16,]S!#=":[<V[6]S';&,+'$\T<
M@+PEC C0!#KYO+74,PGA"#5'AG56*!5PP9"^020K#9@ 2&)& N3BLJ,\N.)!
M (6!8\>Y%--=BPSYUBZ;:EUJK"20G4VO(MM9^BQ!262"2*2$!UUL!G)!Z!2-
MC4D.IJ/1BSR6)W .8)P?BZLLIXA'#.74$&[N><CWEQ+:*6DCC=<W%Q;M&Q21
MM0T228B(<=Y\)RO+8C<>P7!Y:AS@$@X4-D9&,Y W!%<=T\ON-T3D>P1;;1@W
M9&T[0NX_!FHPTQ8AL"%,9IK>&E!;Y1]*W,Q%1<8IL8&;'#]C1Z+!9:*'/E8B
MJ5Q127NLN#\3ECMG-\UO:<Y26#WFFVFDBN9490L0B>5NS2H[6TDKPNP$V@DB
MCSP@L.6&<J0 0G?52H(W.0!J# .%##=<U]Y;R>XWL%;)CM* 6[3<TOBX8[(I
MK!(<-C.W-<,-O@]/3^:>5BEC1&0L-=FCHZZ++8 P-F4:D11< W)QY[B4Q[;\
M(XG)K+7LC&QMYG1+>>622UNC8R7MM;D/H6-KF.-P3;M)H*21R%9%*U%KB$:<
M1@<QP,N@4,@E6)VVR3I)!&K&05(R*R?/D]QL/QD+JE?0<G*8&P .?0K0K[6>
MN5%)+K L%E4Z![5"1A_)<8.PBJB$,E2^+(Z3!3AA)!N 9W$&DD, V)2D\*XI
M'(]V;^)=,CVT]^+JXQ'=QR0V[V<DHCY[S+SH23&LD!A/,$IBC=DD)X"!&(SN
MH=8]"@&,JS"0*3I5#I8=[2=6Q&37#67)WCSN0YYSAFFB4YD4ICHX63<!M6P]
M.2QW29:-:N.M,I^L6D6+\G$D\=F"$<XS';G"#W(>;3$PM\A&W[[.5YPCB5B@
M6>\2"*.1V77=RF&6^CEO(R( L8"3$VLA$DH15UQEYU,JJ.1W,,NZ(7) ! 0:
MEC98SWN\=2^N*2$U9 .%.DUNPMK'6KDF%-N->P=<S&EG3F.EEHF 5)@'#XKD
M=>KA7^8_)T*6>&\LC#I5BJAFX*Y9$%LLW=[K7\'M5R%=!<3A) !(O.DTR ((
MP'75A@(P$ 8$! %'=VK5H38Z5R#D'2-CG.1ML<DGW]^M4+:OUH?.JR@[KN#&
MI*NPP%+R(M$@!$ZL,3P73P&JEW@]8@HPP3<N4\&>;C)OC@X7QLG;%52V1+JY
MC3EQW$\<>K5RTFD1-60=6A6"ZL@'.,Y .=A0HC'+(I/G*@G\Y%<C^L];RIIF
MPE&OH1)&*A)@949GXH!,-,S L9<*,*YMR+!PCD2'!\LA+!]EA=TS&978-U4V
MM[I4CN;F(ZHKB>,A&C!CED0Z'?F,F58'0S]]EZ%^\03O0JK>R53OG< [XQG<
M=<;9ZXVZ5F:**3=))NW230003P1111PQ22122QM@FDDGA;'!--/#''####&V
M.&-K8XVM:UK522222222223DDG<DD[DD]34J^E<I2E*Q:'=XEW^^F<_Q3:0V
MJZ?V:_U-O_AXJBO0_C/_ 'C64U34J4I2E*4I2E*4I2E*4I6*X_;NM^]5M_A=
MW5O] /ZT_P!Q:C]W_P /^=95552I2E*4I2E*4I2E*4I2E8,X^Z4(_>-(O\/Q
M?_16@?:K_E$?[.6H_=CSZ6_6O_?6<UGJ5*4I2E*4I2E*4I2E*4I2E8/*_MAU
MG^_(E_B[G57P_8[K^H7_ !5M4&ZQ^ES^S<UG%45.E*4I2E*4I2E*4I2M5^2>
MI#>R2.LS4?"&ERD(?25TUE,'VF2U9L:+K%V8Q-),([LP(1:518]F.LRFT3F3
M9T)?((!WF XGFPS:9^KPV\2V2ZCDD4)<+$&AFM4NK:4(7WD!998IHP^8)82'
M4LXUIJ!JF5"Q1@"2FK!5BCC.-@>A4D#4#L< X.*T>E?#?E1(8B1C;^210G,"
M<$BL=0V*RE;Z-!@T<'\<R6M9QJ=& !(Z,C^02;;)<+2AP^&!1 %3"0+G\0(0
MA%H^#O[D7&>%1S+)'%,D*S2R&W>%)7DE;B27,%V9WE:020VP$85G>0&,1\R1
M99)*S&WG9"K,FIE494E0HY3(RZ0 ""YST (.< J!5O><*>1SU"PV29QZ<-?9
M U_(H6X?[.D3)MJ=I$.5IK;LD?LA=Q"J)A68:J<1N)H#D;8IMW<9: W62 7!
MN]3MCXYPQ,/&)(&[-=Q3A+6-C=M/PE;.)6?6"@AN^9,6.[+(S[N2M<:WF/=)
M##7&4)?:,)+K8@8WU)A< ;8& , UZ*[*U?)9=N344Y$N&#4+"H/O..&5UG2R
M))$AL4=!6D?7'MTD,[+I(*QT@H]4NX;J-NC:Z6*UU,O%_,VUU%#9W<#AB\T]
MC*@"@J5MFN#(&).Q(E4*-)!WSC&^MT9I$8' "2J=R#E]&G'YB?1BO/QKP\Y-
MR_&$B=CD1MX[#X#J.$DF>.VI40M+3&MN./(C6Y:8.T60\;UL?V;/]=2QL@16
M</E/,B4@)^*.1\<C7TC\;X5'S7MHVUS7=]<[VD0Y45WQ+AMRD +,WV*UM[F$
MZ<+WRBDI*]8UMY\@.VRQ11@\QMVCAE0N0!U,CHV^20N3N #W[</.0XIE8:H[
M83**JQ?/QT,<[;EX?*^WC7'W7T)<[84D"C1T]R>@MHQF5'+Y8*7?J*R]Q/!J
M&<J8),W$6XSPQSJ"/#,)LB<6D+ 6<?$KBX6T$88+A[26&/==(Y(@8\IM0ZMO
M.IW(*:,%-1&9#"BF3/79U?H<D/J&XJK[AER&91-$BE)&TQW1A/9Q)7$J,SXM
MA")/FY<12\*<SJ,YC6DE:L&R(D]FR+:SFT-F>MLSA?&-8GTI,801@O&N&M-I
M,30V/(@BY4=O'VB)1S^?V>36T18ZX\I=0S0W/+0R<OE+JF8)=!P0TF6.6=M)
M.4QJ&S =TD%&4H"0,ZCCUT3MG9-.RO@W4MAC92^'A>!?/P;>'X'AWOGX/A=?
M!\*]\NG3PKWOUO7R!QDXZ>&>N/36VN=*4I2E*4I2E*4I2E*4I2E*4I2M2>5O
M)HGQVCUWD8@*.R)1C")YL"\=<27*+(>8(0K%@=[W)IA) IBZ*S.?0D$W3R'V
M3P9D"I*RJJHM,>^]G@_"DXG,$FN3:1&>"W$HA,QYDXED]AKC&E(+>>1CJSJ5
M%QARRYKF<P+J5.80K,1G3LN -\'<LRKTQ@DYVP8:A7:1:JD<ZV:$."G<?A$*
MU]KF<1N;-%WLA4F"DCU'M3<FP!=PHX/;$/[',<U:6&*.+E""AR2)%0J;0>[&
MHX$-=QY-7<,-LZ.LD\]Q<020$+'RN7>6UE;N'9^^+F2Y5P H"1%')97R.+=Q
ML6!!4*JL#N<Y0R,, ;: ,'KD[;;9P<%VINOW)%3"50(Y%00Z5FP9 YC<_(\R
MP]"4\@XO'586(C\1>OCAXFKHS%X2"%+1] >E(G#8>5,OPJ+0SHF\E+A,+%<Q
MS.T,,BKZW"$9X.'32"=Y9E6.-!?E5D3F:N6K,L:N2E:7R,,LI4:W7.&)8*TJ
MJ5 4Y+<O."1@$@$D#,@*=I?QZ"2B9A9T1>PL;&Y A'6+HJS()F\WH<9FXV;G
M)H\NP;+1I'6);#$.?O@[+*.5%D%QR;BRR*:F4^3/$6B@DA03&6(2L$*F,+*Q
M%J(Y Q$IND!>/91C(.,9JWM4>6!.,$@==1T@<S(QMH)PPR<?H$A;.YT:?TQ)
M-K"=GLY1&8[JGV//.,YQ%7)1PMCL"'RJ;I*L%FN?AII!@L0+7=^.OY0_=IV9
M"&SYYDDW5IM> 7M]%9/:&*:6]-P$M]8213;SPP8.K )=YDQC9%.IRH.0:ZCC
M:4/E5B"$OC((=2V=N@ !]_! W%4+\^^.P)N_(ER<R9 @QM0,>DBD$D>0".X>
MR"3U4S.'B"313$3&RVP@$GBX<T\P3:D'\6/*(7NS:)N7!/)[B3LJ(D+2/&'C
MC$\>N4]F2[,<:Y[\J6TD4SHI)5)H\[L0!NH0"Q+:0Q4MI)"X8IEMMEU*P!/4
MJ?1G3O>?+K@AR?0CD8V(RVD9B4-3PV:*V% I1L'5TB@D[9G83%X^%;RC6DMB
M$P!F9 PVA'RC57&0-!*C(BU8D<L"^6+%#U;'A/'>&&22W:VCEFS;/!/';W,=
MQ 4GDE<Q7,4T,B1M;2*PY;."K,HT=XUO-;RE0P=@.\&4NI4L0%&4*L-08$9(
M!V\<5O)Q%$:DU_#)+I/34'] 8AJF1MLAPY8L>.DI$/V9'Q&U&<Z.EY:HO+R$
MBDZ\O?WDCB5/"!R\A'E<')!VG@BI7B\8:\GFAOKV?M$MW$VIM$:+$UK*]H]N
MB0^L+%%R1RN2%C,3(0H.H5?#H 9(UTA"/$DL'4.&);O9(.#J[P((W !.V5>1
M5U*4I2E*4K"XNT:N==QUB2QM9DXA8EH0P5SR0M9JJ#;HNL5%;9)YHV\5DI;/
M.V>&2=NN5LL;X];7S$BYE93N)Y"I !W$A(.-P=\;;@^FH)NBYZ%!U]X=:U5'
MZ4X82%[&V<4DP%*1QR*1F!14CK_?$B#S,5&-,QF21Y@%$FXG.VDB2PCT8FYQ
MI*,TG=W3YJ1:N92J[59#%VOJF^XU&LIDCD,4LTEQ,EQ8120/-=RQ2,[QRV[1
M'F2PQ&,%=*L,1!0S!JN7;DC! 95"J5D8,JHK  $,",*QR>I!RV<"K,7C7"IT
M^'A$EV4S5VHVW!DD0CNP9%*F)>TBBVL=,;5P?RAK+'#)L3>1<U Q*B;HHF4P
M4S7+"+8G%7CIQ..;C>EV ,0MNQZEDMXHF40RW-[::8N2&*+*EPX*KHP-#G0
M!QE@RIZEM>"&+ ZU1'))8C)!4;G/B-\U;GO&O@59W+S#T['4/(7TU%2;%3D)
M*FPB(&]@'1$JFN& ZVPDQ<+DAV00(49>N6K869P=1G'-!5%-BMAA->*^4!6*
M,)(P<0/'_P"CX2\R6L;Q0$L+?5-'%'<,J@ED ER1E@2Y-MN=MBP/KC;&1@S?
M==TL5'3![H'@,9C?C[PQ&R5NW(.(NN<;)8[ "1J1;<-%&P $A,\-M/RD6B!J
M8.A\>@Y66C6\ID;0*+9Q0XD)8HF&[L0*:-6U0XGQLQL4YH1QV>26.SC0R/R.
MQ*LLL<(:2X2%S%&[L9HS(S(1)(S$8+<L,@$CO %R<#7S3A2Q 4L Q  4@#;
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M;+\S_P#$4R_M!\?_ *:>FW('X!XK]-C?]'E=Y-A^&RY_(]O\1_E3+^T'Q_\
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&4Z4I7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g487902g01p31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g487902g01p31.jpg
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M P8'   $!0,& 0('  @)$1(3%!4A(@H6%SE1=K88&20Q.EER=WB8M+75_\0
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M$4;A6:O6#B;AFC75A\JGJ5BDYR]I,$.IKFJVIU/L%/.7LABPS])C:[B.K2W
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MK:O(VLFN<[XQ?]WCY>_^:U'_ %B]\[W\1?ZK/A7_ +L[_E4ZT;;_ /2;<_\
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M&9*4,0]C%$MYS<KUP-:A>9P[96=S9FSB5V&UL/C.!O2@NIVGS)#*B+W'7L+
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M)1PLZ]@7T>O;VYEOA/OS/;?HCB#RB/\ PSAU%$U:&5K0D6E3&!" JVE-586
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M-)E9):HKHNROB+?VDBWBK-&KG]MY&9F_@\AQ*"(H$3;7,EN%+&" 0T32Y+(
M)E<,$&CK^9V^C*FJTMS*.1K\>&ZC\\1',B+!@@DQ&9F1F# QYF(*1F1E,&'Q
M]?,7TL#?F_6_E76KN3$1_P <R9\UY<L1]*:I<X_%.+,Y0U^@O8R#A?N')EGO
MS#7;$N^Q>&.F9(IMN7OKX48\XR&+^&;&9,9\BUY#),=CU.CV)"I[[R9$#X(8
M&DO[1U\<\3%46$W2^)19W&(UI^DBKUQ"P0?;CN"TG$D/J>7E]_?:/O;/Z?\
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M2630PA&N,-9-R3C"B2<S2D:SN_XDV]X[;PV&R-0YR&-OVK]K*E:$QNG9*S,
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MQ-6HP^P(L9&9><VM1^'FRD9G HW/95?W.851SUC%LQO:[5."M(I+:UJ[H])
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M1)\* %BB\]KA.7"=@ 5,]0)DS A.L6'=7&TA8OW,TS62X')*L_)C,!VDBDT
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MF.8U]MJ9.X\2V%G*@HY$39 %*P(O#U$CB.HD7$]8F8F>)XU!EUL5J]%?D/\
M9#V.Z!R#K/3/7SW YWP\(+IW'Z$[ZDRXU=^)5P^H$4RWU:LP&6136+B&7K8H
M'P@) !+K=>!'$01HRE675-%;>FQ-O[?HY7&8[.[5OYDSQV5NIQJ\M3S%A=H;
ME6S8(*[;%0QFN2#,6"F&',B,KAD-ILP^<OWWUK-BEE$5(BQ52=DJC:BY5*6K
M7$L!;HGR08Q(R<C'$SVD7TYEWO'LAQ'J=WF]:NVHZI'!<D-;YUUVII*3<NY5
MD>L1R;S(Z=9'PTZ93=B2CZRDAOV]:T/TQ$Q+V%6F;2#Z3D<)_)_,8VF.X<.^
MU)5'V+^*M.N5,-9*S,1#K==!0YM,1"RXJ,6)">5A!,"(*YKW?GZ=EWR%L%<-
M!:+*P2VXN%_<%,.) 73)+#S>."C@IF!GF**.>2=MYI=N65KXRJ=\@]!,E968
M3J'JA[C4BV2>K?)*A#3K(=#$@O/11I!ZNV'N<:*&K"U"_N8;5'+)+,6,-J2"
MZ[1?C#Y"IDK'Q%N;%O!"ZYXW<VT[E6-R92W-NN!2^G0(2LJ*I+BLE;I)FK,1
M B12)IU!'S==M8, K-HGLR+&-RB6SCJRO$R8@'/CA90[I"X4\_)]YF([0?4;
MY^;]="U"/6^6)'E.ZZWJ=,K&G6;?R^Y59?;1T:82V,33JH>I2 $V;\0K.0;2
M?8(>&,EG&/!%'%KC>&./7;2WQV2L)L8U+KM@<=5R%6S-<V.;45TL@UC8J0?C
M*8^HR@!@CF9CGDN=1+-8#5:)2EQ9;7:N&P 0TI)9" RSB"F.>..2B(XC[<:7
M_'L!QS<4-%57T]\LS <Y&LY11QXGG7M5,)4,EJAL-'%D#.H=ANMBV'4NS;UM
M2T%'4_:SL+6H94N-8M21LG//?X+E.U0Q[BN56YG+"5:E&)"R+LUD69" A%J]
MNJZ0E77CB=9LXR5W,57BRMR"K_G*L\ HY<PH(!KIB"LP$3$M\B8ZDACV< <N
M\0)#ZC)4B<:E7D_%#H/]3;_UN!<=TWN4,8-K5 %99H:%S\)9(GJW(:N9*,+@
MU2@7$&'6-Y@$/:WW5S8'N1 D^U?1I-KLV:E0U5<+Y0HU+<W1>T86^_D9772>
M2>H)D4SX*=2K4K!,C5I54B9-MLN6K,NM4F/F'V8@K%SB&B,]@2D1Z+JJF8CD
M5C,R9]8EK2,YB!Z "VT-BQ1T[UAZPRE@7L^<,:+Q+J,>N\,DV=>B2(O7ME0]
M39-M]A8:WUM#0+[8 ))/NC(&SMG6+;3?:2-11"MQ[XQ BJMC["WWL>KE4H":
M1Q=VTNNV/J64;7K7'KJ0<<MW:$0OOUDJ]$D"Z%DI@2KDFI8C_4^0HRB)YGK"
M[ )>8_O_ $C[ZV/VX_$T;]"JTF)X3;3PE'S:LMX<:2:J;?VV^/N:I5<D6WU_
M%BZ1F&J]"),8@VV6?@UVPPD78S/H0N'[3-D,3%?=K<NNZ$00K9M[&JR3ZS!G
MF(&YBIRM7S%'17GD!F++ZL3[RG!&Y<\Q+:85UG$_E;;>=< F/O'F@B#F?7T\
M1/>1T[=VHU7Z&@FK5M5ZLELA AXN\<Y*]FG;KIM2E+^O.5\PK:O6-*9I&<DL
M"4P%NH.BB,7F#D1Z28K:ERQ1<+ZQ]#B)$H(08IJR_.EZ6"2GH9'TM2X#4P?I
M,)CUJX<E;PE;1[#,P4>Y$@(9Y$P,9@EL">" PD3 HB1F)CG2_P"-.L<XB5UR
MSU)UV^LAV5BS"O\ 5HZG%:3%KV-Z*>!TRC'G5D"1K%%8,P0OZ!$Q2V#,1!3*
MH\_#'B@+\/Q6.LS0LXJTO%V:V8?DK%&\Q\H$KTWXM,QUY:G%*41?:::M[I90
MM25!<R3N3U!XLUX &*.X M(Q>OQ0R19Y(*+"2E8]HAG$&B" _<DI Q[F#CU8
M8U;E?*T5E#CBM=:YK2JV\DDE&/+@9J:VK!:B[-(-Y]"\:GC3?DG@)E')DU_/
M'O)KMKOF7E;*[.2R;JYS-6QD+EA,1!+ EML,-1>*8&1Y60\"0P0Q],Q''&I=
M59+KUA9'#5UU ?/$S!"L8*.T<\_5$\S$S$_?WJ3?*[4C1XTT>--'C31XTT>-
M-'C31XTT>--'C31XTT>--'C31XTT>--'C31XTT>--'C31XTT>--'C31XTT>-
M-5W]P)YAQ3'1ZOW)U-4.!=H,N-@JEH2+F3-E7.I7I%N)=5.X%?7M[ &SA(C>
M]1IEJC6LEVS^SV(-C+6RJC3,6;9,9A[V=RF%RV'0BQE-ORM]R@<K5^(MKK50
MQN3<]K$(8NIBAG!/IFSNRO\ *-$6]&%7H;DUZDN7</Q4K<M-3 $B)=IR^K1D
M0$C@HX.PEL"0^1C(+QRI/DP_( ^L]UO5;MW2:Q/6M1-^>/K\1 TKL]0MU7YF
M"1:.%Z5Q4LL+-Z(PLW4K$[[OJ0W7*B*I6M5?-[!HR=BQG06671CL/)%C<BQP
M15RM"M3(+'==K*V*R\G9LDY"T0S&XVE^ A\NQ@W&6[-\.%>(0^51LW'+;87*
M^/ ;I@ERIJZ\2RGXQ$R."998=WDQ&5KZ5S[&,%%E'FDZO]'C31XTT>--'C31
MXTT>--'C31XTT>--'C31XTT>--'C31XTT>--'C31XTT>--'C31XTT>--'C37
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g487902g42h54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g487902g42h54.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1DR4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &1:^9"(X0DE-! 0      $L< 5H  QLE1QP"   "  $< E  "')R,CDS
M-S0X' (% "I-:6-R;W-O9G0@5V]R9" M(%!23$0@+2!&;W)M(%,M,R R,#(Q
M+F1O8W@ .$))300E       0$GU9\_Y\N7653>?RW9(R 3A"24T$.@
MY0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          CA"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              1L   ,7
M          $                          0             #%P   1L
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   1L
M    4F=H=&QO;F<   ,7    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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MPNJ)#)LR6L]=^&][F_S;Z?T^S9_AG^G;Z>/L1/6Z@*GXCJ;LECQL;O:T6MF
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M!'TF/8Z'L>W]QZ=+'.(LC3N@$%M)
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 /_A0 =H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_
M(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#
M;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @
M(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,C$M,3$M,3%4,#<Z-3@Z-#(K,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/E!38W)I<'0U
M+F1L;"!697)S:6]N(#4N,BXR/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @
M(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3$Q+3$Q5# X.C Q.C0V*S U.C,P/"]X
M;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R
M,2TQ,2TQ,50P.#HP,3HT-BLP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^
M06-R;V)A="!$:7-T:6QL97(@,3 N,2XQ-B H5VEN9&]W<RD\+W!D9CI0<F]D
M=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD
M8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@
M+2!04DQ$("T@1F]R;2!3+3,@,C R,2YD;V-X/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @
M/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/G)R,CDS-S0X/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z
M9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@
M(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I)
M;G-T86YC94E$/GAM<"YI:60Z-#A".$(P1C$Y,#0R14,Q,4%%,S9$,S4P1#=!
M0CA%.$,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U
M;65N=$E$/GAM<"YD:60Z-#9".$(P1C$Y,#0R14,Q,4%%,S9$,S4P1#=!0CA%
M.$,\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^>&UP+F1I9#HT-D(X0C!&,3DP-#)%0S$Q044S-D0S-3!$
M-T%".$4X0SPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z-#9".$(P1C$Y,#0R14,Q,4%%,S9$,S4P1#=!0CA%.$,\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M
M,3$M,3%4,#@Z,#$Z-#,K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HT-T(X0C!&,3DP-#)%
M0S$Q044S-D0S-3!$-T%".$4X0SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,2TQ,50P.#HP,3HT-BLP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV
M97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z-#A".$(P1C$Y,#0R14,Q,4%%,S9$,S4P1#=!0CA%.$,\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M
M,3$M,3%4,#@Z,#$Z-#8K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z-#=".$(P1C$Y,#0R14,Q,4%%
M,S9$,S4P1#=!0CA%.$,\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-#9".$(P1C$Y,#0R14,Q,4%%
M,S9$,S4P1#=!0CA%.$,\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HT-D(X0C!&,3DP
M-#)%0S$Q044S-D0S-3!$-T%".$4X0SPO<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO
M<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" !; /T# 1$  A$! Q$!_\0 '@   @(" P$!
M      @'"0$&! 4* P+_Q  ^$  !! (" 0," P0&" <    $ @,%!@$'  @1
M"1(3%"$5,5$6%R)!"CEQ@;;P(S(X875WD;0D)28G0G9X_\0 ' $!  ,! 0$!
M 0            0%!@,' @$(_\0 11$  @(! P,"! ,""P8$!P   0(#! 4
M$1(&$R$4,0<B05$5(S)A@18D,S4W0G%R=)&T-E*QLK/P)76AT31#4V)S=N'_
MV@ , P$  A$#$0 _ /?QQIHXTT<::.--0=O6^V>GQ%0@J*V*F[;+O$11("4D
M8TB7B:PT8+(R\];92.&>%^L'@*]#R9(01)T:')S:XB)?D!OQ!&56&/2B/56\
MF\BTJ%;OO'%N);5B6:&I2IHZJYC%F[9@2:;@W8K=Z<C:(D1K,KQK&D0'=GE6
M)&92RINK.\C*"NX1$8@<E#-Q4L =]02QO'=2IAO3+<=5OWFJC';PUL^2BC%4
M7]S0[>&WKN=4P)84]5V&L"D4DVB#3PHN97WV4>6;@L8!3/B3I^7!+UB[VXL*
M:JM-BEDC&1ARHB,TN.-IHY8Q52!)+(NF&1PB&H8FL R:B^ILEQ5 C[Y7NBPR
MGM>F'_S3$&#=P.1$8N0'+=^87QIB-(;#E=C4C!UF&A@+O7)R>I5]C*^609#@
M6ZK2+L;)ICG3&V34@G-I%E@62V\OM!2 [:GBL)24_"RE)*=B+L&4U;=2ID*;
M3!1*:UR!)D5RH"L\+,\$C*%#21,>$9)19=:5I8MY @E1FBF6,DH)(SQ;B3YX
MGPP!\@, =_<R_P K=2-'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&F
MCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FN!*GMQ49(RCK;[S4:"6>XR
M*W\Q+K8C#A"VAVL>,NO.);RAIO&<96O*4XSYSS[C0R21Q@JID=(P6.R@NP4%
MC] "=R?H-SK\8\59C[*"3M[[ ;G;]NWL/J=*I%]BM@B1L/:;?I@MZD3D179M
MN8UE9,;"FX0*SM#O1SLM5D0T-)2XC"2%-'F4M5E=9('7AB/)9=;>Y8RU\,+]
M[%)F#5R-&W'5X9>H<=3N=WG'%+5O=V>&+N6HWJJE_P!+QEX]QXU=2T);4_%)
M'K<HY K!J\G>90X4@M&51F4;^6BYD;$\=MR&.IEZJ&PX(>RTJPQ=DA"5N-(/
MBRD$-MD,Y]I A3?\+X9HR_X"@BVF"QG,9;?9;5CQR+<I6\?.]:[7EK3IL3'*
MI4E2-U=#Y5XV_JR(61O=6(U*BECF0/$ZNA]BI_\ 0CW!^X(!'U&H;VO'F%;B
MTN8SAAM@"M;A2V82\K#8<R6!3L1#GTONPV3EUL>1'4I>,98;=6I#B%+QA?*W
M/,G3F8JUV1);MK%Q([_22-<A/74>"")+<=>,KN"W(<?F"ZX3 FS6( V$=GYC
M_58B/B=MQO['?Q^\:563#E#*)-=T(<EJ6+BKT5:HM(YAC<7.=3XAXZNS,&Z$
MCQEUE^G'6';(8B&4OEW$*"(=;-R(,*O4UHH7J1=%,Z&K?QO!C+3/.'J#(,F1
MB_+!24R)*8<)S8K(M9Y0RJS2;P6W:-LDI5B).8.QXOC5W4KQ ).\):PNPY&3
MAR!VXZ932)T5'[7W=6XT 09%EQ1=P*E@A_B$LTG;H5ZLS1HKV/.#?PYBEU\4
MI_.<+0\2AK*$XPGSF:_?FZ>Q,MAU>S1M9?$6U0%8X9H[8RG;5&9F0A\K/%(K
M!#WZ\WRC;838"BV+4:+Q#]JUN/:1IDXNP\#_ .FH_8?IIA+7;JS1H(^S6^<C
M:[ 1;6'3I25+:$$82I6$-HRXZK&7'GW%(9&':PX02^MM@=IQYQ"%?E:K9NSQ
MUJD$MBQ*>,<42%W8[$GP/90 2S,0JJ"S$ $ZDR2)$I>1E1%]V8[ ?_T_0>Y^
MFE@F^S5L:CRKC :?EDZVB\E.E3UWF?V)M,Z)&R# LD]5**3#R$ME/TSJGHC-
MN?JCTW(9$AQQ6"9 1UR=%4Q;W:V).86QF+EV:C%6QU5[U.O)7@::U)=R2.E=
M(:CKZ>S)6%F.*;>/N/(.WJ(]N0*TBUF[2 DM*W:D<!@&,<15G( .Z\^!<[*!
MY!TWR%X6E*L?_).%>,X\9QYQY\9QG[XSCSXS_OY5>WU_9]/)_=X_RU.U^^--
M'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&F
MCC31QIHXTTH^U)^\D;QA:*Y<).E:^-UD99X=< P(P7:[A%V5N/L<5-SY$;*G
M1,?"0,C R<>Q$"8P7]9,%S+J@(QIER7<G3&].G+5:L-K(09=*]DWHII\=7I3
M5B:O?6J3/7%F=9PV09'AJM!$KH>]Y@RM+ZH1F1HH/3F0% F\DJR!75G=6*!$
M9& 0 G=BS!1L5YTS5]NTTZ?T=7[["3[>NAF"=?U3:$(PV[8-"SZVE02:KL^G
M-MY(?I$KAVN%F'UBS_3'0<"D@6)CYP IRRS"X#K*E1ZEN8RUBY<G#8I9>UB9
M8+2)E&A[LJ]BR9:\U>Q**F7I6:EN$%N^I5YX9XHXE:.Q"6JQRI(L&W:2Q& 7
MJ. 4[=B,^3$P*$M$VS( 0%96UV=H=)@K0J\$UJY]9-PR([K\O;HZM$WW4=XD
M8=D=E3FQY"FLIKEIB9J+%0'%OVYRD7R',1E%;-!44_DKE4@S%&%J]9\=UEAK
M%599<>;/H<GCLI$J]Z;%1V@EVNU^(.9$J)<QQLUXFM1.T[[_ &[!3W&26A99
MCO(L;302E1L&L/$.W(I4!5:3MRKOLA^AX!NP=[=@)D&,HU%'BY:&H\K7$;L@
M90&:T_&6"]25;679(A-A5!6N6(K=?KQLF/7,UDMYF8D(6+E36ARR#&M%-B>G
MJ5%9+]V5X)<ICLK%B+->2',F/$F6U7@GCB$M: V+,T<+S/.@$23R1Q%T2,_'
MJ+=EBD$81A$T?JU(:NIE*@N@?A(Q1%8F/@3R*JS#R=6*5^HU^LU&&HT3&!C5
MB!KX%8CH=MA"0&(2-CFHL6/2/]V\"H!90/AGQE'Q8]GC..8V>U8LVYKLTCM9
MGL26I)N1YM/+(97D+#8\C(Q;?[^??5LJ(B+&J@(B!%7;P$4!0NWV  &WVU6V
M9*;(ZEV2)E).BV"TT"G04YJF&L0LI$MU<JAS,R'8=6V2[6>2<!:U^B@R292A
M7@D^--";ACZS8HYXT0>69!VE7'X_J 7NQD8J=G(S095\>4D:2/)QI/\ CK5J
ML<;29&SEC,MVJ$L<MZ\E=Q$[)SIRTU&17>.22*)&KK)W%,9@)[D#RNW$0]I^
M4,A(*B,HZ[CD%[&/MT?;K4-=ILQ/9?<<8&3)4Z@ZG2U8]4:UDW4OI@VXB4-(
M;IU>G6(LIPZ2V#?)V.M$U]2D& %A0G&*YS-6DSUNLU3&T1TE@TC,LE_/DULE
MF9IIFBI-<BC#7IJU:*/\1?%XR!ZZ2-6CFF::.2RW198W?FQ6_97<QQUMG@@;
MSVRKL3"C\22TTC\_.\:*"$U\=E0NV[[L'76IK?8:W18>3+ V19:C2UR,]=8W
M6NMS@9: 1.WDP)X<Z>LFW<5]UR#KE6#8EXV(L3;5B(;!4M/Q2BP71F,R6=QY
M;)9(UDZ>P]W,)VX!-:A?\1])B:CRW<A*M-KMR:4SH\EJU0BDKUPHF;\F6Q-+
M#7E98XV83RI%N\P@AV9 \K!@SO9* JD8#*&'+8'>7=2P\S ]D)6NURZ;/LM:
MA-:&R&UOWBW"0M;+UVLLW!N:Z_#026W(ZIRS=>B[B;)0\,[&X;ASJ^])0WR&
MB%)ZQ6+%KI=)\ICH*UB7*(F'M"K2I6[=*O#/^)S2UZ2+QIFU+32HMGG.LB6%
M)0QR(>M=&2XR)-/(BP%IQ/*TNTKNA@ !V6-A&LA95 W#*2OD,7BY3:L]'&FJ
M9NQGK;=<NMF^=@]>[1K7<]FN6N2P!)DFH0,/)1C_ .(0T7--/B9<F&"_A0/*
MCM.+>&:PE_"DX\XRG.?7>GO@WU!U%A*&>K9'$5JF021X4MSRQR 1SRP$/M"4
MW+0L0 Q\;:S-WJBE1MS4W@M22P%0YB167=D5_'S@[ ./<#SJ'T?TB#J8PMM<
MQJ#L?#1^5I0[($TJ'6TS[L^,9RC]H&\+SGQGPE+F%9\>,8\Y\<MC\ ^J2"(<
MKT]-)](UNR@GZ^_8.WC[C48=9X[W:M>1?JS0C8?NY;ZLKZI=_P#JOW0$,SHG
M9@4W8(L5LR:H\V*57+O#LK2UE;I->E6V7S!&%O(8?DHAR2BVR,_#DWY/X>>=
M=3]"]3](,OXYC7@KR,5ANPNEBE*PW^46(BRHY Y+',(I2OGM[:O<?E\?DP?2
M6%=U&[1,"DJCV)*-L2 ?!9>2[^-].=S(ZLM'&FCC31QIHXTU%V[]AOZCTUM;
M:8L8U-DZYUW<KP/#ODK#9E'JK7I";;CWBVV2'!6S%@X'60AAY3*7,N):7E/M
MS98:@,KE\7C&E,*Y#(4Z33!0[1+:GC@,BH64,4Y\@I8 [;;C7"U,:]:Q.%Y&
M&&24*3MRX(6VW'D;[;;CV]]+_P"G_P!K9/NGUAI/826IH-",MLC:0EUF/EWY
MP8-%=L)\&VYB1)!CG75E)"^=:,BI2VI?L2M6,>>7O772\?1W4MW 17'OI5CJ
MR"S)$L#OZFO'.08UDD "%R@/,[@>=CJ'B,@V3H0W&B$)E,@,8?F!VY&3<-L/
M?COMMXTZ/,AJST<::.--'&FCC32<=^.TDCTSZN;"[$150"O1E'?JS2*P?+/0
M@T@FQ6F'KBU+DAP9!QA0J93)2$X&7AU36&\Y1A658UO0_34?5_4M# 2VWHI=
M6T39CB69HS7K2V !&SQAN1CX^6&P)/G;;5;E[[8RA/=6,2F'M_ELQ0-SD6/]
M0!VVY;^WTU->@MF$;GT?J';I<4S!$[.UM2[X_"#E+-8B'K77H^;<CF3'&1W"
MVPU&Y800MAE3N$87EI&<^W%-G,<N(S66Q2RF=<;DKM%9F4(TJU;$D D* D*7
M"<N() WVW.I52<V:M:P5"F>"*8J#N%,B*_$$^^V^V_UU+G*O4C1QIHXTT<::
MA7>>JG]GU8)5>DV:WL>DR[-QUA;W&%$?LY;@1B1,8*:0MM9$'8(@Z3K%E"\J
MP7!3!V&TX*;%=:L<==6JUB"QZAL=D:[T<G#6E$4TM61DD#P2,KJEFM-'%:K.
MR,HGA17#1-(K1[,!F0<&[<T3"2"3_<D7?W]]T=28Y!L=T8^-]M)G/WK]K:"S
MO")AR->[4T!,V&?LE<-P\PJ'+K(JF=NZQN46$I+,I$3U69>Q"VBMJ+K\M*9I
M=Z9"1@8%G-9AX1TWU9+TM>DDM8SJ41Q06\=&(:^0KW)7&$SS8J4R"O-5LI M
MFWCFY*6NTK\5/N2Q1P))3) ;21F"2FSRNK  H8EVLUY0/#(\?S1LAX,>U*-C
MX-E0!C,D %(,85\!P@QC/R)PESXBF4/MX6GSGVK]CF/<GSGVJ\X\Y_/G1T,;
MNC;<HV9&V.XW4[-L?J-QX/UU; [@$?4 _P">N7A*4_EC&/[,>/\ /^?TY\Z_
M=9XTU\7QV"F71R66B!WVULOL/MH=9>9<3E#C3K3F%(<:<0I25MK2I"TYRE6,
MXSG'/T$JP92592"K D%2#N""/((/L1Y'TT(!!!&X/@@^Q'V.N'&P\1"#9$AH
MJ.B1/>I[Z2,!% 'RZO&,*<^ 5IIKY%X2G"E^WW*PE.,YSXQSZEEEF;G-+),X
M '.61Y&V7R!R8LVP^V_W\:_ H7PH 'V V'^0\:K^>V(="$;EV^.',3UVONT"
M-.ZDI@RV6")->OI@NC5N"#E75.+%A9NPC6W8MH7"C+-C:>Z=*R6<MPF<\G7*
M39?)XCI^O,\6/Q>,3)9O(TZOISCS=CAR-Y[F3L&3E**LE+&TZM2$/+:5(S*B
MV>25G=*>IL[<Y9)S6KQ @%^R_96,,=]@TBRSR<?(BW8C=-BVVE-8YU=2VXV3
MD&9^[6 \JV;(MK8ZAUVN]S26ES<LE#JW26HT?XAX:N $/OKAZQ%PT,AU3(#>
M>?F2NQW+ ]-$];'UD%7&TWD>5JE&-F,43.[,7F=G>>U+N.]:FFF(!D.IM>'L
M1\20TCL9)G\_/*_EV\DD+_50$GB@5?IJ7>5^N^CC37G.ZG!AF^O7Z@;1H@IC
M6-4PJ\-E#M$(2K 6G\84E+R%X2KQG./=C&,^,YQY\9SS^@.J7=/@=T$49D/X
MI."58J2.YE_!V(W'[/OYUB\: >K<YN ?R(MMP#M\M;SY_P M>A-^K5@II3)-
M<@2&5_ZS3\1'O-*_3W-N#J2KQ_OQSP46+"G=9YE(]BLL@(_L(8$?NUL3&A&Q
M1"/L5!'_  UYAO5QTM1NB_8[J/WFZX0\=K.ZS.X6JM>ZQ4XY$37;>E3:9$Z1
M)C(YT05LB:B7I6$GA61TL3#10Y!&,%,NN$_TA\*LQ>ZUP'57174,TN2IPXEK
M-*S;D,MBJ?Y-(UED#,5@E$4]=RQ>)E=5W4@+A>HJL.)NX[+446"9[(BE2->*
M2[[$LRJ0.3H61_'SC;?V\WQ]ONW5,Z;:!.[!WJMV6S5J/DJU&/Q%8Q'YF/FL
MY;8@CG_F908WQ,.N)P__ *7+GWQ[$*QYRGQ'I/I6YU=G(\#2LUJ]F2*S*)K/
M<[6U9"[C\M';DP!X^ /N1K6Y+(Q8RHUR9'>-612$VY?F'8'9B!L#[^=]+1V?
M]7/J[U9HVO9VW+LMEV%M"D5Z^57352'"D;NS#V:*;E(MZRN8*Q$U\=[+F0VW
MGRWWC"$.+CA#!FW7V]%TW\+.I>IKN0@JBO6H8R[9HV<O:9XZ;3593'*M8!#-
M.PVYD*@5%($CHQ"F#?ZBH8^*%Y2[S6(HYHZL8#2A)%Y*9//% =]MR?)]@=.;
MUZWY&[WZ_P!&W^96Y/643<JV5:"J_<B&1I&L1XAD@.]F;*<;$'82V. H]U]:
M&F6QG$K4KV)RO.1S^#DP>>O8)+$>2EIV4K+8IJS1VG=(W7L("[,29 @4%B6!
M \^-6=.VMNG#<*- LL9D*2D!HP"0>9\ >!N3[ :K1MWK4ZWF;W-T/JGUUWSW
M!>K!)0E@M6J:\ZW31R U-X=3&R[P1[\FQGWK^(OZ$08K#670G2AEM$+]%J_!
M[(PT8;W4_4&"Z2%E5>O5RM@&VRMOMW8E=%B/@;KS=EWV<*P*BCDZG@>9X<?2
MN9+MDAY*R;1[CW"LP^;;S[ ;_3<>=33U+]5S0O9[8;FD9VLW[KYOQ#9#C.I]
MQQ/X%*S'TWR+=9KTDK#0TF<@=I1?X:\R!(OC)=>"%+:'(6U3]4_##.=-T/QF
M"S1SV"Y*K97$2]^*'GL UB,;M%&6(3NJTD:L0'9"R[R<?U!3O3>E>.:G<V)%
M:RG!FV\D(WLQV\\2%8C<@$ Z:SN?_LB=G_\ D!M[_ ,_S,=(?[5]-?\ GV)_
MU\&K')?S?>_PEC_I/I$/0A_JU-,?\>V9_C^?YM?C=_2/F/\ #8W_ $4&JGI3
M^8ZO]^S_ *B733:R[UZ\VCW&W/TOB*I;8^^Z4K#=IG[+(?A?[,283CE4;2S%
MY8,=D?G\VT+./J1&D>!R/*L9]F,YK)=%7\9TCB.L);522CF;)JP5XS*;,3@6
MR3+RC$>P](^_%B=V7;?SJ?!E8)\E9QBQRB:K&)'=@O;8?E^%V8MO^:ON!]?[
M-/!S&ZM-)/J;O%K_ &[VWWOT_A:K:XZ[Z"A YRR6.2_"_P!FY4<UVOM--1/T
MYCLC\WFPC*_\4*RC*&'\Y5C/QI5L<KT9?Q/2N#ZLGM5)*6=F>"M7B,ILQ,@G
M),P:,1\?XNWZ78@LOC;<BLKY6&QD;>-5)%FJ('=V X,"4 XD'??=O8CV&_U&
MF6VIM?7>D:'8=G;5ML/2*+5@\FS=AG"<#!BM96EIII&,86\484^ML<($1I\L
MPEQL<9EUU:49SF-QE_,7H,;BZDUV[9;A#7A4LSGZDG]*(H^9W<JB*"S$*"=3
M;%B&K$\]B18HHQN[N=@!]!]R2?  !)/@ G5)SGKPU2VRLJ_H;IEV@WCK^'4_
ME_8-<K:A(\ID3PDM\0%F/F%)0RO/V:,-%+4GVY=&85E24^R+\$;56*)<YU?T
MUA;\H7C0L6.<BE_**TADB&[ 'RB.NX\,P\ZS'\+(Y&)J8S(6X1[SQQ@+L!\Q
M ().QV&W@^^X!&VHU]1#O3HONIZ6/9]_5QTY#7*EGZN'O^K[Q%.5W8-+?<VC
M4&TKEH1Y;F78YQ_.6&94)T@-3Z?IGECF84,F?T%T5F^COB;TTN3C@FIW(\FU
M#)TIA9H7 ,;;)$4R@;2!?F:)PK[?,H9-F/#,Y6IE,!?].SK)&8!-!*ICFB/?
MC\NA]U\>&4E2=AOY&KDNBO\ L6=3O_SMIW_ 4%SR3K3_ &PZI_\ V#,?Z^?6
MEQ7\V8__  57_HII?.WOJF=?.I]P$U(W'7'=^^I%E#P>FM01F+%9A$NH0\SB
MP/MJ6/"./BJ46R$I!DJL9&"51R!7&R%7W2?PTSW5-5\H9*F&P<9V?,9:7T]9
M]B0?3J=FG"MLK/ND08\1(7!40\CGJ>/D%?C+:ML-UJUD+R>?;F?TH2/(!W;;
MSMMYTN,'ZV=&JMR@ZMVLZN]A>ID99GQ!86\;&KCQM2^<UQ2!_P 4+8CX\L$?
MV-O.O/C"2.1VVEN/LMLX4ZG0S?!R[:J3V>E^ING^JI:P=IJ6.L".UQ0 D1*T
MDB.YW 56>,,3L&)V!@KU1#'*L>0H7<<KD!99T#1;GVY,NQ7?]@)\;[;;:NJA
MYB*L$5'3D'(A2\-+@BR47*1I+)L?(QYK*"!#0BQUN,$BDL.(=8?96MMQM:5)
M5G&<9YX[)'+#))#-&\,T3O'+%*I22.1&*NCHP#*ZL"&4@$$$'6H5E=0RD,K
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MS&,2KVYXV59(+$>X)BLUY \-B,D ]N9'4, P&X!USEABF"B1%?BW)"1\R,/
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M+O([EG=V8DLS$DDDDDZFWU5,;<1%546E.JJH 55$+ !0/  '@ > -)1Z$/\
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MIU([F$_'A>%)_,%TN^;ZH'3(O156[^1A:])$\D2C'0V9I)#$C"0B1:S!5!+
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M[G;6\TSL#'7+L3NCKTQ6SP9/355UE:3K(\<,Z!.,;+8GWA!0P4-))$=B_P
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M8$Z:=VK9'J6N;S3VB\TK.M?P?YE0""?,>FLX1A20DX#\YSC*L^\Q]=H?B@M
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#7__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
